
<html lang="en"     class="pb-page"  data-request-id="3b955833-e71c-42d5-890a-7e9a2e945b6e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00058;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction" /></meta><meta name="dc.Creator" content="Saktimayee&#xA;M.  Roy" /></meta><meta name="dc.Creator" content="George  Minasov" /></meta><meta name="dc.Creator" content="Ottavio  Arancio" /></meta><meta name="dc.Creator" content="Laura W.  Chico" /></meta><meta name="dc.Creator" content="Linda J.  Van Eldik" /></meta><meta name="dc.Creator" content="Wayne F.  Anderson" /></meta><meta name="dc.Creator" content="Jeffrey C.  Pelletier" /></meta><meta name="dc.Creator" content="D. Martin  Watterson" /></meta><meta name="dc.Description" content="The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of pre..." /></meta><meta name="Description" content="The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of pre..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 12, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00058" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00058" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00058" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00058" /></link>
        
    
    

<title>A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00058" /></meta><meta property="og:title" content="A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0001.jpeg" /></meta><meta property="og:description" content="The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00058"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00058">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00058&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00058&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00058&amp;href=/doi/10.1021/acs.jmedchem.9b00058" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5298-5311</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01808" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.8b01325" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.0c01060"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Saktimayee M. Roy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Saktimayee M. Roy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Northwestern University, 320 East Superior Street, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Saktimayee%0AM.++Roy">Saktimayee M. Roy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">George Minasov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">George Minasov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Northwestern University, 320 East Superior Street, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=George++Minasov">George Minasov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ottavio Arancio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ottavio Arancio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Columbia University, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ottavio++Arancio">Ottavio Arancio</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6335-164X" title="Orcid link">http://orcid.org/0000-0001-6335-164X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laura W. Chico</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura W. Chico</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Northwestern University, 320 East Superior Street, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura+W.++Chico">Laura W. Chico</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linda J. Van Eldik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda J. Van Eldik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Kentucky, Lexington, Kentucky 40536, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda+J.++Van+Eldik">Linda J. Van Eldik</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wayne F. Anderson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wayne F. Anderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Northwestern University, 320 East Superior Street, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wayne+F.++Anderson">Wayne F. Anderson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4181-8127" title="Orcid link">http://orcid.org/0000-0003-4181-8127</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey C. Pelletier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey C. Pelletier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Northwestern University, 320 East Superior Street, Chicago, Illinois 60611, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+C.++Pelletier">Jeffrey C. Pelletier</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">D. Martin Watterson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">D. Martin Watterson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Northwestern University, 320 East Superior Street, Chicago, Illinois 60611, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 312-420-2879. E-mail: <a href="/cdn-cgi/l/email-protection#15713b783b627461617067667a7b557278747c793b767a78"><span class="__cf_email__" data-cfemail="80e4aeedaef7e1f4f4e5f2f3efeec0e7ede1e9ecaee3efed">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=D.+Martin++Watterson">D. Martin Watterson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7605-5866" title="Orcid link">http://orcid.org/0000-0001-7605-5866</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00058&amp;href=/doi/10.1021%2Facs.jmedchem.9b00058" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5298–5311</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 12, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 January 2019</li><li><span class="item_label"><b>Published</b> online</span>12 April 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 June 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00058" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00058</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00058"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4745</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00058" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Saktimayee\nM.&quot;,&quot;last_name&quot;:&quot;Roy&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Minasov&quot;},{&quot;first_name&quot;:&quot;Ottavio&quot;,&quot;last_name&quot;:&quot;Arancio&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;W. Chico&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;J. Van Eldik&quot;},{&quot;first_name&quot;:&quot;Wayne&quot;,&quot;last_name&quot;:&quot;F. Anderson&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;C. Pelletier&quot;},{&quot;first_name&quot;:&quot;D.&quot;,&quot;last_name&quot;:&quot;Martin Watterson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;5298-5311&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00058&quot;},&quot;abstract&quot;:&quot;The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in ea&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00058&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00058" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00058&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00058" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00058&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00058" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00058&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00058&amp;href=/doi/10.1021/acs.jmedchem.9b00058" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00058" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00058" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00058%26sid%3Dliteratum%253Aachs%26pmid%3D30978288%26genre%3Darticle%26aulast%3DRoy%26date%3D2019%26atitle%3DA%2BSelective%2Band%2BBrain%2BPenetrant%2Bp38%25CE%25B1MAPK%2BInhibitor%2BCandidate%2Bfor%2BNeurologic%2Band%2BNeuropsychiatric%2BDisorders%2BThat%2BAttenuates%2BNeuroinflammation%2Band%2BCognitive%2BDysfunction%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D11%26spage%3D5298%26epage%3D5311%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292039" title="Pharmacology">Pharmacology</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/jmcmar.2019.62.issue-11/20190613/jmcmar.2019.62.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A theme in pathophysiology progression among diverse central nervous system (CNS) diseases is the involvement of synaptic dysfunction and neuroinflammation as part of pathophysiology progression. In some cases, a neuroinflammation–synaptic dysfunction axis is considered a common disease progression mechanism. For example, innate immune cells, such as glia in the brain, communicate with neurons through an array of secreted and contact-dependent signals. The glia-neuron interactions influence axon homeostasis, plasticity, and synaptic transmission.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> As a result of these reciprocal interactions, pathological processes are destined to affect both innate immunity and synaptic communication, either locally or across physiological axes. The identification of risk-modifying genetic polymorphisms and pathology studies<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> provide clinical evidence in support of the neuroimmune–synaptic dysfunction mechanism of disease progression. On the basis of p38αMAPK involvement in both neuroinflammation and synaptic dysfunction, it is a logical discovery target for alteration of disease or disease susceptibility when the neuroimmune and synaptic dysfunction pathophysiology mechanisms are involved.</div><div class="NLM_p">Previous clinical trials with p38MAPK inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 1S in Supporting Information</a>) used experimental therapeutics not optimized for CNS pharmacological exposure and employed mixed-kinase inhibitors, some of which exhibited dose limiting toxicity. Clearly, when targeting CNS disorders, there is a need for clinical therapeutic candidates that are selective p38αMAPK inhibitors with improved pharmacological properties and adequate brain exposure. CNS disorders offer an enhanced potential for p38αMAPK inhibitor drug efficacy due to pleiotropic pharmacology driven by multiple pharmacological actions from a single target engagement versus pleiotropic pharmacology due to multiple targets for a single drug. In attempts to address the unmet need, we developed a selective, brain penetrant p38αMAPK inhibitor, MW01-18-150SRM (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), that is a novel drug candidate currently in phase 1 clinical trials. In this review, we summarize the biological rationale and refinement approach.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the human p38αMAPK:<b>11</b> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C">4R3C</a>). The protein is shown as a gray surface representation, and compound <b>11</b> is shown in a stick representation with the atoms colored white for carbon and blue for nitrogen. The mesh over compound <b>11</b> reflects the refined experimental electron density for compound <b>11</b>. (A) Compound <b>11</b> binds within the active site cleft, located between the bilobed catalytic domain, and has interactions with the connecting hinge region and a proximal hydrophobic pocket. (B) The compound <b>11</b> pyridine ring nitrogen forms a hydrogen bond interaction with the amide backbone at amino acids Leu108 and Met109, while the vicinal 2-naphthyl substituent fills the proximal hydrophobic pocket that adds to kinome selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Overview</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The biological rationale of our approach was a focus on pathophysiology progression mechanisms common to multiple CNS diseases. In this regard, the discovery process was somewhat disease agnostic because common pathophysiology progression mechanisms were targeted in medicinal chemistry refinement and secondary pharmacology screening. This is in contrast to focusing solely on single disease efficacy and primary target affinity that is a prevailing theme in drug discovery and preclinical development. However, deliverables from each stage of refinement (hit-to-lead and lead-to-candidate) were studied in discrete models of disease that exhibit the targeted pathophysiology progression processes.</div><div class="NLM_p">A key aspect of medicinal chemistry refinement was the extensive use of secondary pharmacology assays during the SAR analyses, which embed a systems analysis dimension to the single target process. Secondary pharmacology outcomes at each stage restrict the chemical diversification process in order to minimize potential pharmacological liabilities and enhance CNS drug related properties.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref20 ref21">(9−14,20,21)</a> Therefore, the overall number of new compound syntheses is restricted as diversifications into chemical space associated at early stages with adverse pharmacology and toxicity are avoided.</div><div class="NLM_p">High resolution crystallographic structures of enzyme:ligand complexes were used in the design and in the interpretation of deliverables from each phase of refinement, starting with fragment expansion based on crystallography of enzyme:ligand complexes.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Chemical diversifications during refinement were restricted to those that retained key target recognition features of human p38αMAPK:small molecule complexes (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y">4F9Y</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9W">4F9W</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C">4R3C</a>; CCDC 1851508 and 1851509) and avoided introduction of potential pharmacological liabilities based on pharmacoinformatics or secondary pharmacology screen outcomes.<a onclick="showRef(event, 'ref13 ref14 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref20 ref21">(13,14,20,21)</a> As is typical of structure-assisted fragment expansion, the number of syntheses required to attain the campaign goal is lessened. Recognition features included retention of the pyridine ring nitrogen charge properties, as evidenced by potentiometric titration, and orientation relative to the vicinal aromatic substituent, as evidenced by the crystallographic structure of human p38αMAPK:small molecule complexes at each stage.</div><div class="NLM_p last">Primary data and outcomes at discrete stages of the preclinical development of MW150 are described in the literature.<a onclick="showRef(event, 'ref4 ref12 ref13 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref4 ref12 ref13 ref15 ref16 ref17 ref18 ref19">(4,12,13,15−19)</a> The SAR studies driven by structure and secondary pharmacology filtering improved kinome-wide selectivity, metabolic stability, bioavailability, and function. Dose-limiting toxicology and adverse pharmacology liabilities were identified and removed during early stage hit-to-lead refinement. The process established that p38αMAPK is not a neurotoxic target as previously hypothesized. However, the process did not allow a single off-target kinase or GPCR to be identified as a toxicology associated target. While progression from hit to lead compound removed crossover to a subset of kinase targets seen in earlier campaigns, it also resulted in removal of GPCR agonist and antagonist off-target activity.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Lead compounds that were inhibitors of both p38αMAPK and p38βMAPK, yet had kinome selectivity and no GPCR agonist or antagonist activity, also did not reveal overt toxicity in secondary pharmacology screens.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Therefore, there is inadequate evidence to support the perspective that p38αMAPK and p38βMAPK crossover activity is a significant contributor to dose-related adverse pharmacology observed in previous p38MAPK campaigns (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 1S</a>). Overall, an accumulating body of evidence from studies of genetically modified mice and comparative studies of compounds <b>9</b>–<b>11</b> raises the possibility that inhibitors engaging both p38αMAPK and p38βMAPK, but having kinome-wide selectivity for the p38MAPK family and lacking key GPCR agonist activity, might be adequate for a variety of pharmacological indications.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Fragment to Hit to Lead Compound</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17080" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17080" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An arylpyridazine fragment (compound <b>1</b>) was chosen as the starting fragment based on pharmacological precedents (see ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> for discussion). Briefly, the pyridazine ring can be exploited as a biologically friendly fragment for kinase inhibitor development through at least two distinct mechanisms. First, it has the potential to serve a ligand recognition role via its ring nitrogens engaged in H-bonding with the hinge region. Second, the pyridazine ring can serve a nonhinge binding role when it is a chemotype in the context of a more basic substituent that fulfills the ligand recognition role, such as the pyridine ring nitrogen of compound <b>1</b>. The nonhinge binding role provides a framework for pyridazine ring diversifications that sample alternative chemical space as long as the relative charge and orientation of the pyridine ring nitrogen are retained. The hydrogen bonding interaction with the hinge region of the kinase is an interaction also used by ATP. However, the vicinal aromatic group occupancy of the proximal hydrophobic pocket provides potential for selectivity as the pocket is not occupied by ATP and is rare among known kinase structures. The proximal hydrophobic pocket also offers opportunity to increase apparent affinity through increased space filling by lipophilic substituents. The structure of the p38αMAPK:compound <b>1</b> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a>) reveals adequate space for diversification at R<sup>3</sup> without disturbing these two key target interactions. The amine, piperazinylpyrimidine, chosen for diversification of compound <b>1</b> to generate hit compound <b>3</b> was selected based on prior use of this pharmacophore. Especially relevant was its presence in MW01-6-189WH, a clinically safe CNS aminoarylpyridazine therapeutic candidate (NCT02942771, NCT01357421) that contains a pyridine substituent but is not a protein kinase inhibitor (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Tables 2S and 3S</a> and compound <b>2</b> in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 5S</a>).</div><div class="NLM_p">The p38αMAPK inhibitor hit, compound <b>3</b>, retains the two key target recognition features (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a>) and is within the multiproperty molecular confines identified by in vivo data for orally bioavailable CNS drugs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Independent confirmation of the functional importance of the interaction between the phenyl substituent and the hydrophobic pocket is provided by the failure of compounds to inhibit the point mutant p38αMAPK (T106M).<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a>The methionine side chain in the enzymatically active p38αMAPK (T106M) does not allow phenyl group access to the pocket. The hit compound <b>3</b> was found to be comparatively selective in terms of kinome crossover (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 4S</a>). It exhibited brain exposure and in vivo function in attenuating neuroinflammation, synaptic dysfunction, and cognition-related behavioral deficits.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, it has the same liability of prior p38MAPK inhibitors in that it was a multikinase inhibitor (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Further, an initial dose range finding screen revealed a dose limiting therapeutic index (including neurotoxicity) observed at doses >12-fold above efficacy doses.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Hit design via fragment expansion. Diversification of the inactive fragment compound <b>1</b> by amination yields the active hit compound <b>3</b>. The crystal structure of the p38αMAPK:<b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a>) identifies key molecular recognition features that are retained in the p38αMAPK:<b>3</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a>). The key features include the position and net charge of the pyridine ring nitrogen that allows H-bonding with the peptide backbone of the kinase hinge region and the occupancy of the localized hydrophobic pocket by the vicinal phenyl substituent. The representation and orientation of structures shown are as in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome target selectivity of hit compound <b>3</b> vs off-target kinases of widely used p38MAPK inhibitors. Red circles denote inhibition at specific kinases with IC<sub>50</sub> < 1 μM. (A) Kinase inhibition profile for the widely used p38αMAPK inhibitors VX-745, BIRB-796, and SB203580.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Crossover kinases with IC<sub>50</sub> < 1 μM for VX-745 include ABL1, ABL2, p38β, PDGFRβ, SRC; for BIRB-796 include BLK, CDK5, CDK8, DDR1, DDR2, EPHA3, EPHA7, EPHA8, EPHB2, p38β p38γ, FLT1, FRK, NTRK1, JNK1, JNK2, JNK3, KIT, MAP4K4, MRCKβ, PTK2β, RET, SLK, STK10, TIE1, TIE2, TNIK, TRKB, TRKC, ZAK; and for SB203580 include BRAF, CIT, CK1δ, CK1ε, DMPK, GAK, JNK2, JNK3, NLK, p38β, RIPK2, STK36, TNIK. (B) Kinase targets (IC<sub>50</sub> < 1 μM) for compound <b>3</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 4S</a>). Crossover kinases with IC<sub>50</sub> < 1 μM for compound <b>3</b> include CK1α, CK1δ, CK1ε, PKD3, RIPK2, and TNIK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The next step to explore improvement in safety, improvement in comparative kinase inhibition activity, and retention of the H-bond interaction with the hinge with vicinyl aromatic occupancy of the proximal pocket was simplification of the amine substituent of compound <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Simplification was required so that subsequent SAR could explore expansion of the aromatic at R<sup>6</sup> while remaining within the property constraints that pharmacoinformatics identified among CNS drug profiles.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The crystallographic structures revealed exploitable chemical space around R<sup>3</sup> that should retain the key recognition features. The substitution of the piperazinylpyrimidine substituent with methylpiperazine yielded compound <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The use of secondary pharmacology screens revealed that simplification of the amine at R<sup>3</sup> also removed<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> the dose limiting toxicity found in dose range finding studies (increasing maximal tolerated dose in mice from 60 mg/kg for compound <b>3</b> to >200 mg/kg for compound <b>4</b>). While a range of simplified R<sup>3</sup> amines that retained the IC<sub>50</sub> were identified, secondary pharmacology screens revealed that compound <b>4</b> did not solve the perplexing issue<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> that widely used p38αMAPK inhibitors can be good inhibitors of CK1δ. CK1 is a challenging off-target kinase<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> with potential toxicology associations and pharmacodynamics that can overlap those of multikinase p38αMAPK inhibitors. The preference of p38MAPK inhibitors for CK1δ and crossover to other kinome targets also places severe limits on the interpretation of efficacy studies. A logical next step provided by compound <b>4</b> was to explore variation of the amine substituent and screen for selectivity for p38MAPKs vs CK1δ (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, this strategy, exemplified by compounds <b>5</b>–<b>8</b>, generated compounds that retained or improved CK1δ inhibitory activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Nevertheless, these more simplified structures with retention of p38αMAPK inhibitor activity allowed pursuit of vicinal aromatic substituents while staying within the overall multiproperty limits of the approach (MW < 400, log <i>P</i> < 4, PSA ∼ 40).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Hit Compound <b>3</b> to Lead Compound <b>9</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0013.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Footnote: *Primary screen assay linearity 0.01 to 10 μM. Values are the mean ± SD. Values outside linearity are reported as >10 μM.</p></div></div><div></div></div><div class="NLM_p">The crystallographic structures of the human p38αMAPK:fragment and p38αMAPK:hit compound complexes (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) revealed significant unoccupied space within the pocket. Inspection of available structures in the PDB for other kinases also did not reveal a similar pocket in close proximity to the established kinase hinge binding region. The hypothesis that better occupancy of the proximal pocket via aryl substituent diversification could generate additional enhancement of kinase selectivity was explored using CK1δ as an internal control (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), resulting in the delivery of compound <b>9.</b><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The kinase activity screen and the crystal structure of the human p38αMAPK:<b>9</b> complex (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y">4F9Y</a>) demonstrated<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> the feasibility of this approach.</div><div class="NLM_p">Subjecting compound <b>9</b> to kinome-wide, hierarchal, concentration dependent inhibitor screens documented (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) its improved kinome-wide selectivity (within drug target class).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Secondary pharmacology screening for functional GPCR agonist and antagonist activity demonstrated<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> that there was no crossover to this other major CNS drug target class, a concern when molecular recognition is altered by increased lipophilicity. The absence of certain GPCR agonist activities, such as those associated with cardiotoxicity,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> also reduced campaign risk for later stage drug development. Additional in vitro and in vivo pharmacological screens of the lead compound <b>9</b> confirmed drug target engagement and pharmacodynamic biomarkers.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> Compound <b>9</b> was subjected to a final check for function and shown in distinct animal models to have in vivo efficacy.<a onclick="showRef(event, 'ref13 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref17">(13,17)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinome selectivity of lead compound <b>9</b> and candidate compounds <b>10</b> and <b>11</b>. (A) Progression from compound <b>3</b> to compound <b>9</b> improved kinome selectivity to p38αMAPK, p38βMAPK, and atypical p38MAPK (NLK). In parallel with kinome selectivity improvement, crossover activity in GPCR agonist and antagonist cell based screens was removed as was in vivo dose limiting toxicity. (B) Refinement to compounds <b>10</b> and <b>11</b> biased inhibition toward p38αMAPK with retention of overall kinome selectivity, absence of GPCR agonist or antagonist activity, and absence of dose limiting toxicity. Red circles reflect inhibition at specific kinases with IC<sub>50</sub> < 1 μM.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">At this stage of the campaign, compound <b>9</b> delivered a new and more selective p38MAPK inhibitor with in vivo function, had an IC<sub>50</sub> for CK1δ well above the canonical 1 μM mark, and retained activity below 1 μM for p38αMAPK and p38βMAPK.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">From Lead Compound to Candidate</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The crystal structure of the p38αMAPK:<b>9</b> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y">4F9Y</a>; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) forecast as a reasonable next step continued exploration of better pocket occupancy to further enhance kinome selectivity and metabolic stability. A logical extension was testing a 2-naphthyl substituent at R<sup>6</sup>. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compound <b>10</b> yielded an improved compound that also provided some separation of p38αMAPK inhibitor activity from that for p38βMAPK while not allowing CK1δ crossover activity to move below the 1 μM cutoff. The crystal structure of the p38αMAPK:<b>10</b> complex confirmed a more intimate filling of the proximal pocket (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9W">4F9W</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of the p38αMAPK:<b>9</b> and p38αMAPK:<b>10</b> complexes. Shown are the representation and the orientation of (A) compound <b>9</b> and (B) compound <b>10</b> in the kinase active site. Perspective is the same as for compound <b>11</b> in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B. The hydrogen bond interaction of the pyridine ring nitrogen with the amide backbone of the kinase is retained in all structures, and the vicinal naphthyl groups of compounds <b>9</b>–<b>11</b> occupy the proximal hydrophobic pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Lead Compound <b>9</b> to Candidate Compound <b>11</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Footnote: *Activity screen assay linearity from 0.01 to 10 μM. Values are mean ± SD. Values outside linearity, >10 μM. Human liver microsome assay, linear to 60 min.</p></div></div><div></div></div><div class="NLM_p">Secondary pharmacology screens such as liver microsome assays can add drug-related considerations, versus ligand focus, and can alert one to first-pass metabolism related liabilities during refinement. As indicated in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, this secondary pharmacology screen embedded in the SAR efforts revealed that compound <b>10</b> had less than ideal liver microsomal stability. The methylpiperazine once again provided an excellent starting point for the R<sup>3</sup> substituent as it doubled the liver microsome stability time in the context of the 2-naphthylpyridazine scaffold as evidenced by comparison of compound <b>10</b> to compound <b>11</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Additional probing of improvement in metabolic stability potential involved the synthesis and testing of fluorine analogs of the 2-naphthyl substituent. However, there was not a straightforward trend. For example, compounds <b>12</b>–<b>15</b> offered no clear advantage over compound <b>11</b> in terms of liver microsome stability. Surprisingly, compound <b>14</b> lost the metabolic stability seen in compound <b>11</b>. While there was a trend toward greater reduction in p38βMAPK and CK1δ inhibitory activity with other analogs, it sometimes came at the cost of worsening of p38αMAPK inhibitory activity. The results also suggested that the biosteric effect of fluorine might be more in line with localized lipophilic or electronegative effects of fluorine dependent on intermolecular interactions.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Consistent with that hypothesis, introduction of an indoyl analog (compound <b>16</b>) provided a differential effect on kinase crossover with p38βMAPK vs CK1δ. Additional exploration of changes at the R<sup>3</sup> position in the context of 2-naphthyl at the R<sup>6</sup> position (compounds <b>17</b>–<b>20</b>) did not yield advantages in kinase selectivity or liver microsome stability compared to compound <b>11</b>. Therefore, compound <b>11</b> was chosen for further characterization. While not pursued further as part of this study, the trend suggests that future optimization based on strategic introduction of more electronegative atoms in the context of next generation analogs of compound <b>11</b> is worth pursuit for additional separation of kinase crossover to p38βMAPK or CK1δ and potential increase in selective affinity for p38αMAPK.</div><div class="NLM_p last">The more advanced secondary pharmacology screens documented the selectivity of compounds <b>10</b> and <b>11</b> within the kinome drug target class.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Secondary pharmacology screening for functional GPCR agonist and antagonist activity demonstrated that there was no crossover of compounds <b>10</b> and <b>11</b> to this major CNS drug target class.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Secondary pharmacology screens showed compound <b>11</b> had the potential for improved metabolic stability and exposure.</div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Candidate Compound <b>11</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>11</b>, produced by the GMP scheme shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, is a crystalline drug substance. It has good oral bioavailability, selectivity, metabolic stability, safety, and exposure in plasma and brain tissue (key attributes summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>; <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Tables 7S and 8S</a> provide a summary of additional key chemical and physical data for compound <b>11</b> that contributed to its selection<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> as a development candidate.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Production scheme for compound <b>11</b>. The regulatory starting material (RSM) was prepared as previously described.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The intermediate compound was prepared by chlorination of the arylpyridazinone by POCl<sub>3</sub> in acetonitrile (ACN).<a onclick="showRef(event, 'ref13 ref14 ref22'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref22">(13,14,22)</a> The product substance (API) was generated by treatment with 1-methylpiperazine in ethanol. The summary chemical and physical properties, including crystal structure (CCDC deposit numbers 1851508 and 1851509), are in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Tables 8S and 9S</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Exposure of compound <b>11</b> in plasma and brain after oral administration. Oral gavage administration results in comparable profiles for plasma (A) and brain (B). Oral doses (mg/kg): 1.25 (circles), 2.5 (squares), 5 (triangles), 10 (diamonds). Sampling time points (h): 0.25, 0.5, 1, 3, 6, 8, 12. Drug concentrations in biological matrices were determined by LC–MS/MS as described in <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Parameters of Compound <b>11</b> in Rat<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (route)</th><th class="colsep0 rowsep0" align="center">male</th><th class="colsep0 rowsep0" align="center">female</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2 mg/kg (iv)</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 2.07 ± 0.313</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 3.73 ± 0.288</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CL (L h<sup>–1</sup> kg<sup>–1</sup>): 1.46 ± 0.236</td><td class="colsep0 rowsep0" align="left">CL (L h<sup>–1</sup> kg<sup>–1</sup>): 0.677 ± 0.099</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg): 3.57 ± 0.424</td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg): 3.02 ± 0.372</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2 mg/kg (po)</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 3.13 ± 2.25</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 4.71 ± 0.543</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL): 222 ± 69.6</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL): 363 ± 116</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (h·ng/mL): 739 ± 84.8</td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (h·ng/mL): 2035 ± 193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral bioavailability</td><td class="colsep0 rowsep0" align="left">53.0% ± 6.09</td><td class="colsep0 rowsep0" align="left">67.8% ± 6.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6 mg/kg (po)</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 2.87 ± 0.504</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 5.07 ± 0.244</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL): 392 ± 216</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL): 646 ± 98.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (h·ng/mL): 2601 ± 965</td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (h·ng/mL): 6632 ± 949</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg (iv)</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 2.38 ± 0.210</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 3.73 ± 0.676</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CL (L h<sup>–1</sup> kg<sup>–1</sup>): 1.71 ± 0.0512</td><td class="colsep0 rowsep0" align="left">CL (L h<sup>–1</sup> kg<sup>–1</sup>): 0.816 ± 0.206</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg): 4.63 ± 0.365</td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg): 3.76 ± 1.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg (po)</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 3.47 ± 1.26</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h): 4.45 ± 0.383</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL): 649 ± 180</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL): 1203 ± 72.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (h·ng/mL): 3841 ± 152</td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (h·ng/mL): 10615 ± 738</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral bioavailability</td><td class="colsep0 rowsep0" align="left">55.1% ± 2.18</td><td class="colsep0 rowsep0" align="left">70.7% ± 4.92</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values are the mean ± SD.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of Compound <b>11</b> Secondary Pharmacology Screen Outcomes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">screen</th><th class="colsep0 rowsep0" align="center">results</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Kinome-wide off-target (305 kinases)</td><td class="colsep0 rowsep0" align="left"><b>Negative</b> except for p38αMAPK (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Functional GPCR agonist and antagonist (166 GPCRs)</td><td class="colsep0 rowsep0" align="left"><b>Negative</b> (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Panlabs and others (44 targets)</td><td class="colsep0 rowsep0" align="left"><b>Negative</b> (see <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><u class="uu">Enzymes</u>: MAO A/B, acetyl cholinesterase, COX-1, COX-2, PDE3A, PDE4D2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><u class="uu">Receptors</u>: Adenosine A<sub>2A</sub>, adrenergic (α<sub>1A</sub>, α<sub>2A</sub>, β<sub>1</sub>, β<sub>2</sub>), androgen, cannabinoid (CB<sub>1</sub>, CB<sub>2</sub>), GABA<sub>A</sub>, dopamine (D<sub>1</sub>, D<sub>2S</sub>), cholecystokinin CCK<sub>1</sub>, glucocorticoid, histamine (H<sub>1</sub>, H<sub>2</sub>), muscarinic (M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>), NMDA, α4β2 nicotinic acetylcholine, opiate (OP1, OP2, OP3), serotonin (5-HT<sub>1A</sub>, 5- HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>3</sub>), vasopression V<sub>1A</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><u class="uu">Channels</u>: L-type calcium channel, potassium channel ([K<sub>A</sub>], hERG), sodium channel</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><u class="uu">Transporters</u>: Dopamine, norepinephrine, Serotonin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Liver microsome stability</td><td class="colsep0 rowsep0" align="left">Human, <i>T</i><sub>1/2</sub> > 60 min; rat, <i>T</i><sub>1/2</sub> > 40 min (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hepatocyte stability</td><td class="colsep0 rowsep0" align="left">Human, <i>T</i><sub>1/2</sub> > 120 min; dog, <i>T</i><sub>1/2</sub> > 120 min (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP inhibition: (1A2, 2B6, 2D6, 2C8, 2C9, 2C19, 3A4)</td><td class="colsep0 rowsep0" align="left"><b>Negative</b> (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP substrate: (1A2, 2B6, 2D6, 2C8, 2C9, 2C19, 3A4)</td><td class="colsep0 rowsep0" align="left"><b>Negative</b> (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP induction</td><td class="colsep0 rowsep0" align="left"><b>Negative</b> (see <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Permeability, pump substrate status:</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-gp/Caco-2</td><td class="colsep0 rowsep0" align="left">Not substrate/highly permeable (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCRP/MDCK</td><td class="colsep0 rowsep0" align="left">Not substrate/highly permeable (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dose range finding: 14-day daily oral with TK (rat)</td><td class="colsep0 rowsep0" align="left">NOAEL<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> = 125 mg/kg; HED<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> = 20.0 mg/kg (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aged AD KI mouse, oral, single administration: behavior and pathology</td><td class="colsep0 rowsep0" align="left">NOAEL<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> ≥ 250 mg/kg; HED<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> = 20.0 mg/kg (see ref <a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">NOAEL= no observable adverse effect level; HED = human equivalent dose.</p></div></div></div></div><div id="sec1_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Efficacy and Pharmacodynamics of Compound <b>11</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> summarizes the previously described<a onclick="showRef(event, 'ref4 ref14'); return false;" href="javascript:void(0);" class="ref ref4 ref14">(4,14)</a> efficacy and pharmacodynamics of compound <b>11</b> in amyloid-based Alzheimer’s disease (AD) pathophysiology progression models<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> and in autism spectrum disorder (ASD) models.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Compound <b>11</b> Efficacy and Pharmacodynamics</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">experimental system</th><th class="colsep0 rowsep0" align="center">end point</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Efficacy</td><td class="colsep0 rowsep0" align="left">Autism spectrum disorder (ASD) model: SERT Ala56 mouse (ip injection daily for 7 d)</td><td class="colsep0 rowsep0" align="left">MW150 repeat administration mitigates SERT Ala56-mediated 5-HT receptor hypersensitivities and altered social interaction; reverses SERT Ala56-mediated reductions in intestinal motility</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">APP/PS1 transgenic (oral gavage daily for 1–2 mos)</td><td class="colsep0 rowsep0" align="left">Improved performance in contextual fear memory and radial arm water maze (RAWM) with no effect on sensory, motor, and motivational mechanisms; no effects on open field tasks; dose-dependent efficacy at 0.5–2.5 mM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">APP<sup>Nlh/Nlh</sup>/PS1<sup>P264L/P264L</sup> knock-in (KI) (ip injection daily for 14 d)</td><td class="colsep0 rowsep0" align="left">Improved performance in RAWM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Tauopathy model: infusion of synthetic 4R/2N human tau into dorsal hippocampus (single ip injection of MW150)</td><td class="colsep0 rowsep0" align="left">Attenuates defects in associative memory (contextual fear learning paradigm); attenuates defects in short-term spatial memory (RAWM); no effect on sensory, motor, and motivational mechanisms; no effects on open field tasks</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Tauopathy model: rTg4510 (human tau, P301L mutation) (oral gavage daily for 45 d)</td><td class="colsep0 rowsep0" align="left">Attenuates defects in associative memory (contextual fear learning paradigm); attenuates defects in short-term spatial memory (RAWM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pharmacodynamic end points</td><td class="colsep0 rowsep0" align="left">Autism spectrum disorder (ASD) model: SERT Ala56 mouse</td><td class="colsep0 rowsep0" align="left">MW150 repeat administration normalizes 5-HT clearance in SERT Ala56 mice; no effects on SERT protein levels; no effects on brain 5-HT levels or turnover</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Anisomycin-treated CHO cell line</td><td class="colsep0 rowsep0" align="left">Decrease in anisomycin-induced 5-HT uptake</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">LPS treated BV2 microglia cell line</td><td class="colsep0 rowsep0" align="left">Endogenous kinase inhibition measuring phosphorylated substrate pMK2: IC<sub>50</sub> = 332 nM. Inhibition of IL-1β overproduction: IC<sub>50</sub> = 936 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BV2 microglia cell line</td><td class="colsep0 rowsep0" align="left">No effect on cell proliferation, migration, or phagocytosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">APP<sup>Nlh/Nlh</sup>/PS1<sup>P264L/P264L</sup> KI</td><td class="colsep0 rowsep0" align="left">Cortex IL-1β and TNFα levels decreased in mice showing improved performance in RAWM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">APP/PS1 transgenic</td><td class="colsep0 rowsep0" align="left">No effect on Aβ plaque burden</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">APP<sup>Nlh/Nlh</sup>/PS1<sup>P264L/P264L</sup> KI</td><td class="colsep0 rowsep0" align="left">No effect on Aβ plaque levels or volume; no effect on levels of PBS-soluble or formic acid-soluble Aβ40 or Aβ42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">p38αMAPK<sup>T106M</sup> KI</td><td class="colsep0 rowsep0" align="left">Cortex IL-1β and TNFα levels did not change with MW150 treatment of drug resistant mice</td></tr></tbody></table></div></div><div class="NLM_p">In two distinct transgenic and knock-in amyloid based models there is efficacy as measured by molecular end points and quantitative behavioral assays.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Mechanism based pharmacodynamic end points are also demonstrated. Importantly, the efficacy and pharmacodynamics are evident in the absence of detectable effects on the amyloid pathway or plaques.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">The potential of p38αMAPK as a therapeutic target in neuropsychiatric disorders is provided by outcomes of compound <b>11</b> testing in genetics-based animal models of ASD susceptibility.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> For example, a specific type of ASD involving alterations in p38αMAPK mediated serotonin transporter (SERT) activity was reversed by compound <b>11</b> treatment of adult mice. The phenotypes generated by compound <b>11</b> treatment mimic the behavioral and biochemical dysregulation of ASD in patients with genetic alterations in SERT.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> For example, compound <b>11</b> showed efficacy as measured by end points such as altered social interactions and gastrointestinal disturbances due to the SERT point mutation. Further, clinically translatable pharmacodynamic end points were observed in treated animals, such as normalization of disease associated serotonemia.</div><div class="NLM_p">To explore the broader potential of compound <b>11</b> in non-amyloid dementia models, we tested efficacy in two distinct tauopathy animal models. The oligomeric tau infusion model induces reproducible deficits in spatial and associative memory performance, which are attenuated by treatment with compound <b>11</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The reversible transgenic (rTg4510) mouse model overexpresses a human, mutant tau form (P301L) known to lead to dementia, with animals developing age-related cognitive impairment, neurofibrillary tangles, and neuronal loss. Repeat administration of compound <b>11</b> treatment normalized cognitive and behavioral deficits (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B) and mitigated brain tissue degeneration (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C,D). The improved outcomes in cognitive function with two different tauopathy models are consistent with the potential utility of compound <b>11</b> for additional neurodegenerative therapeutic indications such as Lewy body dementia, age-related tauopathy, and progressive supranuclear palsy.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>11</b> treatment rescues tau-induced memory impairment. The effects of compound <b>11</b> administration on hippocampus-dependent reference memory in the radial arm water maze (RAWM) and contextual fear memory in the contextual fear conditioning (CFC) assay were tested. (A) Human tau oligomer infusion (white triangles) into mice brains creates short-term memory impairment as shown by the significantly greater numbers of errors in the RAWM test compared to control, vehicle-infused mice (black circles) (two-way ANOVA, <i>p</i> < 0.01). Compound <b>11</b> administration (light gray diamonds) to the tau-infused animals (5 mg/kg ip, 20 min prior to start of testing) attenuates memory impairment (<i>p</i> < 0.05). Compound <b>11</b> administration in control, vehicle-infused mice (dark gray squares), had no effect. (B) Fear conditioning was assessed by exposing mice to a mild shock and then reassessed 24 h later to gauge “freezing” behavior. Tau-infused mice (white bar) experience reduced rates of freezing relative to control mice (“vehicle”; black bar) or control mice administered compound <b>11</b> (dark gray bar). Compound <b>11</b> administration in tau-infused mice (light gray bar) significantly increases freezing rates, demonstrating protection against tau-related memory impairment (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>11</b> treatment rescues cognitive deficits and cortex size in tau transgenic animal model. (A) Compound <b>11</b> treatment of rTg4510 mice (white triangles) results in a reduction in errors in the RAWM cognitive function assay compared to vehicle-treated rTg4510 animals (gray squares). Outcomes for compound <b>11</b> treated mice are comparable to disease state control mice (black circles; doxy-treated rTg4510 mice). (B) Contextual fear conditioning shows that compound <b>11</b> treatment (white bar) rescues the freezing deficit seen in rTg4510 mice treated with vehicle (gray bar), reaching levels similar to the control doxy-treated rTg4510 animals (black bar). (C) Vehicle-treated rTg4510 mice (gray bar) show reduced cerebral cortex size compared to control doxy-treated mice (black bar), and compound <b>11</b> treatment of rTg4510 mice (white bar) prevents the cortical tissue loss (<i>t</i> test: <i>p</i> < 0.05 vs Tg4510 vehicle). (D) Reductions in hippocampal size also manifest in the rTg4510 mice (gray bar) compared to the doxy mice (black bar). Compound <b>11</b> treatment of the rTg4510 mice (white bar) shows a trend toward rescuing the size deficit but does not reach statistical significance (<i>p</i> = 0.104 comparing compound <b>11</b>-treated rTg4510 mice vs vehicle treated rTg4510 mice).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compound <b>11</b> (MW150) is a novel, CNS-penetrant, pharmacologically selective p38αMAPK inhibitor clinical candidate for neurological disorders. The discovery approach involved the integrated use of high resolution crystallography of p38αMAPK:ligand complexes, pharmacoinformatics-driven novel compound design, and outcomes from secondary pharmacology screens as progressive Go or No Go criteria. Disease-relevant efficacy screens of best-in-class lead compounds and the drug candidate provided preclinical proof-of-concept for attenuation of disease progression and the biological rationale for clinical development. The overall approach provided a focused route to high value lead compounds. The small number of novel compounds needed to arrive at a viable clinical candidate is characteristic of fragment-based approaches, especially when the process is driven by safety and pharmacodynamic considerations inherent in secondary pharmacology outcomes. Treatment with compounds <b>9</b>–<b>11</b> or cell-selective genetic knock-down of p38αMAPK documents that inhibition of p38αMAPK can mitigate detrimental proinflammatory cytokine overproduction and neuronal/synaptic damage in a variety of animal models,<a onclick="showRef(event, 'ref4 ref13 ref14 ref15 ref16 ref17 ref19 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref4 ref13 ref14 ref15 ref16 ref17 ref19 ref30 ref31">(4,13−17,19,30,31)</a> outcomes consistent with clinical observations and hypotheses. Overall, compound <b>11</b>’s selectivity, comparative lack of prevailing off-target liabilities, and derisked pharmacology, including safety potential, make it attractive for potential use as a monotherapy or as a component of a therapeutic combination regimen for complex CNS disorders.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General</h3><div class="NLM_p">All NMR spectra were recorded on Bruker Avance III 500 MHz system equipped with a DCH CryoProbe and Mercury 300 MHz FT-NMR spectrometer. Data are reported in the following order: chemical shifts δ values in ppm downfield with the deuterated solvents are reported in parts per million (ppm) using tetramethylsilane (TMS) as an internal standard (signal = 0 ppm) (s = singlet, d = doublet, t = triplet, br = broad, m = multiplate), integration, coupling constant (Hz). LC/MS data were determined with a Waters Alliance 2695 HPLC/MS (Waters Symmetry C18, 4.6 mm × 75 mm, 3.5 μm) with a 2996 diode array detector from 210–400 nm; the solvent system is 5–95% ACN in water (0.1% TFA) over 9 min using a linear gradient, and retention times are in minutes. Accurate-mass/high-resolution mass spectrometry (HRMS) analysis was performed using an Agilent 6210A LC-TOF mass spectrometer in positive ion mode (ambient temperature). Purity of all final compounds was determined by HPLC (Dionex System, Sunnyvale, CA), with UVD170U ultraviolet detector and P680 pump. The column was a Phenomenex (Torrance, CA) Luna C18, 5 μm particle size (250 mm × 2.0 mm), supported by Phenomenex Security Guard cartridge kit C18 (4.0 mm × 2.0 mm) at a flow rate of 0.2 mL/min and using a mobile phase composed of 0.1% (v/v) formic acid (Fluka) in water as solvent A and 80% acetonitrile, 0.08% formic acid/water as solvent B (gradient from 0% to 100% B, 15 min; isocratic 22 min). Compounds were analyzed at ∼0.50 μg level, and peak quantification was performed based upon relative area% absorption at 260 nm. Purity of all compounds was determined to be >95% by HPLC. Unless otherwise noted, all synthesis was carried out in reagent grade solvents and was used as purchased without further purification unless otherwise stated. Compound 11 crystal structure was determined as previously described .<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a></div><div class="NLM_p">Compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> were synthesized using synthetic <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a> below. Details of preparation and characterization for key compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> are found in prior literature.<a onclick="showRef(event, 'ref12 ref13 ref14 ref22'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref22">(12−14,22)</a> Analytical data for additional compounds are summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 6S</a>.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>3</b>–<b>8</b>, <b>11</b>, and <b>17</b>–<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-butanol/ethanol, reflux, 15–48 h at 110–130 °C.</p></p></figure><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>9</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-butanol, R<sup>3</sup>-amiine, 120 °C; (b) R<sup>6</sup>-boronic acid, DME/water, Na<sub>2</sub>CO<sub>3</sub>, tetrakis(triphenylphosphine)palladium(0), 110 °C .</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, starting materials (previously described<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> or commercially available) were taken in 1-butanol and reacted with an approximate (3–10) mole excess of the respective amine, the reaction mixture was cooled to ambient temperature, deionized water added, and the mixture subjected to repeat extraction with dichloromethane. The organic layers were taken to drying with anhydrous sodium sulfate and concentration in vacuo. The final products were purified by silica gel column chromatography using volatile solvents for elution and final processing.</div><div class="NLM_p last">In <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, amination was done using 3,6-dichloro-4-(pyridin-4-yl)pyridazine and workup, organic phase extraction, and purification were done as in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> in combination with Suzuki reaction using boronic acid and tetrakis(triphenylphosphine)palladium(0) to yield compounds <b>9</b>–<b>16</b>.</div></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 3-Phenyl-4-(pyridin-4-yl)-6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine (MW069a) (<b>3</b>)</h3><div class="NLM_p last">Compound 3 was prepared following <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> above as previously described<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> using discovery chemistry and starting with 6-chloro-3-phenyl-4-(pyridin-4-yl)pyridazineas previously described<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> using a 5-fold mole excess of 2-(piperazin-1-yl)pyrimidine in the <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> protocol to give compound <b>3</b> as pale yellowish powder in 62% yield (gravimetric). Purity of >98% was determined by HPLC. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.58–8.57 (m, 2H), 8.36–8.33 (dd, <i>J</i> = 1.4, 4.75 Hz, 2H), 7.35–7.25 (m, 5H), 7.15–7.13 (dd, <i>J</i> = 1.65, 4.35 Hz, 2H), 6.88 (s, 1H), 6.57–6.35 (dd, <i>J</i> = 1.4, 4.75 Hz, 1H), 4.05–4.02 (dd, <i>J</i> = 3.5, 5.1 Hz, 4H), 3.89–3.87 (dd, <i>J</i> = 3.15, 5.4 Hz, 4H). ESI-MS <i>m</i>/<i>z</i>: 396.3 [M + 1]<sup>+</sup>. HRMS calculated for C<sub>23</sub>H<sub>21</sub>N<sub>7</sub> 395.18584, found 395.18542.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>,<i>N</i>-Dimethyl-6-(naphthalen-1-yl)-5-(pyridin-4-yl)pyridazin-3-amine (MW181) (<b>9</b>)</h3><div class="NLM_p last">Compound <b>9</b> was prepared following <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> above. Amination was done using 3,6-dichloro-4-(pyridin-4-yl)pyridazine using a 6-fold mole of 40% dimethylamine in combination with Suzuki reaction using 1-naphthylboronic acid and tetrakis(triphenylphosphine)palladium(0) (1:0.09) as described previously<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> to give compound <b>9</b> as a light yellow crystals in 56% yield (gravimetric). Purity of >98% was determined by HPLC. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ: 8.34 (dd, <i>J</i> = 1.65, 4.6 Hz, 2H), 7.82 (dd, <i>J</i> = 1.3, 8.7 Hz, 2H), 7.68 (dd, <i>J</i> = 1.3, 8.8 Hz, 1H), 7. 43–7.32 (m, 3H), 7.28 (dd, <i>J</i> = 1.25, 7.0 Hz, 1H), 6.99–6.97 (m, 2H), 6.84 (s, 1H), 3.32 (s, 6H). HRMS calculated for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub> 326.15315, found 326.1526.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 6-(4-Methylpiperazin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine (MW150) (<b>11</b>)</h3><div class="NLM_p">Compound <b>11</b> was prepared following both <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Following the same method as above for compound <b>9</b>, amination was done using 3,6-dichloro-4-(pyridin-4-yl)pyridazine as in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> using a 5-fold mole of 1-methylpiperazine in combination with Suzuki reaction using 2-naphthylboronic acid and tetrakis(triphenylphosphine)palladium(0) (1:0.09) as described previously<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> to give compound <b>11</b> as a pale yellow crystals in 68% yield (gravimetric). Purity of >97% was determined by HPLC.</div><div class="NLM_p last">Large scale production of compound <b>11</b> was made as in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> starting with 6-chloro-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine as previously described<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> using a 5 fold mole excess of 1-methylpiperazine in the protocol to give compound <b>11</b> as a pale yellow solid in 92% yield (gravimetric). Purity of >97% was determined by HPLC. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.55–8.53 (dd, <i>J</i> = 1.7, 4.35 Hz, 2H), 7.94 (d, <i>J</i> = 1.9 Hz, 1H), 7.80–7.78 (dd, <i>J</i> = 1.85, 7.45 Hz, 1H), 7.73–7.69 (m, 2H), 7.49–7.43 (m, 2H), 7.36–7.34 (m, 1H), 7.15–7.13 (dd, <i>J</i> = 1.7, 4.25 Hz, 2H), 6.87 (s, 1H), 3.84 (t, <i>J</i> = 4.85, 5.1 Hz, 4H), 2.63 (t, <i>J</i> = 4.85, 4.95 Hz, 4H), 2.40 (s, 3H); HRMS calculated for C<sub>24</sub>H<sub>23</sub>N<sub>5</sub> 381.19535, found 381.19603.</div></div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Pharmacology Screens. Kinome-Wide Inhibitor Screening</h3><div class="NLM_p last">The hierarchal screening was done as previously described.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Briefly, the screen was done using Eurofins kinase profiler test system that includes 299–412 mammalian kinases representative of all major kinome branches as well as isoforms of individual families. The list of protein and lipid kinases and their NCBI Entrez accession numbers are provided in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 3S</a>. The initial profiling was performed at inhibitor concentrations of 10 or 20 μM based on previous activity analysis. Preliminary hits were validated as true or false positive hits by a concentration-dependent determination of an IC<sub>50</sub> value using a standardized assay protocol. An apparent <i>K</i><sub>i</sub> value is determined for any kinase for which the inhibitor exhibits IC<sub>50</sub> < 1 μM.</div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Large Scale Functional Screen for GPCR Agonist and Antagonist Activity</h3><div class="NLM_p last">As described previously,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> a hierarchical approach was used to test compounds <b>9</b>–<b>11</b> (10–12.5 μM) for any off-target activity with the largest known family of small molecule drug targets, G-protein-coupled receptors (GPCRs). The Eurofins GPCR profiler test system employs a cell-based functional screen and a real-time calcium flux FLIPR assay on a panel of 166 GPCRs to detect both antagonists and agonists.</div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> PanLab Screens</h3><div class="NLM_p last">Compound <b>11</b> was tested at 10 μM against a panel of 44 safety targets in a commercial screen (<a href="http://www.eurofinsdiscoveryservices.com" class="extLink">www.eurofinsdiscoveryservices.com</a>) that includes both enzymatic and radioligand binding assays. Several targets in the panel are associated with in vivo adverse drug reactions. Biochemical assay results were presented as the percent inhibition of specific binding or activity. Reference standards were run as an integral part of each assay to ensure the validity of the results obtained.</div></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Liver Microsome Stability</h3><div class="NLM_p last">Human and rat liver microsome stability screens were done as previously described<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> using a standard microsome buffer containing test compounds at 1 μM. The reactions were terminated at time points of 15, 30, 45, and 60 min, samples were processed, and analysis was done by LC–MS/MS to monitor parent compound. The peak area response ratio to internal standard at each time point was compared to the response ratio at time 0 to determine the percent remaining. The assay was linear over 60 min with <i>r</i><sup>2</sup> = 0.969–1.00. The half-life was calculated based on <i>t</i><sub>1/2</sub> = 0.693/<i>k</i>, where <i>k</i> is the elimination rate constant based on the results of nonlinear fitting. The intrinsic clearance (CL<sub>int</sub>) was calculated based on CL<sub>int</sub> = <i>k</i>/<i>D</i>, where <i>k</i> is the elimination rate constant and <i>D</i> is protein concentration.</div></div><div id="sec3_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Hepatocyte Stability</h3><div class="NLM_p last">Compound <b>11</b> was tested for stability in mixed gender human cryopreserved hepatocytes and male beagle dog cryopreserved hepatocytes using a validated protocol at CiTox Lab (Hungary). Compound <b>11</b> (1 μM) was added into the hepatocyte suspension (1.5 × 10<sup>6</sup> cells/mL), and reaction mix aliquots were withdrawn at 0, 15, 30, 60, and 120 min. Reactions were terminated and protein was precipitated by adding three volumes of ice-cold acetonitrile (ACN) containing internal standard. After centrifugation, an aliquot of the supernatant was analyzed by LC–MS/MS. The peak area response ratio (PARR) to internal standard was compared to the PARR at time 0 to determine the percent remaining at each time point. Half-life and clearance values were calculated using GraphPad software, fitting to a single phase exponential decay equation. Positive controls were performed in parallel to confirm the activity of the hepatocytes.</div></div><div id="sec3_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> CYP Inhibitor Screen</h3><div class="NLM_p last">Compounds were screened as potential inhibitors of CYPs 1A2, 2B6, 2D6, 2C8, 2C9, 2C19, and 3A4<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> at a final concentration of 10 μM over 10–30 min at 37 °C in the presence of a CYP-specific probe substrate (at concentration approximating its <i>K</i><sub>m</sub> value) and, after reaction termination, metabolites monitored by LC–MS/MS. Positive controls were performed in parallel using a known inhibitor of the individual CYP isoform. Percent inhibition was calculated as the percent of control metabolite formed in the reaction mix with test compound relative to percent of metabolite formed in reaction without the test compound.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_m001.gif" alt="" id="_i27" /></img></span>where PARR is the peak area response ratio of analyte to internal standard.</div></div><div id="sec3_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> CYP Substrate Status</h3><div class="NLM_p last">Compounds at a final concentration of 0.1 μM were screened as potential substrates for the CYPs 1A2, 2B6, 2D6, 2C8, 2C9, 2C19, and 3A4.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><i>T</i><sub>1/2</sub> was estimated from the slope of the linear portion of the curve for percentage of remaining parent compound versus time assuming first order kinetics. Substrate stability, expressed as percent of the parent compound remaining, was calculated by comparing the peak area of the compound at the time point relative to that at time 0. A reference compound specific for each CYP was run in parallel. The half-life (<i>T</i><sub>1/2</sub>) was estimated from the slope of the initial linear range of the logarithmic curve of compound remaining (%) vs time assuming the first-order kinetics.</div></div><div id="sec3_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> CYP Induction</h3><div class="NLM_p last">Primary hepatocyte cultures from rats, dogs, and humans were incubated with compound <b>11</b> at six concentrations ranging from 0.5 to 50 μM (<i>N</i> = 3) for 48 h, followed by extraction of total RNA and PCR-driven synthesis of cDNA using probes for rat CYP1A2, CYP2B1, and CYP3A1; dog CYP1A2, CYP2B11, and CYP3A12; and human CYP1A2, CYP2B6, and CYP3A4. The induction potential of compound <b>11</b> was assessed by comparing mRNA expression in cells treated with 0.1% DMSO (control), positive control, and compound <b>11</b>. The potential for drug–drug interactions was assessed by comparing the expression of mRNA coding for the three human cytochromes with expected free <i>C</i><sub>max</sub> concentration in human subjects at pharmacologically relevant doses.</div></div><div id="sec3_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Permeability and Efflux Pump Substrate Status</h3><div class="NLM_p last">Cell permeability and efflux pump substrate status tests were done at a final compound concentration of 5 μM in the Caco-2/P-gp and MDCK/BCRP screening systems as previously described.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Permeation and concentration of inhibitor on both apical side (A → B) and basolateral side (B → A) were determined by LC–MS/MS. The apparent permeability, <i>P</i><sub>app</sub> (10<sup>–6</sup> cm s<sup>–1</sup>), was calculated as follows: <i>P</i><sub>app</sub> = (d<i>C</i><sub>r</sub>/d<i>t</i>) × <i>V</i><sub>r</sub>/(<i>A</i> × <i>C</i><sub>A</sub>). Substrate status was determined by measuring the effect of a specific pump inhibitor (1 μM or 10 μM) on the bidirectional flux. The compound was considered a nonsubstrate if the efflux ratio of <i>P</i><sub>app</sub>(A→B)/<i>P</i><sub>app</sub>(B→A) is <2.0.</div></div><div id="sec3_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Dose Range Finding Screen with Toxicokinetics</h3><div class="NLM_p last">Compound <b>11</b> was administered orally once a day for 14 days to male and female Sprague Dawley rats. Blood samples were collected up to 24 h after dosing on days 1 and 14, and concentrations were determined by LC–MS/MS. Pharmacokinetic parameters were calculated using WinNonlin. NOAEL for compound <b>11</b> was the highest dose tested (125 mg/kg).</div></div><div id="sec3_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Aged Wild Type and AD-Model Mouse Toxicity Screen</h3><div class="NLM_p last">Compound <b>11</b> was administered at 250 mg/kg, 100× efficacy dose, to 11-month-old APP/PS1 knock-in (KI) mice and wild-type (WT) control animals. Observed signs for toxicity included palpebral closure, abnormal lacrimation (tears), excessive defecation or urination, gait disturbances, and tremors or seizures. Animals were euthanized for liver, brain, and serum harvest at 48 h after administration. No drug-related abnormalities were observed in the liver tissue in either WT or APP/PS1 KI mice.</div></div><div id="sec3_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Oral Bioavailability Screen</h3><div class="NLM_p last">Compound <b>11</b> was administered by oral gavage to male and female Sprague Dawley rats at 2, 6, and 10 mg/kg and by iv administration at 2 and 10 mg/kg. Blood samples were collected up to 24 h postdose and plasma concentrations determined by LC–MS/MS. Pharmacokinetic parameters were calculated using Phoenix WinNonlin.</div></div><div id="sec3_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Effects of Compound <b>11</b> in Tauopathy Animal Models</h3><div class="NLM_p last">All protocols involving mice were approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University, New York, NY. C57BL/6J and rTg4510 mice and their littermates were obtained from breeding colonies at Columbia University. Both male and female mice were used, and equal gender distribution was used when possible. All animal experiments and data analyses were done by investigators who were blinded to the experimental groups.</div></div><div id="sec3_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Cognitive Behavior Testing</h3><div class="NLM_p last">Mice were tested in the 2-day radial arm water maze (RAWM) test for reference memory impairment as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> As controls for these experiments, visible platform testing was conducted to exclude that visual, motor, or motivation deficits affect the mouse performance. Mice were also tested in a contextual fear conditioning (CFC) test as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Controls for these experiments included a threshold assessment test to check sensory perception of electric shock, and the open-field test to evaluate exploratory behavior. For more details of these behavior tests, see Fiorito et al.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec3_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Oligomeric Tau Infusion Model</h3><div class="NLM_p last">Preparation of recombinant tau and tau oligomers was done as previously described.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Oligomeric tau (500 nM) or vehicle was infused via bilateral cannulas into the dorsal mouse hippocampi of wild-type (WT) C57Bl/6 mice. Infusion solutions were diluted in a final volume of 1 μL and infused over 1 min bilaterally (one injection, 20 min prior to testing for fear conditioning, and 20 min prior to the first and sixth sessions for RAWM). MW150 (5 mg/kg) or saline vehicle was administered by intraperitoneal (ip) injection 20 min prior to testing for fear conditioning or prior to the first and sixth sessions of RAWM.</div></div><div id="sec3_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Transgenic rTg4510 Model</h3><div class="NLM_p last">Adult (3 month old) rTg4510 mice or rTg4510 mice that had been administered doxycycline to turn off tau expression (control mice) were treated with vehicle or MW150 (2.5 mg/kg, orally, every other day) for 45 days. Mice were then subjected to behavior testing in RAWM and CFC.</div></div><div id="sec3_2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Measurement of Brain Tissue Size</h3><div class="NLM_p last">Following behavioral studies, mice were perfused PBS. Brains were removed, split sagittally into two hemispheres along the midline, and immersion-fixed in 4% paraformaldehyde (PFA). Brain size was determined in blind using separate delineation of the regions of interest, the cerebral cortex and the hippocampus.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00058" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00058" class="ext-link">10.1021/acs.jmedchem.9b00058</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Tables 1S–8S listing clinical trials of previous p38MAPK inhibitors, SMILES for compounds mentioned in this article, accession numbers and summary data for protein kinases and GPCR tested as part of secondary pharmacology, X-ray crystal structure and additional characterizations of the GMP drug substance (API) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf">jm9b00058_si_001.pdf (3.9 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes for structures of p38αMAPK:compound complexes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a> (p38αMAPK:<b>1</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a> (p38αMAPK:<b>3</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y">4F9Y</a> (p38αMAPK:<b>9</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9W">4F9W</a> (p38αMAPK:<b>10</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C">4R3C</a> (p38αMAPK:<b>11</b> (MW150)); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2">4FA2</a> (p38αMAPK:SB239063).</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00058" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">D. Martin Watterson</span> - <span class="hlFld-Affiliation affiliation">Northwestern
University, 320 East Superior Street, Chicago, Illinois 60611, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7605-5866" title="Orcid link">http://orcid.org/0000-0001-7605-5866</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d4b0fab9faa3b5a0a0b1a6a7bbba94b3b9b5bdb8fab7bbb9"><span class="__cf_email__" data-cfemail="21450f4c0f564055554453524e4f61464c40484d0f424e4c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saktimayee
M. Roy</span> - <span class="hlFld-Affiliation affiliation">Northwestern
University, 320 East Superior Street, Chicago, Illinois 60611, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Minasov</span> - <span class="hlFld-Affiliation affiliation">Northwestern
University, 320 East Superior Street, Chicago, Illinois 60611, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ottavio Arancio</span> - <span class="hlFld-Affiliation affiliation">Columbia
University, New York, New York 10032, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6335-164X" title="Orcid link">http://orcid.org/0000-0001-6335-164X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura W. Chico</span> - <span class="hlFld-Affiliation affiliation">Northwestern
University, 320 East Superior Street, Chicago, Illinois 60611, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda J. Van Eldik</span> - <span class="hlFld-Affiliation affiliation">University
of Kentucky, Lexington, Kentucky 40536, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wayne F. Anderson</span> - <span class="hlFld-Affiliation affiliation">Northwestern
University, 320 East Superior Street, Chicago, Illinois 60611, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4181-8127" title="Orcid link">http://orcid.org/0000-0003-4181-8127</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey C. Pelletier</span> - <span class="hlFld-Affiliation affiliation">Northwestern
University, 320 East Superior Street, Chicago, Illinois 60611, United
States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">CCDC deposit numbers for compound <b>11</b> (MW150) are 1851508 and 1851509.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was supported in part by NIH Awards U01AG043415, R01NS056051, R01AG031311, and R01NS093920 as well as ADDF Award 261108. We thank Dr. Christos D. Malliakas for his assistance with crystallographic structure and physical property studies of compound <b>11</b> and James Schavocky for his assistance and help with manuscript preparation.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">API</td><td class="NLM_def"><p class="first last">active pharmaceutical ingredient</p></td></tr><tr><td class="NLM_term">ASD</td><td class="NLM_def"><p class="first last">autism spectrum disorder</p></td></tr><tr><td class="NLM_term">CK1δ</td><td class="NLM_def"><p class="first last">casein kinase 1δ</p></td></tr><tr><td class="NLM_term">GMP</td><td class="NLM_def"><p class="first last">good manufacturing practice</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">ICH</td><td class="NLM_def"><p class="first last">International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use</p></td></tr><tr><td class="NLM_term">KI</td><td class="NLM_def"><p class="first last">knock-in</p></td></tr><tr><td class="NLM_term">MW150</td><td class="NLM_def"><p class="first last">MW01-18-150SRM</p></td></tr><tr><td class="NLM_term">PARR</td><td class="NLM_def"><p class="first last">peak area response ratio</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barres, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B.</span></span> <span> </span><span class="NLM_article-title">Do Glia Drive Synaptic and Cognitive Impairment in Disease?</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1038/nn.4142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnn.4142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=26505565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=1539-1545&author=W.+S.+Chungauthor=C.+A.+Welshauthor=B.+A.+Barresauthor=B.+Stevens&title=Do+Glia+Drive+Synaptic+and+Cognitive+Impairment+in+Disease%3F&doi=10.1038%2Fnn.4142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Do glia drive synaptic and cognitive impairment in disease?</span></div><div class="casAuthors">Chung, Won-Suk; Welsh, Christina A.; Barres, Ben A.; Stevens, Beth</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1539-1545</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Synaptic dysfunction is a hallmark of many neurodegenerative and psychiatric brain disorders, yet we know little about the mechanisms that underlie synaptic vulnerability.  Although neuroinflammation and reactive gliosis are prominent in virtually every CNS disease, glia are largely viewed as passive responders to neuronal damage rather than drivers of synaptic dysfunction.  This perspective is changing with the growing realization that glia actively signal with neurons and influence synaptic development, transmission and plasticity through an array of secreted and contact-dependent signals.  We propose that disruptions in neuron-glia signaling contribute to synaptic and cognitive impairment in disease.  Illuminating the mechanisms by which glia influence synapse function may lead to the development of new therapies and biomarkers for synaptic dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkpLYG_8HG6rVg90H21EOLACvtfcHk0ljC2saBHhc8hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsrjL&md5=639d69e48e525d53d6b4bad3ecd81786</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnn.4142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.4142%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DW.%2BS.%26aulast%3DWelsh%26aufirst%3DC.%2BA.%26aulast%3DBarres%26aufirst%3DB.%2BA.%26aulast%3DStevens%26aufirst%3DB.%26atitle%3DDo%2520Glia%2520Drive%2520Synaptic%2520and%2520Cognitive%2520Impairment%2520in%2520Disease%253F%26jtitle%3DNat.%2520Neurosci.%26date%3D2015%26volume%3D18%26spage%3D1539%26epage%3D1545%26doi%3D10.1038%2Fnn.4142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudy, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsberger, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. N.</span></span> <span> </span><span class="NLM_article-title">The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease</span>. <i>Aging Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.14336/AD.2014.0423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.14336%2FAD.2014.0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=25821641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnpt1WrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=131-148&author=C.+C.+Rudyauthor=H.+C.+Hunsbergerauthor=D.+S.+Weitznerauthor=M.+N.+Reed&title=The+Role+of+the+Tripartite+Glutamatergic+Synapse+in+the+Pathophysiology+of+Alzheimer%E2%80%99s+Disease&doi=10.14336%2FAD.2014.0423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease</span></div><div class="casAuthors">Rudy Carolyn C; Hunsberger Holly C; Weitzner Daniel S; Reed Miranda N</div><div class="citationInfo"><span class="NLM_cas:title">Aging and disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-48</span>
        ISSN:<span class="NLM_cas:issn">2152-5250</span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is the most common form of dementia in individuals over 65 years of age and is characterized by accumulation of beta-amyloid (Aβ) and tau.  Both Aβ and tau alter synaptic plasticity, leading to synapse loss, neural network dysfunction, and eventually neuron loss.  However, the exact mechanism by which these proteins cause neurodegeneration is still not clear.  A growing body of evidence suggests perturbations in the glutamatergic tripartite synapse, comprised of a presynaptic terminal, a postsynaptic spine, and an astrocytic process, may underlie the pathogenic mechanisms of AD.  Glutamate is the primary excitatory neurotransmitter in the brain and plays an important role in learning and memory, but alterations in glutamatergic signaling can lead to excitotoxicity.  This review discusses the ways in which both beta-amyloid (Aβ) and tau act alone and in concert to perturb synaptic functioning of the tripartite synapse, including alterations in glutamate release, astrocytic uptake, and receptor signaling.  Particular emphasis is given to the role of N-methyl-D-aspartate (NMDA) as a possible convergence point for Aβ and tau toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRm5-JqzaQwHP6AExegM5LLfW6udTcc2eYAbDDQSGlmHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnpt1WrtQ%253D%253D&md5=daeca277592e2a6349610b8c0ca9442e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.14336%2FAD.2014.0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14336%252FAD.2014.0423%26sid%3Dliteratum%253Aachs%26aulast%3DRudy%26aufirst%3DC.%2BC.%26aulast%3DHunsberger%26aufirst%3DH.%2BC.%26aulast%3DWeitzner%26aufirst%3DD.%2BS.%26aulast%3DReed%26aufirst%3DM.%2BN.%26atitle%3DThe%2520Role%2520of%2520the%2520Tripartite%2520Glutamatergic%2520Synapse%2520in%2520the%2520Pathophysiology%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAging%2520Dis.%26date%3D2015%26volume%3D6%26spage%3D131%26epage%3D148%26doi%3D10.14336%2FAD.2014.0423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huentelman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siniard, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Both, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richholt, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balak, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigio, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyer, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesulam, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogalski, E. J.</span></span> <span> </span><span class="NLM_article-title">Associations of MAP2K3 Gene Variants with Superior Memory in SuperAgers</span>. <i>Front. Aging Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">155</span>, <span class="refDoi"> DOI: 10.3389/fnagi.2018.00155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.3389%2Ffnagi.2018.00155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=29896098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbms1ygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=155&author=M.+J.+Huentelmanauthor=I.+S.+Pirasauthor=A.+L.+Siniardauthor=M.+D.+De+Bothauthor=R.+F.+Richholtauthor=C.+D.+Balakauthor=P.+Jamshidiauthor=E.+H.+Bigioauthor=S.+Weintraubauthor=E.+T.+Loyerauthor=M.+M.+Mesulamauthor=C.+Geulaauthor=E.+J.+Rogalski&title=Associations+of+MAP2K3+Gene+Variants+with+Superior+Memory+in+SuperAgers&doi=10.3389%2Ffnagi.2018.00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers</span></div><div class="casAuthors">Huentelman Matthew J; Piras Ignazio S; Siniard Ashley L; De Both Matthew D; Richholt Ryan F; Balak Chris D; Jamshidi Pouya; Bigio Eileen H; Weintraub Sandra; Loyer Emmaleigh T; Mesulam M-Marsel; Geula Changiz; Rogalski Emily J; Bigio Eileen H; Weintraub Sandra; Rogalski Emily J; Mesulam M-Marsel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in aging neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155</span>
        ISSN:<span class="NLM_cas:issn">1663-4365</span>.
    </div><div class="casAbstract">Introduction: SuperAgers are adults age 80+ with episodic memory performance that is at least as good as that of average middle-aged adults.  Understanding the biological determinants of SuperAging may have relevance to preventing age-related cognitive decline and dementia.  This study aimed to identify associations between genetic variations and the SuperAging phenotype using Whole Exome Sequencing (WES).  Methods: Sequence Kernel Association Combined (SKAT-C) test was conducted at the gene level including both rare and common variants in 56 SuperAgers and 22 cognitively-average controls from the Alzheimer's disease Neuroimaging Initiative (ADNI).  Results: The SuperAging phenotype was associated with variants in the Mitogen-Activated Protein Kinase Kinase 3 (MAP2K3) gene.  Three single nucleotide polymorphisms (SNPs) contributed to the significance (rs2363221 [intron 1], rs2230435 [exon 5], rs736103 [intron 7]).  Conclusions: MAP2K3 resides in a biological pathway linked to memory.  It is in a signaling cascade associated with beta-amyloid mediated apoptosis and has enriched expression in microglia.  This preliminary work suggests MAP2K3 may represent a novel therapeutic target for age-related memory decline and perhaps Alzheimer's disease (AD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTai27mQTtuYOR_TJajKxJDfW6udTcc2eYAbDDQSGlmHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbms1ygug%253D%253D&md5=646b4c020600ee22145d13cbeb444bd5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffnagi.2018.00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnagi.2018.00155%26sid%3Dliteratum%253Aachs%26aulast%3DHuentelman%26aufirst%3DM.%2BJ.%26aulast%3DPiras%26aufirst%3DI.%2BS.%26aulast%3DSiniard%26aufirst%3DA.%2BL.%26aulast%3DDe%2BBoth%26aufirst%3DM.%2BD.%26aulast%3DRichholt%26aufirst%3DR.%2BF.%26aulast%3DBalak%26aufirst%3DC.%2BD.%26aulast%3DJamshidi%26aufirst%3DP.%26aulast%3DBigio%26aufirst%3DE.%2BH.%26aulast%3DWeintraub%26aufirst%3DS.%26aulast%3DLoyer%26aufirst%3DE.%2BT.%26aulast%3DMesulam%26aufirst%3DM.%2BM.%26aulast%3DGeula%26aufirst%3DC.%26aulast%3DRogalski%26aufirst%3DE.%2BJ.%26atitle%3DAssociations%2520of%2520MAP2K3%2520Gene%2520Variants%2520with%2520Superior%2520Memory%2520in%2520SuperAgers%26jtitle%3DFront.%2520Aging%2520Neurosci.%26date%3D2018%26volume%3D10%26spage%3D155%26doi%3D10.3389%2Ffnagi.2018.00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski-Kurdziel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra-VanderWeele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">p38α MAPK Signaling Drives Pharmacologically Reversible Brain and Gastrointestinal Phenotypes in the SERT Ala56 Mouse</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">E10245</span>– <span class="NLM_lpage">E10254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1809137115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1073%2Fpnas.1809137115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=30297392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10245-E10254&issue=43&author=M.+J.+Robsonauthor=M.+A.+Quinlanauthor=K.+G.+Margolisauthor=P.+A.+Gajewski-Kurdzielauthor=J.+Veenstra-VanderWeeleauthor=M.+D.+Gershonauthor=D.+M.+Wattersonauthor=R.+D.+Blakely&title=p38%CE%B1+MAPK+Signaling+Drives+Pharmacologically+Reversible+Brain+and+Gastrointestinal+Phenotypes+in+the+SERT+Ala56+Mouse&doi=10.1073%2Fpnas.1809137115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse</span></div><div class="casAuthors">Robson, Matthew J.; Quinlan, Meagan A.; Margolis, Kara Gross; Gajewski-Kurdziel, Paula A.; Veenstra-VanderWeele, Jeremy; Gershon, Michael D.; Watterson, D. Martin; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10245-E10254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a common neurobehavioral disorder with limited treatment options.  Activation of p38 MAPK signaling networks has been identified in ASD, and p38 MAPK signaling elevates serotonin (5-HT) transporter (SERT) activity, effects mimicked by multiple, hyperfunctional SERT coding variants identified in ASD subjects.  Mice expressing the most common of these variants (SERT Ala56) exhibit hyperserotonemia, a biomarker obsd. in ASD subjects, as well as p38 MAPK-dependent SERT hyperphosphorylation, elevated hippocampal 5-HT clearance, hypersensitivity of CNS 5-HT1A and 5-HT2A/2C receptors, and behavioral and gastrointestinal perturbations reminiscent of ASD.  As the α-isoform of p38 MAPK drives SERT activation, we tested the hypothesis that CNS-penetrant, α-isoform-specific p38 MAPK inhibitors might normalize SERT Ala56 phenotypes.  Strikingly, 1-wk treatment of adult SERT Ala56 mice with MW150, a selective p38α MAPK inhibitor, normalized hippocampal 5-HT clearance, CNS 5-HT1A and 5-HT2A/2C receptor sensitivities, social interactions, and colonic motility.  Conditional elimination of p389α MAPK in 5-HT neurons of SERT Ala56 mice restored 5-HT1A and 5-HT2A/2C receptor sensitivities as well as social interactions, mirroring effects of MW150.  Our findings support ongoing p38α MAPK activity as an important determinant of the physiol. and behavioral perturbations of SERT Ala56 mice and, more broadly, supports consideration of p38α MAPK inhibition as a potential treatment for core and comorbid phenotypes present in ASD subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpZykHY5klbVg90H21EOLACvtfcHk0lgbQypPg16_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N&md5=ea39d3218225fab9b9ef7a1465a80887</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1809137115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1809137115%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DQuinlan%26aufirst%3DM.%2BA.%26aulast%3DMargolis%26aufirst%3DK.%2BG.%26aulast%3DGajewski-Kurdziel%26aufirst%3DP.%2BA.%26aulast%3DVeenstra-VanderWeele%26aufirst%3DJ.%26aulast%3DGershon%26aufirst%3DM.%2BD.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3Dp38%25CE%25B1%2520MAPK%2520Signaling%2520Drives%2520Pharmacologically%2520Reversible%2520Brain%2520and%2520Gastrointestinal%2520Phenotypes%2520in%2520the%2520SERT%2520Ala56%2520Mouse%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D43%26spage%3DE10245%26epage%3DE10254%26doi%3D10.1073%2Fpnas.1809137115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, X. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, G.</span></span> <span> </span><span class="NLM_article-title">p38 MAP Kinase is Activated at Early Stages in Alzheimer’s Disease Brain</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1016/S0014-4886(03)00180-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2FS0014-4886%2803%2900180-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=14552880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2003&pages=394-405&author=A.+Sunauthor=M.+Liuauthor=X.+V.+Nguyenauthor=G.+Bing&title=p38+MAP+Kinase+is+Activated+at+Early+Stages+in+Alzheimer%E2%80%99s+Disease+Brain&doi=10.1016%2FS0014-4886%2803%2900180-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinase is activated at early stages in Alzheimer's disease brain</span></div><div class="casAuthors">Sun, Anyang; Liu, Mei; Nguyen, Xuan V.; Bing, Guoying</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">394-405</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The regional, cellular, and subcellular localization of phosphorylated p38 MAPK (pp38) was examd. by immunocytochem., immuofluorescent multiple labeling, and immunoblotting of exts. as well as immunoppts. of human postmortem tissue from control and Alzheimer's disease (AD) cases at different Braak stages.  "Early AD" cases (Braak stages IV-V) and a subset of Braak stage VI cases have high levels of pp38 immunoreactivity, with the most dense immunoreactivity located in CA2 and subiculum followed by CA1 in the hippocampus.  On the contrary, very little pp38 was detected in age-matched controls (Braak stages 0-II).  More importantly, as revealed by various multiple labeling expts., pp38 immunoreactivity is mainly located in neurons bearing early neurofibrillary pathol., but not in typically fibrillar tangles that are densely stained by thioflavin-S.  Most pp38-pos. neurons only contain a small amt. of phospho-tau.  Addnl., pp38 immunoreactivity was not assocd. with senile plaques.  At the subcellular level, pp38-immunoreactive granules are usually larger than the granules stained with the lysosomal marker cathepsin D.  Immunoblotting with different extn. buffers and immunopptn. indicate that pp38 does not or only loosely binds to phospho-tau.  Taken together, this study demonstrates that p38 MAPK is activated at early stages of neurofibrillary degeneration in AD hippocampus.  The p38 activation may also be linked to neurodegeneration through mechanisms other than neurofibrillary tangle formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxxwaFL8EObVg90H21EOLACvtfcHk0lht1WwN0wAJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D&md5=9823c9aa4ce32ba4b9c68e005b198593</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0014-4886%2803%2900180-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4886%252803%252900180-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DX.%2BV.%26aulast%3DBing%26aufirst%3DG.%26atitle%3Dp38%2520MAP%2520Kinase%2520is%2520Activated%2520at%2520Early%2520Stages%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Brain%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D183%26spage%3D394%26epage%3D405%26doi%3D10.1016%2FS0014-4886%2803%2900180-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delahanty, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folstein, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">Allelic Heterogeneity at the Serotonin Transporter Locus (SLC6A4) Confers Susceptibility to Autism and Rigid-Compulsive Behaviors</span>. <i>Am. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1086/432648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1086%2F432648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=15995945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms12jurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=265-279&author=J.+S.+Sutcliffeauthor=R.+J.+Delahantyauthor=H.+C.+Prasadauthor=J.+L.+McCauleyauthor=Q.+Hanauthor=L.+Jiangauthor=C.+Liauthor=S.+E.+Folsteinauthor=R.+D.+Blakely&title=Allelic+Heterogeneity+at+the+Serotonin+Transporter+Locus+%28SLC6A4%29+Confers+Susceptibility+to+Autism+and+Rigid-Compulsive+Behaviors&doi=10.1086%2F432648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors</span></div><div class="casAuthors">Sutcliffe, James S.; Delahanty, Ryan J.; Prasad, Harish C.; McCauley, Jacob L.; Han, Qiao; Jiang, Lan; Li, Chun; Folstein, Susan E.; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-279</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Autism is a spectrum of neurodevelopmental disorders with a primarily genetic etiol. exhibiting deficits in (1) development of language and (2) social relationships and (3) patterns of repetitive, restricted behaviors or interests and resistance to change.  Elevated platelet serotonin (5-HT) in 20%-25% of cases and efficacy of selective 5-HT reuptake inhibitors (SSRIs) in treating anxiety, depression, and repetitive behaviors points to the 5-HT transporter (5-HTT; SERT) as a strong candidate gene.  Assocn. studies involving the functional insertion/deletion polymorphism in the promoter (5-HTTLPR) and a polymorphism in intron 2 are inconclusive, possibly because of phenotypic heterogeneity.  Nonetheless, mounting evidence for genetic linkage of autism to the chromosome 17q11.2 region that harbors the SERT locus (SLC6A4) supports a genetic effect at or near this gene.  We confirm recent reports of sex-biased genetic effects in 17q by showing highly significant linkage driven by families with only affected males.  Assocn. with common alleles fails to explain obsd. linkage; therefore, we hypothesized that preferential transmission of multiple alleles does explain it.  From 120 families, most contributing to linkage at 17q11.2, we found four coding substitutions at highly conserved positions and 15 other variants in 5' noncoding and other intronic regions transmitted in families exhibiting increased rigid-compulsive behaviors.  In the aggregate, these variants show significant linkage to and assocn. with autism.  Our data provide strong support for a collection of multiple, often rare, alleles at SLC6A4 as imposing risk of autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2we43zGjOjrVg90H21EOLACvtfcHk0lht1WwN0wAJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms12jurc%253D&md5=763cce96557c332d5a8b4e4900bd529f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1086%2F432648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F432648%26sid%3Dliteratum%253Aachs%26aulast%3DSutcliffe%26aufirst%3DJ.%2BS.%26aulast%3DDelahanty%26aufirst%3DR.%2BJ.%26aulast%3DPrasad%26aufirst%3DH.%2BC.%26aulast%3DMcCauley%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DFolstein%26aufirst%3DS.%2BE.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3DAllelic%2520Heterogeneity%2520at%2520the%2520Serotonin%2520Transporter%2520Locus%2520%2528SLC6A4%2529%2520Confers%2520Susceptibility%2520to%2520Autism%2520and%2520Rigid-Compulsive%2520Behaviors%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2005%26volume%3D77%26spage%3D265%26epage%3D279%26doi%3D10.1086%2F432648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleasby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seavers, L. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel p38h MAP Kinase Inhibitors Using Fragment-Based Lead Generation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1021/jm049575n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049575n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=414-426&author=A.+L.+Gillauthor=M.+Fredericksonauthor=A.+Cleasbyauthor=S.+J.+Woodheadauthor=M.+G.+Carrauthor=A.+J.+Woodheadauthor=M.+T.+Walkerauthor=M.+S.+Congreveauthor=L.+A.+Devineauthor=D.+Tisiauthor=M.+O%E2%80%99Reillyauthor=L.+C.+A.+Seaversauthor=D.+J.+Davisauthor=J.+Curryauthor=R.+Anthonyauthor=A.+Padovaauthor=C.+W.+Murrayauthor=R.+A.+Carrauthor=H.+Jhoti&title=Identification+of+Novel+p38h+MAP+Kinase+Inhibitors+Using+Fragment-Based+Lead+Generation&doi=10.1021%2Fjm049575n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation</span></div><div class="casAuthors">Gill, Adrian L.; Frederickson, Martyn; Cleasby, Anne; Woodhead, Steven J.; Carr, Maria G.; Woodhead, Andrew J.; Walker, Margaret T.; Congreve, Miles S.; Devine, Lindsay A.; Tisi, Dominic; O'Reilly, Marc; Seavers, Lisa C. A.; Davis, Deborah J.; Curry, Jayne; Anthony, Rachel; Padova, Alessandro; Murray, Christopher W.; Carr, Robin A. E.; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">414-426</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the structure-guided optimization of the mol. fragments 2-amino-3-benzyloxypyridine 1 (IC50 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC50 35 μM) identified using X-ray crystallog. screening of p38α MAP kinase.  Using two sep. case studies, the article focuses on the key compds. synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate significant increases in activity.  We describe the process of compd. elaboration either through the growing out from fragments into adjacent pockets or through the conjoining of overlapping fragments and demonstrate that we have exploited the mobile conserved activation loop, consisting in part of Asp168-Phe169-Gly170 (DFG), to generate significant improvements in potency and kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOROTrqNSv97Vg90H21EOLACvtfcHk0lht1WwN0wAJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nJ&md5=a128859d7f3725f2672512331b6bdc83</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm049575n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049575n%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DCongreve%26aufirst%3DM.%2BS.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%2BA.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DAnthony%26aufirst%3DR.%26aulast%3DPadova%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%2BA.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520Novel%2520p38h%2520MAP%2520Kinase%2520Inhibitors%2520Using%2520Fragment-Based%2520Lead%2520Generation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D414%26epage%3D426%26doi%3D10.1021%2Fjm049575n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleasby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickle, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Lead Discovery Using X-ray Crystallography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1021/jm0495778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0495778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=403-413&author=M.+J.+Hartshornauthor=C.+W.+Murrayauthor=A.+Cleasbyauthor=M.+Fredericksonauthor=I.+J.+Tickleauthor=H.+Jhoti&title=Fragment-Based+Lead+Discovery+Using+X-ray+Crystallography&doi=10.1021%2Fjm0495778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Lead Discovery Using X-ray Crystallography</span></div><div class="casAuthors">Hartshorn, Michael J.; Murray, Christopher W.; Cleasby, Anne; Frederickson, Martyn; Tickle, Ian J.; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">403-413</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment screening offers an alternative to traditional screening for discovering new leads in drug discovery programs.  This paper describes a fragment screening methodol. based on high throughput x-ray crystallog.  The method is illustrated against five proteins (p38 MAP kinase, CDK2, thrombin, RNase A, and PTP1B).  The fragments identified have weak potency (>100 μM) but are efficient binders relative to their size and may therefore represent suitable starting points for evolution to good quality lead compds.  The examples illustrate that a range of mol. interactions (i.e., lipophilic, charge-charge, neutral hydrogen bonds) can drive fragment binding and also that fragments can induce protein movement.  The authors believe that the method has great potential for the discovery of novel lead compds. against a range of targets, and the companion paper illustrates how lead compds. have been identified for p38 MAP kinase starting from fragments such as those described in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeepqN9_V8prVg90H21EOLACvtfcHk0liH4CyGVdlFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nK&md5=41f6e394812669bde519ab7366fea9d6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm0495778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0495778%26sid%3Dliteratum%253Aachs%26aulast%3DHartshorn%26aufirst%3DM.%2BJ.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DFragment-Based%2520Lead%2520Discovery%2520Using%2520X-ray%2520Crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D403%26epage%3D413%26doi%3D10.1021%2Fjm0495778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elayan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagadeesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laniyonu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Secondary Pharmacology Data to Assess Potential Off-Target Activity of New Drugs: A Regulatory Perspective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1038/nrd3845-c1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnrd3845-c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=25792260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=294-296&author=T.+Papoianauthor=H.-J.+Chiuauthor=I.+Elayanauthor=G.+Jagadeeshauthor=I.+Khanauthor=A.+A.+Laniyonuauthor=C.+X.+Liauthor=M.+Saulnierauthor=N.+Simpsonauthor=B.+Yang&title=Secondary+Pharmacology+Data+to+Assess+Potential+Off-Target+Activity+of+New+Drugs%3A+A+Regulatory+Perspective&doi=10.1038%2Fnrd3845-c1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective</span></div><div class="casAuthors">Papoian, Thomas; Chiu, Haw-Jyh; Elayan, Ikram; Jagadeesh, Gowraganahalli; Khan, Imran; Laniyonu, Adebayo A.; Li, Cindy Xinguang; Saulnier, Muriel; Simpson, Natalie; Yang, Baichun</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">294</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Useful aspects of submitted secondary pharmacol. data.  Detailed aspects of secondary pharmacol. data that are considered to be useful during regulatory safety assessments are summarized in Table 1.  Incorporation of these aspects into secondary pharmacol. study reports not only enhances the quality and regulatory utility of the reports but also decreases uncertainty in decision making owing to misinterpretation of data.  Regulatory assessment of in vitro secondary pharmacol. data.  Various protocols for secondary pharmacol. studies are commonly available and generally consist of binding assays, functional assays and enzyme assays, all of which provide important information regarding the pharmacol. activity of a drug and possible unanticipated side effects that may be seen in humans.  When the data suggest possible off-target activity, the extent of that risk under clin. relevant conditions and drug exposures is carefully assessed, and safety recommendations are made for the proposed clin. studies or addnl. non-clin. studies are requested to help to better understand or reduce the risk.  In our experience, the panels of targets that are employed vary widely and are often selected without justification or a description of their relevance to human safety.  In such cases, a repeat of the study may be recommended using a more appropriate selection of clin. relevant targets.  It is useful to det. whether a drug shares similar off-target activity with other drugs in the class - for example, the sedative and anticholinergic properties of certain histamine H1 receptor antagonists - so that such side effects in humans can be better anticipated and monitored.  Similarly, target panel selection may also include consideration of whether the intended drug target has structural or functional similarity to a related but unintended target.  If such a relationship is found, then clin. consequences of affecting those targets are considered.  Drugs may also possess specificity for, or a mechanism of action linked to, selected targets from a large family of related targets that have structural or functional similarity (for example, the ATP-binding site of protein tyrosine kinases).  In such cases, a broad panel screen of all closely related family members may be useful in distinguishing intended pharmacol. effects from unintended effects.  It is important to understand how findings relate to those obsd. with other members of the drug class or for a certain mechanism of action.  If the findings are similar, then the clin. risk may be considered to be similar as well.  If they are different, however, then further evaluation, such as follow-up in vitro or animal studies focusing on the different targets affected, may be recommended to better define the risk.  Correlations between pos. secondary pharmacol. results and results seen in animals may be used to det. whether in vitro activity translates to possible human risk under therapeutic conditions.  It is important to note that in vitro panels generally use human-specific targets, and in vitro results may not always correlate with those obsd. in animals.  Correlations between in vitro half-maximal inhibitory concn. (IC50) or inhibition const. (Ki) values with in vivo plasma drug levels are also used to assess possible effects at therapeutic exposures.  The closer the IC50 or Ki values are to plasma drug levels, the more likely the clin. effect.  Also considered in this context are local tissue drug concns. at the site of action that may be higher than circulating levels.  Use of focused profiling may be recommended to address specific issues of concern, such as the safety of active drug metabolites or unique major human metabolites not formed in animals but found during subsequent clin. testing.  Even if a compd. produces a pos. in vitro result at therapeutically relevant concns., certain risk-benefit considerations for particular patient populations are taken into account, such as the seriousness of the therapeutic indication and whether potential adverse effects are considered to be reversible.  Case examples of regulatory actions based on pos. off-target activity are provided in Table 2 and include endocrine disruptors, peroxisome proliferator-activated receptor-γ agonists, cardiac (voltage-gated) ion channel protein antagonists, 5-HT2B (serotonin) receptor agonists, ligand-gated ion channel protein (for example, N-methyl-d-aspartate receptor) antagonists and drugs with potential for abuse.  Although not exhaustive, these examples highlight current experience with certain classes and actions of drugs that have resulted in specific regulatory actions based on their potential risk for human safety.  Timing of secondary pharmacol. data submission.  For proper safety assessment, it is advantageous for secondary pharmacol. data to be available with the initial submission to support first-in-human (Phase I) clin. trials.  Such data can also be used to help to interpret clin. findings or adverse drug reactions that occur as drug development proceeds into later phases of clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD40Aby38TPrVg90H21EOLACvtfcHk0liH4CyGVdlFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D&md5=69b08c957679ef003271b07fef0d4de5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845-c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845-c1%26sid%3Dliteratum%253Aachs%26aulast%3DPapoian%26aufirst%3DT.%26aulast%3DChiu%26aufirst%3DH.-J.%26aulast%3DElayan%26aufirst%3DI.%26aulast%3DJagadeesh%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DLaniyonu%26aufirst%3DA.%2BA.%26aulast%3DLi%26aufirst%3DC.%2BX.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DSecondary%2520Pharmacology%2520Data%2520to%2520Assess%2520Potential%2520Off-Target%2520Activity%2520of%2520New%2520Drugs%253A%2520A%2520Regulatory%2520Perspective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D294%26epage%3D296%26doi%3D10.1038%2Fnrd3845-c1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagadeesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laniyonu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarfman, A.</span></span> <span> </span><span class="NLM_article-title">Regulatory Forum Review: Utility of In Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1177/0192623317690609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1177%2F0192623317690609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=28421966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1Cmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=381-388&author=T.+Papoianauthor=G.+Jagadeeshauthor=M.+Saulnierauthor=N.+Simpsonauthor=A.+Ravindranauthor=B.+Yangauthor=A.+A.+Laniyonuauthor=I.+Khanauthor=A.+Szarfman&title=Regulatory+Forum+Review%3A+Utility+of+In+Vitro+Secondary+Pharmacology+Data+to+Assess+Risk+of+Drug-induced+Valvular+Heart+Disease+in+Humans%3A+Regulatory+Considerations&doi=10.1177%2F0192623317690609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations</span></div><div class="casAuthors">Papoian, Thomas; Jagadeesh, Gowraganahalli; Saulnier, Muriel; Simpson, Natalie; Ravindran, Arippa; Yang, Baichun; Laniyonu, Adebayo A.; Khan, Imran; Szarfman, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Drug-induced valvular heart disease (VHD) is a serious side effect linked to long-term treatment with 5-hydroxytryptamine (serotonin) receptor 2B (5-HT2B) agonists.  Safety assessment for off-target pharmacodynamic activity is a common approach used to screen drugs for this undesired property.  Such studies include in vitro assays to det. whether the drug is a 5-HT2B agonist, a necessary pharmacol. property for development of VHD.  Measures of in vitro binding affinity (IC50, Ki) or cellular functional activity (EC50) are often compared to max. therapeutic free plasma drug levels (fCmax) from which safety margins (SMs) can be derived.  However, there is no clear consensus on what constitutes an appropriate SM under various therapeutic conditions of use.  The strengths and limitations of SM detns. and current risk assessment methodol. are reviewed and evaluated.  It is concluded that the use of SMs based on Ki values, or those relative to serotonin (5-HT), appears to be a better predictor than the use of EC50 or EC50/human fCmax values for detg. whether known 5-HT2B agonists have resulted in VHD.  It is hoped that such a discussion will improve efforts to reduce this preventable serious drug-induced toxicity from occurring and lead to more informed risk assessment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbpv1RzQwmQLVg90H21EOLACvtfcHk0liH4CyGVdlFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1Cmsw%253D%253D&md5=99179d2659014ce01ac730052aee76f0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F0192623317690609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623317690609%26sid%3Dliteratum%253Aachs%26aulast%3DPapoian%26aufirst%3DT.%26aulast%3DJagadeesh%26aufirst%3DG.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DRavindran%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DLaniyonu%26aufirst%3DA.%2BA.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DSzarfman%26aufirst%3DA.%26atitle%3DRegulatory%2520Forum%2520Review%253A%2520Utility%2520of%2520In%2520Vitro%2520Secondary%2520Pharmacology%2520Data%2520to%2520Assess%2520Risk%2520of%2520Drug-induced%2520Valvular%2520Heart%2520Disease%2520in%2520Humans%253A%2520Regulatory%2520Considerations%26jtitle%3DToxicol.%2520Pathol.%26date%3D2017%26volume%3D45%26spage%3D381%26epage%3D388%26doi%3D10.1177%2F0192623317690609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of <i>In Vitro</i>Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+In+VitroPharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0liiY1XFCgtRAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520In%2520VitroPharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranaivo, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">A Novel p38 MAPK Inhibitor Suppresses Brain Proinflammatory Cytokine Up-Regulation and Attenuates Synaptic Dysfunction and Behavioral Deficits in an Alzheimer’s Disease Mouse Model</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-4-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2F1742-2094-4-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=17784957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=21&author=L.+Munozauthor=H.+R.+Ranaivoauthor=S.+M.+Royauthor=W.+Huauthor=J.+M.+Craftauthor=L.+K.+McNamaraauthor=L.+W.+Chicoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=A+Novel+p38+MAPK+Inhibitor+Suppresses+Brain+Proinflammatory+Cytokine+Up-Regulation+and+Attenuates+Synaptic+Dysfunction+and+Behavioral+Deficits+in+an+Alzheimer%E2%80%99s+Disease+Mouse+Model&doi=10.1186%2F1742-2094-4-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model</span></div><div class="casAuthors">Munoz Lenka; Ralay Ranaivo Hantamalala; Roy Saktimayee M; Hu Wenhui; Craft Jeffrey M; McNamara Laurie K; Chico Laura Wing; Van Eldik Linda J; Watterson D Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  An accumulating body of evidence is consistent with the hypothesis that excessive or prolonged increases in proinflammatory cytokine production by activated glia is a contributor to the progression of pathophysiology that is causally linked to synaptic dysfunction and hippocampal behavior deficits in neurodegenerative diseases such as Alzheimer's disease (AD).  This raises the opportunity for the development of new classes of potentially disease-modifying therapeutics.  A logical candidate CNS target is p38 alpha MAPK, a well-established drug discovery molecular target for altering proinflammatory cytokine cascades in peripheral tissue disorders.  Activated p38 MAPK is seen in human AD brain tissue and in AD-relevant animal models, and cell culture studies strongly implicate p38 MAPK in the increased production of proinflammatory cytokines by glia activated with human amyloid-beta (A beta) and other disease-relevant stressors.  However, the vast majority of small molecule drugs do not have sufficient penetrance of the blood-brain barrier to allow their use as in vivo research tools or as therapeutics for neurodegenerative disorders.  The goal of this study was to test the hypothesis that brain p38 alpha MAPK is a potential in vivo target for orally bioavailable, small molecules capable of suppressing excessive cytokine production by activated glia back towards homeostasis, allowing an improvement in neurologic outcomes.  METHODS:  A novel synthetic small molecule based on a molecular scaffold used previously was designed, synthesized, and subjected to analyses to demonstrate its potential in vivo bioavailability, metabolic stability, safety and brain uptake.  Testing for in vivo efficacy used an AD-relevant mouse model.  RESULTS:  A novel, CNS-penetrant, non-toxic, orally bioavailable, small molecule inhibitor of p38 alpha MAPK (MW01-2-069A-SRM) was developed.  Oral administration of the compound at a low dose (2.5 mg/kg) resulted in attenuation of excessive proinflammatory cytokine production in the hippocampus back towards normal in the animal model.  Animals with attenuated cytokine production had reductions in synaptic dysfunction and hippocampus-dependent behavioral deficits.  CONCLUSION:  The p38 alpha MAPK pathway is quantitatively important in the A beta-induced production of proinflammatory cytokines in hippocampus, and brain p38 alpha MAPK is a viable molecular target for future development of potential disease-modifying therapeutics in AD and related neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsGGsjPM4Dps25P7XSLhESfW6udTcc2eYaZZ-M4yI32Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D&md5=e7768f444f68015f134d42880ed01f3b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-4-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-4-21%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DRanaivo%26aufirst%3DH.%2BR.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DCraft%26aufirst%3DJ.%2BM.%26aulast%3DMcNamara%26aufirst%3DL.%2BK.%26aulast%3DChico%26aufirst%3DL.%2BW.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DA%2520Novel%2520p38%2520MAPK%2520Inhibitor%2520Suppresses%2520Brain%2520Proinflammatory%2520Cytokine%2520Up-Regulation%2520and%2520Attenuates%2520Synaptic%2520Dysfunction%2520and%2520Behavioral%2520Deficits%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mouse%2520Model%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2007%26volume%3D4%26spage%3D21%26doi%3D10.1186%2F1742-2094-4-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schavocky, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradaric, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Development of Novel <i>In Vivo</i> Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e66226</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0066226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1371%2Fjournal.pone.0066226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23840427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSlt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=D.+M.+Wattersonauthor=V.+L.+Grum-Tokarsauthor=S.+M.+Royauthor=J.+P.+Schavockyauthor=B.+D.+Bradaricauthor=A.+D.+Bachstetterauthor=B.+Xingauthor=E.+Dimayugaauthor=F.+Saeedauthor=H.+Zhangauthor=A.+Staniszewskiauthor=J.+C.+Pelletierauthor=G.+Minasovauthor=W.+F.+Andersonauthor=O.+Arancioauthor=L.+J.+Van+Eldik&title=Development+of+Novel+In+Vivo+Chemical+Probes+to+Address+CNS+Protein+Kinase+Involvement+in+Synaptic+Dysfunction&doi=10.1371%2Fjournal.pone.0066226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel in vivo chemical probes to address CNS protein kinase involvement in synaptic dysfunction</span></div><div class="casAuthors">Watterson, D. Martin; Grum-Tokars, Valerie L.; Roy, Saktimayee M.; Schavocky, James P.; Bradaric, Brinda Desai; Bachstetter, Adam D.; Xing, Bin; Dimayuga, Edgardo; Saeed, Faisal; Zhang, Hong; Staniszewski, Agnieszka; Pelletier, Jeffrey C.; Minasov, George; Anderson, Wayne F.; Arancio, Ottavio; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e66226</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Serine-threonine protein kinases are crit. to CNS function, yet there is a dearth of highly selective, CNS-active kinase inhibitors for in vivo investigations.  Further, prevailing assumptions raise concerns about whether single kinase inhibitors can show in vivo efficacy for CNS pathologies and debates over viable approaches to the development of safe and efficacious kinase inhibitors are unsettled.  It is crit., therefore, that these scientific challenges be addressed in order to test hypotheses about protein kinases in neuropathol. progression and the potential for in vivo modulation of their catalytic activity.  Identification of mol. targets whose in vivo modulation can attenuate synaptic dysfunction would provide a foundation for future disease-modifying therapeutic development as well as insight into cellular mechanisms.  Clin. and preclin. studies suggest a crit. link between synaptic dysfunction in neurodegenerative disorders and the activation of p38αMAPK mediated signaling cascades.  Activation in both neurons and glia also offers the unusual potential to generate enhanced responses through targeting a single kinase in two distinct cell types involved in pathol. progression.  However, target validation has been limited by lack of highly selective inhibitors amenable to in vivo use in the CNS.  Therefore, the authors employed high-resoln. co-crystallog. and pharmacoinformatics to design and develop a novel synthetic, active site targeted, CNS-active, p38αMAPK inhibitor (MW108).  Selectivity was demonstrated by large-scale kinome screens, functional GPCR agonist and antagonist analyses of off-target potential, and evaluation of cellular target engagement.  In vitro and in vivo assays demonstrated that MW108 ameliorates beta-amyloid induced synaptic and cognitive dysfunction.  A serendipitous discovery during co-crystallog. analyses revised prevailing models about active site targeting of inhibitors, providing insights that will facilitate future kinase inhibitor design.  Overall, the authors' studies deliver highly selective in-vivo probes appropriate for CNS investigations and demonstrate that modulation of p38αMAPK activity can attenuate synaptic dysfunction.  The title compds. thus formed included a (naphthalenyl)(pyridinyl)pyridazinamine deriv. (I).  The synthesis of the target compds. was achieved by a coupling reaction of (chloro)(pyridinyl)pyridazinamine with (naphthalene)boronic acid derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiciSYOCxFa7Vg90H21EOLACvtfcHk0liiY1XFCgtRAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSlt7jI&md5=7c8b917f6e4fec0276073bcfd9e8ec74</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0066226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0066226%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DGrum-Tokars%26aufirst%3DV.%2BL.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DSchavocky%26aufirst%3DJ.%2BP.%26aulast%3DBradaric%26aufirst%3DB.%2BD.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DXing%26aufirst%3DB.%26aulast%3DDimayuga%26aufirst%3DE.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DDevelopment%2520of%2520Novel%2520In%2520Vivo%2520Chemical%2520Probes%2520to%2520Address%2520CNS%2520Protein%2520Kinase%2520Involvement%2520in%2520Synaptic%2520Dysfunction%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0066226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schavocky, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor that Attenuates Disease Progression in Alzheimer’s Disease Mouse Models</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=666-680&author=S.+M.+Royauthor=V.+L.+Grum-Tokarsauthor=J.+P.+Schavockyauthor=F.+Saeedauthor=A.+Staniszewskiauthor=A.+F.+Teichauthor=O.+Arancioauthor=A.+D.+Bachstetterauthor=S.+J.+Websterauthor=L.+J.+Van+Eldikauthor=G.+Minasovauthor=W.+F.+Andersonauthor=J.+C.+Pelletierauthor=D.+M.+Watterson&title=Targeting+Human+Central+Nervous+System+Protein+Kinases%3A+An+Isoform+Selective+p38%CE%B1MAPK+Inhibitor+that+Attenuates+Disease+Progression+in+Alzheimer%E2%80%99s+Disease+Mouse+Models&doi=10.1021%2Facschemneuro.5b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models</span></div><div class="casAuthors">Roy, Saktimayee M.; Grum-Tokars, Valerie L.; Schavocky, James P.; Saeed, Faisal; Staniszewski, Agnieszka; Teich, Andrew F.; Arancio, Ottavio; Bachstetter, Adam D.; Webster, Scott J.; Van Eldik, Linda J.; Minasov, George; Anderson, Wayne F.; Pelletier, Jeffrey C.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">666-680</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncol. indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications.  Stress kinases are of special interest in neurol. and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility.  Clin. and preclin. evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurol. indications.  Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacol. features.  Synaptic dysfunction disorders offer a potential for enhanced pharmacol. efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiol. axis, to be modulated.  We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models.  A synthetic scheme for biocompatible product and pos. outcomes from pharmacol. screens are presented.  The high-resoln. crystallog. structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity.  As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-xfPVSbGEOrVg90H21EOLACvtfcHk0lgMg-1YSVGnjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D&md5=defac1ac010ab8a139647844153c7b86</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00002%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DGrum-Tokars%26aufirst%3DV.%2BL.%26aulast%3DSchavocky%26aufirst%3DJ.%2BP.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DWebster%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520Human%2520Central%2520Nervous%2520System%2520Protein%2520Kinases%253A%2520An%2520Isoform%2520Selective%2520p38%25CE%25B1MAPK%2520Inhibitor%2520that%2520Attenuates%2520Disease%2520Progression%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mouse%2520Models%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D666%26epage%3D680%26doi%3D10.1021%2Facschemneuro.5b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Späni, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Retention of Normal Glia Function by an Isoform-Selective Protein Kinase Inhibitor Drug Candidate that Modulates Cytokine Production and Cognitive Outcomes</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">75</span>, <span class="refDoi"> DOI: 10.1186/s12974-017-0845-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2Fs12974-017-0845-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=28381303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=75&author=Z.+Zhouauthor=A.+D.+Bachstetterauthor=C.+B.+Sp%C3%A4niauthor=S.+M.+Royauthor=D.+M.+Wattersonauthor=L.+J.+Van+Eldik&title=Retention+of+Normal+Glia+Function+by+an+Isoform-Selective+Protein+Kinase+Inhibitor+Drug+Candidate+that+Modulates+Cytokine+Production+and+Cognitive+Outcomes&doi=10.1186%2Fs12974-017-0845-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes</span></div><div class="casAuthors">Zhou, Zhengqiu; Bachstetter, Adam D.; Spani, Claudia B.; Roy, Saktimayee M.; Watterson, D. Martin; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75/1-75/12</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Brain p38α mitogen-activated protein kinase (MAPK), a potential therapeutic target for cognitive dysfunction based on the neuroinflammation-synaptic dysfunction cycle of pathophysiol. progression, offers an innovative pharmacol. strategy via inhibiting the same activated target in both glia and neurons, thereby enhancing the possibility for efficacy.  The highly selective, brain-penetrant p38αMAPK inhibitor MW150 attenuates cognitive dysfunction in two distinct Alzheimer's disease (AD)-relevant models and avoids the problems encountered with previous mixed-kinase inhibitor drug candidates.  Therefore, it is essential that the glial effects of this CNS-active kinase inhibitor be addressed in order to anticipate future use in clin. investigations.  Methods: We explored the effects of MW150 on glial biol. in the AD-relevant APP/PS1 knock-in (KI) mouse model where we previously showed efficacy in suppression of hippocampal-dependent associative and spatial memory deficits.  MW150 (2.5 mg/kg/day) was administered daily to 11-12-mo-old KI mice for 14 days, and levels of proinflammatory cytokines IL-1β, TNFα, and IL-6 measured in homogenates of mouse cortex using ELISA.  Glial markers IBA1, CD45, CD68, and GFAP were assessed by immunohistochem.  Microglia and amyloid plaques were quantified by immunofluorescence staining followed by confocal imaging.  Levels of sol. and insol. of Aβ40 and Aβ42 were measured by ELISA.  The studies of in vivo pharmacodynamic effects on markers of neuroinflammation were complemented by mechanistic studies in the murine microglia BV2 cell line, using live cell imaging techniques to monitor proliferation, migration, and phagocytosis activities.  Results: Intervention with MW150 in KI mice during the established therapeutic time window attenuated the increased levels of IL-1β and TNFα but not IL-6.  MW150 treatment also increased the IBA1+ microglia within a 15 μm radius of the amyloid plaques, without significantly affecting overall microglia or plaque vol.  Levels of IBA1, CD45, CD68, GFAP, and Aβ40 and Aβ42 were not affected by MW150 treatment.  MW150 did not significantly alter microglial migration, proliferation, or phagocytosis in BV2 cells.  Conclusions: Our results demonstrate that MW150 at an efficacious dose can selectively modulate neuroinflammatory responses assocd. with pathol. progression without pan-suppression of normal physiol. functions of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq16MlfxcvdbVg90H21EOLACvtfcHk0lgMg-1YSVGnjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK&md5=9137eff52c9715df75ca1ea1ac2a3656</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1186%2Fs12974-017-0845-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-017-0845-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DSp%25C3%25A4ni%26aufirst%3DC.%2BB.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DRetention%2520of%2520Normal%2520Glia%2520Function%2520by%2520an%2520Isoform-Selective%2520Protein%2520Kinase%2520Inhibitor%2520Drug%2520Candidate%2520that%2520Modulates%2520Cytokine%2520Production%2520and%2520Cognitive%2520Outcomes%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2017%26volume%3D14%26spage%3D75%26doi%3D10.1186%2Fs12974-017-0845-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Target Engagement Analysis and Link to Pharmacodynamic Endpoint for a Novel Class of CNS-Penetrant and Efficacious p38α MAPK Inhibitors</span>. <i>J. Neuroimmune Pharmcol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1007/s11481-014-9543-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1007%2Fs11481-014-9543-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=24789302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC2cnoslOjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=454-460&author=A.+D.+Bachstetterauthor=D.+M.+Wattersonauthor=L.+J.+Van+Eldik&title=Target+Engagement+Analysis+and+Link+to+Pharmacodynamic+Endpoint+for+a+Novel+Class+of+CNS-Penetrant+and+Efficacious+p38%CE%B1+MAPK+Inhibitors&doi=10.1007%2Fs11481-014-9543-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors</span></div><div class="casAuthors">Bachstetter Adam D; Watterson D Martin; Van Eldik Linda J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">454-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The protein kinase, p38α MAPK, is a key intracellular transducer of stressor-induced neuroinflammatory responses and, as such, is of high interest as a potential therapeutic target.  We recently reported the synthesis and evaluation of first-in-class CNS-penetrant and highly specific p38 MAPK inhibitors that avoid target crossover issues seen in popular small molecule p38 MAPK inhibitors used in hundreds of previous reports.  The novel p38 MAPK inhibitors, represented in this study by MW181, are efficacious in vivo.  Pharmacodynamic actions include attenuation of stressor-induced increases in brain proinflammatory cytokine levels.  We report here more detailed analyses of MW181 target engagement and specific linkage to the downstream increase in glia proinflammatory cytokine production.  In vivo validation included demonstration that oral administration of MW181 suppresses lipopolysaccharide-induced increases in mouse brain IL-1β, TNFα, IL-6, IL-10, and CXCL1 but not in a drug-resistant p38α MAPK mutant mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWolJymxo2JeWhZTslLrfffW6udTcc2eZFPYLw33LW07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnoslOjtg%253D%253D&md5=720ce3aa521c0535df86081dc31d9b46</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs11481-014-9543-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11481-014-9543-3%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DTarget%2520Engagement%2520Analysis%2520and%2520Link%2520to%2520Pharmacodynamic%2520Endpoint%2520for%2520a%2520Novel%2520Class%2520of%2520CNS-Penetrant%2520and%2520Efficacious%2520p38%25CE%25B1%2520MAPK%2520Inhibitors%26jtitle%3DJ.%2520Neuroimmune%2520Pharmcol.%26date%3D2014%26volume%3D9%26spage%3D454%26epage%3D460%26doi%3D10.1007%2Fs11481-014-9543-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maphis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokiko-Cochran, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhaskar, K.</span></span> <span> </span><span class="NLM_article-title">Selective Suppression of the α Isoform of p38 MAPK Rescues Late-Stage Tau Pathology</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">54</span>, <span class="refDoi"> DOI: 10.1186/s13195-016-0221-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2Fs13195-016-0221-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=54&author=N.+Maphisauthor=S.+Jiangauthor=G.+Xuauthor=O.+N.+Kokiko-Cochranauthor=S.+M.+Royauthor=L.+J.+Van+Eldikauthor=D.+M.+Wattersonauthor=B.+T.+Lambauthor=K.+Bhaskar&title=Selective+Suppression+of+the+%CE%B1+Isoform+of+p38+MAPK+Rescues+Late-Stage+Tau+Pathology&doi=10.1186%2Fs13195-016-0221-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology</span></div><div class="casAuthors">Maphis, Nicole; Jiang, Shanya; Xu, Guixiang; Kokiko-Cochran, Olga N.; Roy, Saktimayee M.; Van Eldik, Linda J.; Watterson, Martin D.; Lamb, Bruce T.; Kiran, Bhaskar</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54/1-54/15</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Hyperphosphorylation and aggregation of tau protein are the pathol. hallmarks of Alzheimer's disease and related tauopathies.  We previously demonstrated that the microglial activation induces tau hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK) in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1.  Method: We report an isoform-selective, brain-permeable, and orally bioavailable small mol. inhibitor of p38α MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice.  Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the max. effect peaking at 60-90 min after stimulation.  Second, treatment of old (∼20 mo of age) hTau mice with MW181 (1 mg/kg body wt.; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-administered hTau mice.  This also resulted in a significant redn. in AT180 (pT231) site tau phosphorylation and Sarkosyl-insol. tau aggregates.  Third, MW181 treatment significantly increased synaptophysin protein expression and resulted in improved working memory.  Fourth, MW181 administration reduced phosphorylated MAPK-activated protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates of p38α MAPK.  Finally, MW181 reduced the expression of interferon-γ and interleukin-1β.  Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS6AXNcANBc7Vg90H21EOLACvtfcHk0lg6Vzc52cUEzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFait7o%253D&md5=3acd2f928ea95f5089eb1bad61a5cb2c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs13195-016-0221-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-016-0221-y%26sid%3Dliteratum%253Aachs%26aulast%3DMaphis%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DKokiko-Cochran%26aufirst%3DO.%2BN.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DLamb%26aufirst%3DB.%2BT.%26aulast%3DBhaskar%26aufirst%3DK.%26atitle%3DSelective%2520Suppression%2520of%2520the%2520%25CE%25B1%2520Isoform%2520of%2520p38%2520MAPK%2520Rescues%2520Late-Stage%2520Tau%2520Pathology%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2016%26volume%3D8%26spage%3D54%26doi%3D10.1186%2Fs13195-016-0221-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morfini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavassoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigino, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, S. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves Activation of p38 MAP Kinase</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e65235</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0065235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1371%2Fjournal.pone.0065235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23776455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVejsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=G.+A.+Morfiniauthor=D.+A.+Boscoauthor=H.+Brownauthor=R.+Gattoauthor=A.+Kaminskaauthor=Y.+Songauthor=L.+Mollaauthor=L.+Bakerauthor=M.+N.+Marangoniauthor=S.+Berthauthor=E.+Tavassoliauthor=C.+Bagnatoauthor=A.+Tiwariauthor=L.+J.+Haywardauthor=G.+F.+Piginoauthor=D.+M.+Wattersonauthor=C.-F.+Huangauthor=G.+Bankerauthor=R.+H.+Brownauthor=S.+T.+Brady&title=Inhibition+of+Fast+Axonal+Transport+by+Pathogenic+SOD1+Involves+Activation+of+p38+MAP+Kinase&doi=10.1371%2Fjournal.pone.0065235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase</span></div><div class="casAuthors">Morfini, Gerardo A.; Bosco, Daryl A.; Brown, Hannah; Gatto, Rodolfo; Kaminska, Agnieszka; Song, Yuyu; Molla, Linda; Baker, Lisa; Marangoni, M. Natalia; Berth, Sarah; Tavassoli, Ehsan; Bagnato, Carolina; Tiwari, Ashutosh; Hayward, Lawrence J.; Pigino, Gustavo F.; Watterson, D. Martin; Huang, Chun-Fang; Banker, Gary; Brown, Robert H., Jr.; Brady, Scott T.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e65235</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dying-back degeneration of motor neuron axons represents an established feature of familial amyotrophic lateral sclerosis (FALS) assocd. with superoxide dismutase 1 (SOD1) mutations, but axon-autonomous effects of pathogenic SOD1 remained undefined.  Characteristics of motor neurons affected in FALS include abnormal kinase activation, aberrant neurofilament phosphorylation, and fast axonal transport (FAT) deficits, but functional relationships among these pathogenic events were unclear.  Expts. in isolated squid axoplasm reveal that FALS-related SOD1 mutant polypeptides inhibit FAT through a mechanism involving a p38 mitogen activated protein kinase pathway.  Mutant SOD1 activated neuronal p38 in mouse spinal cord, neuroblastoma cells and squid axoplasm.  Active p38 MAP kinase phosphorylated kinesin-1, and this phosphorylation event inhibited kinesin-1.  Finally, vesicle motility assays revealed previously unrecognized, isoform-specific effects of p38 on FAT.  Axon-autonomous activation of the p38 pathway represents a novel gain of toxic function for FALS-linked SOD1 proteins consistent with the dying-back pattern of neurodegeneration characteristic of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirO1D7q7G5bVg90H21EOLACvtfcHk0lg6Vzc52cUEzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVejsLnN&md5=33d6944dc106100da9eedd3d999ad5f7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0065235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0065235%26sid%3Dliteratum%253Aachs%26aulast%3DMorfini%26aufirst%3DG.%2BA.%26aulast%3DBosco%26aufirst%3DD.%2BA.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DGatto%26aufirst%3DR.%26aulast%3DKaminska%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DMolla%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DL.%26aulast%3DMarangoni%26aufirst%3DM.%2BN.%26aulast%3DBerth%26aufirst%3DS.%26aulast%3DTavassoli%26aufirst%3DE.%26aulast%3DBagnato%26aufirst%3DC.%26aulast%3DTiwari%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DL.%2BJ.%26aulast%3DPigino%26aufirst%3DG.%2BF.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DHuang%26aufirst%3DC.-F.%26aulast%3DBanker%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DR.%2BH.%26aulast%3DBrady%26aufirst%3DS.%2BT.%26atitle%3DInhibition%2520of%2520Fast%2520Axonal%2520Transport%2520by%2520Pathogenic%2520SOD1%2520Involves%2520Activation%2520of%2520p38%2520MAP%2520Kinase%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0065235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Origlia, N.</span></span> <span> </span><span class="NLM_article-title">An Isoform-Selective p38α Mitogen-Activated Protein Kinase Inhibitor Rescues Early Entorhinal Cortex Dysfunctions in a Mouse Model of Alzheimer’s Disease</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2Fj.neurobiolaging.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=30007168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=86-91&author=G.+Rutiglianoauthor=M.+Staziauthor=O.+Arancioauthor=D.+M.+Wattersonauthor=N.+Origlia&title=An+Isoform-Selective+p38%CE%B1+Mitogen-Activated+Protein+Kinase+Inhibitor+Rescues+Early+Entorhinal+Cortex+Dysfunctions+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.neurobiolaging.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Rutigliano, Grazia; Stazi, Martina; Arancio, Ottavio; Watterson, D. Martin; Origlia, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-91</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuroinflammation is a fundamental mechanism in Alzheimer's disease (AD) progression.  The stress-induced activation of the p38α mitogen-activated protein kinase (MAPK) leads to increased prodn. of proinflammatory cytokines and neurodegeneration.  We investigated the effects of an isoform selective p38α MAPK inhibitor, MW01-18-150SRM (MW150), administered at 2.5 mg/kg/d (i.p.; 14 days) on early entorhinal cortex (EC) alterations in an AD mouse model carrying human mutations of the amyloid precursor protein (mhAPP).  We used electrophysiol. analyses with long-term potentiation induction in EC-contg. brain slices and EC-relevant associative memory tasks.  We found that MW150 was capable of rescuing long-term potentiation in 2-mo old mhAPP mice.  Acute delivery of MW150 to brain slices was similarly effective in rescuing long-term potentiation, with a comparable efficacy to that of the widely used multikinase inhibitor SB203580.  MW150-treated mhAPP mice demonstrated improved ability to discriminate novel assocns. between objects and their position/context.  Our findings suggest that the selective inhibition of the stress-activated p38α MAPK with MW150 can attenuate the EC dysfunctions assocd. with neuroinflammation in an early stage of AD progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-g02KszQjrrVg90H21EOLACvtfcHk0lihtNbsefZzJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI&md5=dc0717e4b389cb4191e52b15aaff96a6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DRutigliano%26aufirst%3DG.%26aulast%3DStazi%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DOriglia%26aufirst%3DN.%26atitle%3DAn%2520Isoform-Selective%2520p38%25CE%25B1%2520Mitogen-Activated%2520Protein%2520Kinase%2520Inhibitor%2520Rescues%2520Early%2520Entorhinal%2520Cortex%2520Dysfunctions%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2018%26volume%3D70%26spage%3D86%26epage%3D91%26doi%3D10.1016%2Fj.neurobiolaging.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Kinases in Central Nervous System Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">892</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1038/nrd2999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnrd2999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=19876042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=892-909&author=L.+K.+Chicoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=Targeting+Protein+Kinases+in+Central+Nervous+System+Disorders&doi=10.1038%2Fnrd2999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein kinases in central nervous system disorders</span></div><div class="casAuthors">Chico, Laura K.; Van Eldik, Linda J.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">892-909</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues assocd. specifically with CNS drug discovery.  However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclin. and clin. development.  We review candidate compds. and discuss selected CNS protein kinases that are emerging as important therapeutic targets.  In addn., we analyze trends in small-mol. properties that correlate with key challenges in CNS drug discovery, such as blood-brain barrier penetrance and cytochrome P 450-mediated metab., and discuss the potential of future approaches that will integrate mol.-fragment expansion with pharmacoinformatics to address these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzQo2JmuPNlrVg90H21EOLACvtfcHk0lihtNbsefZzJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO&md5=4dc1f6b7542e59c99f91525d37c49973</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2999%26sid%3Dliteratum%253Aachs%26aulast%3DChico%26aufirst%3DL.%2BK.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520Protein%2520Kinases%2520in%2520Central%2520Nervous%2520System%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D892%26epage%3D909%26doi%3D10.1038%2Fnrd2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behanna, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties and CYP2D6 Substrates: Central Nervous System Therapeutics Case Study and Pattern Analysis of a Substrate Database</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2204</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1124%2Fdmd.109.028134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=19661215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOqtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2204-2211&author=L.+K.+Chicoauthor=H.+A.+Behannaauthor=W.+Huauthor=G.+Zhongauthor=S.+M.+Royauthor=D.+M.+Watterson&title=Molecular+Properties+and+CYP2D6+Substrates%3A+Central+Nervous+System+Therapeutics+Case+Study+and+Pattern+Analysis+of+a+Substrate+Database&doi=10.1124%2Fdmd.109.028134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database</span></div><div class="casAuthors">Chico, Laura K.; Behanna, Heather A.; Hu, Wenhui; Zhong, Guifa; Roy, Saktimayee Mitra; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2204-2211</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CYP2D6 substrate status is a crit. Go/No Go decision criteria in central nervous system (CNS) drug discovery efforts because the polymorphic nature of CYP2D6 can lead to variable patient safety and drug efficacy.  In addn., CYP2D6 is disproportionately involved in the metab. of CNS drugs compared with other drug classes.  Therefore, identifying trends in small mol. properties of CNS-penetrant compds. that can help discriminate potential CYP2D6 substrates from nonsubstrates would allow addnl. prioritization in the synthesis and biol. evaluation of new therapeutic candidates.  The authors report the conversion of the CNS drug minaprine from substrate to nonsubstrate, as well as the conversion of the related CNS drug minozac from nonsubstrate to substrate, through the use of analog synthesis and CYP2D6 enzyme kinetic analyses.  No single mol. property strongly correlated with substrate status for this 3-amino-4-methyl-6-phenylpyridazine scaffold, although mol. vol. and charge appeared to be indirectly related.  A parsed database of CYP2D6 substrates across diverse chem. structures was assembled and analyzed for phys. property trends correlating with substrate status.  The authors found that a complex interplay of properties influenced CYP2D6 substrate status and that the particular chem. scaffold affects which properties are most prominent.  The results also identified an unexpected issue in CNS drug discovery, in that some property trends correlative with CYP2D6 substrates overlap previously reported properties that correlate with CNS penetrance.  These results suggest the need for a careful balance in the design and synthesis of new CNS therapeutic candidates to avoid CYP2D6 substrate status while maintaining CNS penetrance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD8Pr6CQrxuLVg90H21EOLACvtfcHk0lihtNbsefZzJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOqtbfI&md5=4cbb608ecd32316c291d3b90095bb768</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028134%26sid%3Dliteratum%253Aachs%26aulast%3DChico%26aufirst%3DL.%2BK.%26aulast%3DBehanna%26aufirst%3DH.%2BA.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DG.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DMolecular%2520Properties%2520and%2520CYP2D6%2520Substrates%253A%2520Central%2520Nervous%2520System%2520Therapeutics%2520Case%2520Study%2520and%2520Pattern%2520Analysis%2520of%2520a%2520Substrate%2520Database%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2204%26epage%3D2211%26doi%3D10.1124%2Fdmd.109.028134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RalayRanaivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behanna, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wing, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Development of a Novel Therapeutic Suppressor of Brain Proinflammatory Cytokine Up-Regulation that Attenuates Synaptic Dysfunction and Behavioral Deficits</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2Fj.bmcl.2006.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=17079143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFGktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=414-418&author=W.+Huauthor=H.+RalayRanaivoauthor=S.+M.+Royauthor=H.+A.+Behannaauthor=L.+K.+Wingauthor=L.+Munozauthor=L.+Guoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=Development+of+a+Novel+Therapeutic+Suppressor+of+Brain+Proinflammatory+Cytokine+Up-Regulation+that+Attenuates+Synaptic+Dysfunction+and+Behavioral+Deficits&doi=10.1016%2Fj.bmcl.2006.10.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits</span></div><div class="casAuthors">Hu, Wenhui; Ranaivo, Hantamalala Ralay; Roy, Saktimayee M.; Behanna, Heather A.; Wing, Laura K.; Munoz, Lenka; Guo, Ling; Van Eldik, Linda J.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">414-418</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We report the development of a novel, aq.-sol., safe, small mol., exptl. therapeutic I that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits.  A good manufg. protocol prodn. of the dihydrochloride hydrate of I as potential active pharmaceutical ingredient is presented.  The development and large-scale availability of this novel compd. allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWTGYkJ4FPULVg90H21EOLACvtfcHk0lihtNbsefZzJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFGktQ%253D%253D&md5=6b55207ab3e1230193a7122eae3b4e84</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DRalayRanaivo%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DBehanna%26aufirst%3DH.%2BA.%26aulast%3DWing%26aufirst%3DL.%2BK.%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520Novel%2520Therapeutic%2520Suppressor%2520of%2520Brain%2520Proinflammatory%2520Cytokine%2520Up-Regulation%2520that%2520Attenuates%2520Synaptic%2520Dysfunction%2520and%2520Behavioral%2520Deficits%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D414%26epage%3D418%26doi%3D10.1016%2Fj.bmcl.2006.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+Fluorinated+Motifs+in+the+Design+and+Application+of+Bioisosteres+for+Drug+Design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lgrLgmfwLeuUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520Fluorinated%2520Motifs%2520in%2520the%2520Design%2520and%2520Application%2520of%2520Bioisosteres%2520for%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J. J.</span></span> <span> </span><span class="NLM_article-title">Selective Brain-Targeted Antagonism of p38 MAPKp Reduces Hippocampal IL-1 Levels and Improves Morris Water Maze Performance in Aged Rats</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.3233/JAD-150277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.3233%2FJAD-150277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=26401942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=219-227&author=J.+J.+Alam&title=Selective+Brain-Targeted+Antagonism+of+p38+MAPKp+Reduces+Hippocampal+IL-1+Levels+and+Improves+Morris+Water+Maze+Performance+in+Aged+Rats&doi=10.3233%2FJAD-150277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats</span></div><div class="casAuthors">Alam John J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  P38 mitogen activated protein kinase (MAPK) α modulates microglia-mediated inflammatory responses and a number of neuronal physiological processes.  OBJECTIVE:  To evaluate pre-clinically the pharmacological effects in the brain of p38 MAPKα inhibition with a brain-penetrant specific chemical antagonist.  METHODS:  VX-745, a blood-brain barrier penetrant, highly selective p38 MAPKα inhibitor, and clinical stage investigational drug, was utilized.  Initially, a pilot study in 26-month-old Tg2576 mice was conducted.  Subsequently, a definitive dose-response study was conducted in aged (20-22 months) rats with identified cognitive deficits; n = 15 per group: vehicle, 0.5, 1.5, and 4.5 mg/kg VX-745 by oral gavage twice daily for 3 weeks.  Assessments in aged rats included IL-1β, PSD-95, TNFα protein levels in hippocampus; and Morris water maze (MWM) test for cognitive performance.  RESULTS:  Drug effect could not be assessed in Tg2576 mice, as little inflammation was evident.  In cognitively-impaired aged rats, VX-745 led to significantly improved performance in the MWM and significant reduction in hippocampal IL-1β protein levels, though the effects were dissociated as the MWM effect was evident at a lower dose level than that required to lower IL-1β.  Drug concentration-effect relationships and predicted human doses were determined.  CONCLUSIONS:  Selective inhibition of p38 MAPKα with VX-745 in aged rats reduces hippocampal IL-1β levels and improves performance in the MWM.  As the two effects occur at different dose levels, the behavioral effect appears to be via a mechanism that is independent of reducing cytokine production.  The predicted human doses should minimize risks of systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfUvQHd8XXxf6BottYdIAWfW6udTcc2eZKt4FkuFGZ67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D&md5=cec29afedc9795bd0680734acc367146</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3233%2FJAD-150277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150277%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DJ.%2BJ.%26atitle%3DSelective%2520Brain-Targeted%2520Antagonism%2520of%2520p38%2520MAPKp%2520Reduces%2520Hippocampal%2520IL-1%2520Levels%2520and%2520Improves%2520Morris%2520Water%2520Maze%2520Performance%2520in%2520Aged%2520Rats%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D48%26spage%3D219%26epage%3D227%26doi%3D10.3233%2FJAD-150277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule–Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule%E2%80%93Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0li3S7rGEbVFYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule%25E2%2580%2593Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0li3S7rGEbVFYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrzaszcz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragisic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, M. S.</span></span> <span> </span><span class="NLM_article-title">MinozacTreatment Prevents Increased Seizure Susceptibility in a Mouse “two-hit” Model of Closed Skull Traumatic Brain Injury and ElectroconvulsiveShock-induced Seizures</span>. <i>J. Neurotrauma.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1295</span>, <span class="refDoi"> DOI: 10.1089/neu.2009.1227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1089%2Fneu.2009.1227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=20486807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC3cjgtVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=1283-1295&author=M.+Chrzaszczauthor=C.+Venkatesanauthor=T.+Dragisicauthor=D.+M.+Wattersonauthor=M.+S.+Wainwright&title=MinozacTreatment+Prevents+Increased+Seizure+Susceptibility+in+a+Mouse+%E2%80%9Ctwo-hit%E2%80%9D+Model+of+Closed+Skull+Traumatic+Brain+Injury+and+ElectroconvulsiveShock-induced+Seizures&doi=10.1089%2Fneu.2009.1227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures</span></div><div class="casAuthors">Chrzaszcz MaryAnn; Venkatesan Charu; Dragisic Tina; Watterson D Martin; Wainwright Mark S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurotrauma</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1283-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mechanisms linking traumatic brain injury (TBI) to post-traumatic epilepsy (PTE) are not known and no therapy for prevention of PTE is available.  We used a mouse closed-skull midline impact model to test the hypotheses that TBI increases susceptibility to seizures in a "two-hit" injury model, and that suppression of cytokine upregulation after the first hit will attenuate the increased susceptibility to the second neurological insult.  Adult male CD-1 mice underwent midline closed skull pneumatic impact.  At 3 and 6 h after impact or sham procedure, the mice were injected IP with either Minozac (Mzc), a suppressor of proinflammatory cytokine upregulation, or vehicle (saline).  On day 7 after sham operation or TBI, seizures were induced using electroconvulsive shock (ECS), and susceptibility to seizures was measured by the current required for seizure induction.  Activation of glia, neuronal injury, and metallothionein-immunoreactive cells were quantified in the hippocampus by immunohistochemical methods.  Neurobehavioral function over 14-day recovery was quantified using the Barnes maze.  Following TBI there was a significant increase in susceptibility to seizures induced by ECS, and this susceptibility was prevented by suppression of cytokine upregulation with Mzc.  Astrocyte activation, metallothionein expression, and neurobehavioral impairment were also increased in the two-hit group subjected to combined TBI and ECS.  These enhanced responses in the two-hit group were also prevented by suppression of proinflammatory cytokine upregulation with Mzc.  These data implicate glial activation in the mechanisms of epileptogenesis after TBI, and identify a potential therapeutic approach to attenuate the delayed neurological sequelae of TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Un0OlAnsP3thwrmtH4OBfW6udTcc2eYGr3t8kaO2k7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjgtVOltQ%253D%253D&md5=e67925069732fb365586beaadd0c0879</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1089%2Fneu.2009.1227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fneu.2009.1227%26sid%3Dliteratum%253Aachs%26aulast%3DChrzaszcz%26aufirst%3DM.%26aulast%3DVenkatesan%26aufirst%3DC.%26aulast%3DDragisic%26aufirst%3DT.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DWainwright%26aufirst%3DM.%2BS.%26atitle%3DMinozacTreatment%2520Prevents%2520Increased%2520Seizure%2520Susceptibility%2520in%2520a%2520Mouse%2520%25E2%2580%259Ctwo-hit%25E2%2580%259D%2520Model%2520of%2520Closed%2520Skull%2520Traumatic%2520Brain%2520Injury%2520and%2520ElectroconvulsiveShock-induced%2520Seizures%26jtitle%3DJ.%2520Neurotrauma.%26date%3D2010%26volume%3D27%26spage%3D1283%26epage%3D1295%26doi%3D10.1089%2Fneu.2009.1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span> <span> </span><span class="NLM_article-title">The Dynamic Nature of the Kinome</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1042/BJ20121456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1042%2FBJ20121456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23343193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2013&pages=1-8&author=L.+M.+Gravesauthor=J.+S.+Duncanauthor=M.+C.+Whittleauthor=G.+L.+Johnson&title=The+Dynamic+Nature+of+the+Kinome&doi=10.1042%2FBJ20121456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The dynamic nature of the kinome</span></div><div class="casAuthors">Graves, Lee M.; Duncan, James S.; Whittle, Martin C.; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in proteomics have facilitated the anal. of the kinome 'en masse'.  What these studies have revealed is a surprisingly dynamic network of kinase responses to highly selective kinase inhibitors, thereby illustrating the complex biol. responses to these small mols.  Moreover these studies have identified key transcription factors, such as c-Myc and FOXO (forkhead box O), that play pivotal roles in kinome reprogramming in cancer cells.  Since many kinase inhibitors fail despite a high efficacy of blocking their intended targets, elucidating kinome changes at a more global level will be essential to understanding the mechanisms of kinase inhibitor pharmacol.  The development of technologies to study the kinome, as well as examples of kinome resilience and reprogramming, will be discussed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruuFxman4qSbVg90H21EOLACvtfcHk0lgErFoz6E7pOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgs78%253D&md5=9748c28a92494f1e9342911b0f77cef4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1042%2FBJ20121456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121456%26sid%3Dliteratum%253Aachs%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DWhittle%26aufirst%3DM.%2BC.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DThe%2520Dynamic%2520Nature%2520of%2520the%2520Kinome%26jtitle%3DBiochem.%2520J.%26date%3D2013%26volume%3D450%26spage%3D1%26epage%3D8%26doi%3D10.1042%2FBJ20121456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. C.</span></span> <span> </span><span class="NLM_article-title">Mitogen-Activated Protein Kinases in Innate Immunity</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nri3495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnri3495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23954936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=679-692&author=J.+S.+C.+Arthurauthor=S.+C.+Ley&title=Mitogen-Activated+Protein+Kinases+in+Innate+Immunity&doi=10.1038%2Fnri3495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinases in innate immunity</span></div><div class="casAuthors">Arthur, J. Simon C.; Ley, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Following pathogen infection or tissue damage, the stimulation of pattern recognition receptors on the cell surface and in the cytoplasm of innate immune cells activates members of each of the major mitogen-activated protein kinase (MAPK) subfamilies - the extracellular signal-regulated kinase (ERK), p38 and Jun N-terminal kinase (JNK) subfamilies.  In conjunction with the activation of nuclear factor-κB and interferon-regulatory factor transcription factors, MAPK activation induces the expression of multiple genes that together regulate the inflammatory response.  In this Review, we discuss our current knowledge about the regulation and the function of MAPKs in innate immunity, as well as the importance of neg. feedback loops in limiting MAPK activity to prevent host tissue damage.  We also examine how pathogens have evolved complex mechanisms to manipulate MAPK activation to increase their virulence.  Finally, we consider the potential of the pharmacol. targeting of MAPK pathways to treat autoimmune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokaFaArJ0-rLVg90H21EOLACvtfcHk0lgErFoz6E7pOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI&md5=385a2fc463805b41ec03296345fb5d86</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnri3495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3495%26sid%3Dliteratum%253Aachs%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DLey%26aufirst%3DS.%2BC.%26atitle%3DMitogen-Activated%2520Protein%2520Kinases%2520in%2520Innate%2520Immunity%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnri3495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">The p383 MAPK Regulates Microglial Responsiveness to Diffuse Traumatic Brain Injury</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">6143</span>– <span class="NLM_lpage">6153</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5399-12.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1523%2FJNEUROSCI.5399-12.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23554495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyjtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=6143-6153&author=A.+D.+Bachstetterauthor=R.+K.+Roweauthor=M.+Kanekoauthor=D.+Gouldingauthor=J.+Lifshitzauthor=L.+J.+Van+Eldik&title=The+p383+MAPK+Regulates+Microglial+Responsiveness+to+Diffuse+Traumatic+Brain+Injury&doi=10.1523%2FJNEUROSCI.5399-12.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury</span></div><div class="casAuthors">Bachstetter, Adam D.; Rowe, Rachel K.; Kaneko, Machi; Goulding, Danielle; Lifshitz, Jonathan; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6143-6153</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neuropathol. after traumatic brain injury (TBI) is the result of both the immediate impact injury and secondary injury mechanisms.  Unresolved post-traumatic glial activation is a secondary injury mechanism that contributes to a chronic state of neuroinflammation in both animal models of TBI and human head injury patients.  We recently demonstrated, using in vitro models, that p38α MAPK signaling in microglia is a key event in promoting cytokine prodn. in response to diverse disease-relevant stressors and subsequent inflammatory neuronal dysfunction.  From these findings, we hypothesized that the p38α signaling pathway in microglia could be contributing to the secondary neuropathol. sequelae after a diffuse TBI.  Mice where microglia were p38α-deficient (p38α KO) were protected against TBI-induced motor deficits and synaptic protein loss.  In wild-type (WT) mice, diffuse TBI produced microglia morphol. activation that lasted for at least 7 d; however, p38α KO mice failed to activate this response.  Unexpectedly, we found that the peak of the early, acute phase cytokine and chemokine levels was increased in injured p38α KO mice compared with injured WT mice.  The increased cytokine levels in the p38α KO mice could not be accounted for by more infiltration of macrophages or neutrophils, or increased astrogliosis.  By 7 d after injury, the cytokine and chemokine levels remained elevated in injured WT mice but not in p38α KO mice.  Together, these data suggest that p38α balances the inflammatory response by acutely attenuating the early proinflammatory cytokine surge while perpetuating the chronic microglia activation after TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeH0wYYUgxmLVg90H21EOLACvtfcHk0lgErFoz6E7pOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyjtL%252FP&md5=e34ee60c9ccb4785fcf474530cec4fa2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5399-12.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5399-12.2013%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DRowe%26aufirst%3DR.%2BK.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DGoulding%26aufirst%3DD.%26aulast%3DLifshitz%26aufirst%3DJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DThe%2520p383%2520MAPK%2520Regulates%2520Microglial%2520Responsiveness%2520to%2520Diffuse%2520Traumatic%2520Brain%2520Injury%26jtitle%3DJ.%2520Neurosci.%26date%3D2013%26volume%3D33%26spage%3D6143%26epage%3D6153%26doi%3D10.1523%2FJNEUROSCI.5399-12.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Microglia p38M MAPK is Critical for LPS-Induced Neuron Degeneration Through a Mechanism Involving TNF</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">84</span>, <span class="refDoi"> DOI: 10.1186/1750-1326-6-84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2F1750-1326-6-84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=22185458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVOqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=84&author=B.+Xingauthor=A.+D.+Bachstetterauthor=L.+J.+Van+Eldik&title=Microglia+p38M+MAPK+is+Critical+for+LPS-Induced+Neuron+Degeneration+Through+a+Mechanism+Involving+TNF&doi=10.1186%2F1750-1326-6-84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα</span></div><div class="casAuthors">Xing, Bin; Bachstetter, Adam D.; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The p38α MAPK isoform is a well-established therapeutic target in peripheral inflammatory diseases, but the importance of this kinase in pathol. microglial activation and detrimental inflammation in CNS disorders is less well understood.  To test the role of the p38α MAPK isoform in microglia-dependent neuron damage, we used primary microglia from wild-type (WT) or p38α MAPK conditional knockout (KO) mice in co-culture with WT cortical neurons, and measured neuron damage after LPS insult.  Results: We found that neurons in co-culture with p38α-deficient microglia were protected against LPS-induced synaptic loss, neurite degeneration, and neuronal death.  The involvement of the proinflammatory cytokine TNFα was demonstrated by the findings that p38α KO microglia produced much less TNFα in response to LPS compared to WT microglia, that adding back TNFα to KO microglia/neuron co-cultures increased the LPS-induced neuron damage, and that neutralization of TNFα in WT microglia/neuron co-cultures prevented the neuron damage.  These results using cell-selective, isoform-specific KO mice demonstrate that the p38α MAPK isoform in microglia is a key mediator of LPS-induced neuronal and synaptic dysfunction.  The findings also provide evidence that a major mechanism by which LPS activation of microglia p38α MAPK signaling leads to neuron damage is through up-regulation of the proinflammatory cytokine TNFα.  Conclusions: The data suggest that selective targeting of p38α MAPK signaling should be explored as a potential therapeutic strategy for CNS disorders where overprodn. of proinflammatory cytokines is implicated in disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_XrXkCLeNbVg90H21EOLACvtfcHk0lgErFoz6E7pOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVOqurY%253D&md5=cb3f5f671704d3262be633221f517f7e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-6-84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-6-84%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DB.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DMicroglia%2520p38M%2520MAPK%2520is%2520Critical%2520for%2520LPS-Induced%2520Neuron%2520Degeneration%2520Through%2520a%2520Mechanism%2520Involving%2520TNF%26jtitle%3DMol.%2520Neurodegener.%26date%3D2011%26volume%3D6%26spage%3D84%26doi%3D10.1186%2F1750-1326-6-84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiorito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakkar, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Quinoline Derivatives: Discovery of a Potent and Selective Phosphodiesterase 5 Inhibitor for the Treatment of Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2Fj.ejmech.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23313637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVemsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=285-294&author=J.+Fioritoauthor=F.+Saeedauthor=H.+Zhangauthor=A.+Staniszewskiauthor=Y.+Fengauthor=Y.+I.+Francisauthor=S.+Raoauthor=D.+M.+Thakkarauthor=S.-X.+Dengauthor=D.+W.+Landryauthor=O.+Arancio&title=Synthesis+of+Quinoline+Derivatives%3A+Discovery+of+a+Potent+and+Selective+Phosphodiesterase+5+Inhibitor+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Fiorito, Jole; Saeed, Faisal; Zhang, Hong; Staniszewski, Agnieszka; Feng, Yan; Francis, Yitshak I.; Rao, Sudha; Thakkar, Devarshi M.; Deng, Shi-Xian; Landry, Donald W.; Arancio, Ottavio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">285-294</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphodiesterase type 5 (PDE5) mediates the degrdn. of cGMP in a variety of tissues including brain.  Recent studies have demonstrated the importance of the nitric oxide/cGMP/cAMP-responsive element-binding protein (CREB) pathway to the process of learning and memory.  Thus, PDE5 inhibitors (PDE5Is) are thought to be promising new therapeutic agents for the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory loss.  To explore this possibility, a series of quinoline derivs. were synthesized and evaluated.  We found that compd. I selectively inhibits PDE5 with an IC50 of 0.27 nM and readily crosses the blood brain barrier.  In an in vivo mouse model of AD, compd. I rescues synaptic and memory defects.  Quinoline-based, CNS-permeant PDE5Is have potential for AD therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6B39cj4LBh7Vg90H21EOLACvtfcHk0lhnMJftPH2efA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVemsrg%253D&md5=335f11f0576ec3fe8dc1bcf5df2cebdc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DFiorito%26aufirst%3DJ.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DFrancis%26aufirst%3DY.%2BI.%26aulast%3DRao%26aufirst%3DS.%26aulast%3DThakkar%26aufirst%3DD.%2BM.%26aulast%3DDeng%26aufirst%3DS.-X.%26aulast%3DLandry%26aufirst%3DD.%2BW.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DSynthesis%2520of%2520Quinoline%2520Derivatives%253A%2520Discovery%2520of%2520a%2520Potent%2520and%2520Selective%2520Phosphodiesterase%25205%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D60%26spage%3D285%26epage%3D294%26doi%3D10.1016%2Fj.ejmech.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piacentini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltrons, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li Puma, D.D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulisano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidowitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroutunian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honig, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moe, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Adamio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaan, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Extracellular Tau Oligomers Produce an Immediate Impairment of LTP and Memory</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19393</span>, <span class="refDoi"> DOI: 10.1038/srep19393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fsrep19393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=26786552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ertrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=19393&author=M.+Faauthor=D.+Puzzoauthor=R.+Piacentiniauthor=A.+Staniszewskiauthor=H.+Zhangauthor=M.+A.+Baltronsauthor=D.D.+Li+Pumaauthor=I.+Chatterjeeauthor=J.+Liauthor=F.+Saeedauthor=H.+L.+Bermanauthor=C.+Ripoliauthor=W.+Gulisanoauthor=J.+Gonzalezauthor=H.+Tianauthor=J.+A.+Costaauthor=P.+Lopezauthor=E.+Davidowitzauthor=W.+H.+Yuauthor=V.+Haroutunianauthor=L.+M.+Brownauthor=A.+Palmeriauthor=E.+M.+Sigurdssonauthor=K.+E.+Duffauthor=A.+F.+Teichauthor=L.+S.+Honigauthor=M.+Sierksauthor=J.+G.+Moeauthor=L.+D%E2%80%99Adamioauthor=C.+Grassiauthor=N.+M.+Kanaanauthor=P.+E.+Fraserauthor=O.+Arancio&title=Extracellular+Tau+Oligomers+Produce+an+Immediate+Impairment+of+LTP+and+Memory&doi=10.1038%2Fsrep19393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory</span></div><div class="casAuthors">Fa, M.; Puzzo, D.; Piacentini, R.; Staniszewski, A.; Zhang, H.; Baltrons, M. A.; Li Puma, D. D.; Chatterjee, I.; Li, J.; Saeed, F.; Berman, H. L.; Ripoli, C.; Gulisano, W.; Gonzalez, J.; Tian, H.; Costa, J. A.; Lopez, P.; Davidowitz, E.; Yu, W. H.; Haroutunian, V.; Brown, L. M.; Palmeri, A.; Sigurdsson, E. M.; Duff, K. E.; Teich, A. F.; Honig, L. S.; Sierks, M.; Moe, J. G.; D'Adamio, L.; Grassi, C.; Kanaan, N. M.; Fraser, P. E.; Arancio, O.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19393</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Non-fibrillar sol. oligomeric forms of amyloid-β peptide (oAβ) and tau proteins are likely to play a major role in Alzheimer's disease (AD).  The prevailing hypothesis on the disease etiopathogenesis is that oAβ initiates tau pathol. that slowly spreads throughout the medial temporal cortex and neocortices independently of Aβ, eventually leading to memory loss.  Here we show that a brief exposure to extracellular recombinant human tau oligomers (oTau), but not monomers, produces an impairment of long-term potentiation (LTP) and memory, independent of the presence of high oAβ levels.  The impairment is immediate as it raises as soon as 20 min after exposure to the oligomers.  These effects are reproduced either by oTau extd. from AD human specimens, or naturally produced in mice overexpressing human tau.  Finally, we found that oTau could also act in combination with Aβ to produce these effects, as sub-toxic doses of the two peptides combined lead to LTP and memory impairment.  These findings provide a novel view of the effects of tau and Aβ on memory loss, offering new therapeutic opportunities in the therapy of AD and other neurodegenerative diseases assocd. with Aβ and tau pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnnD-KPPHPobVg90H21EOLACvtfcHk0lhnMJftPH2efA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ertrg%253D&md5=72adf9bf06a4051973905912b73931d4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fsrep19393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep19393%26sid%3Dliteratum%253Aachs%26aulast%3DFa%26aufirst%3DM.%26aulast%3DPuzzo%26aufirst%3DD.%26aulast%3DPiacentini%26aufirst%3DR.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBaltrons%26aufirst%3DM.%2BA.%26aulast%3DLi%2BPuma%26aufirst%3DD.D.%26aulast%3DChatterjee%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DBerman%26aufirst%3DH.%2BL.%26aulast%3DRipoli%26aufirst%3DC.%26aulast%3DGulisano%26aufirst%3DW.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DCosta%26aufirst%3DJ.%2BA.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DDavidowitz%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DW.%2BH.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DBrown%26aufirst%3DL.%2BM.%26aulast%3DPalmeri%26aufirst%3DA.%26aulast%3DSigurdsson%26aufirst%3DE.%2BM.%26aulast%3DDuff%26aufirst%3DK.%2BE.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DHonig%26aufirst%3DL.%2BS.%26aulast%3DSierks%26aufirst%3DM.%26aulast%3DMoe%26aufirst%3DJ.%2BG.%26aulast%3DD%25E2%2580%2599Adamio%26aufirst%3DL.%26aulast%3DGrassi%26aufirst%3DC.%26aulast%3DKanaan%26aufirst%3DN.%2BM.%26aulast%3DFraser%26aufirst%3DP.%2BE.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DExtracellular%2520Tau%2520Oligomers%2520Produce%2520an%2520Immediate%2520Impairment%2520of%2520LTP%2520and%2520Memory%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D19393%26doi%3D10.1038%2Fsrep19393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolomanov, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puschmann, H.</span></span> <span> </span><span class="NLM_article-title">OLEX2: A Complete Structure Solution, Refinement and Analysis Program</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1107/S0021889808042726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1107%2FS0021889808042726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=339-341&author=O.+V.+Dolomanovauthor=L.+J.+Bourhisauthor=R.+J.+Gildeaauthor=J.+A.+K.+Howardauthor=H.+Puschmann&title=OLEX2%3A+A+Complete+Structure+Solution%2C+Refinement+and+Analysis+Program&doi=10.1107%2FS0021889808042726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">OLEX2: a complete structure solution, refinement and analysis program</span></div><div class="casAuthors">Dolomanov, Oleg V.; Bourhis, Luc J.; Gildea, Richard J.; Howard, Judith A. K.; Puschmann, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-341</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">New software, OLEX2, was developed for the detn., visualization and anal. of mol. crystal structures.  The software has a portable mouse-driven workflow-oriented and fully comprehensive graphical user interface for structure soln., refinement and report generation, as well as novel tools for structure anal.  OLEX2 seamlessly links all aspects of the structure soln., refinement and publication process and presents them in a single workflow-driven package, with the ultimate goal of producing an application which will be useful to both chemists and crystallographers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIYSUbyzIgxbVg90H21EOLACvtfcHk0liAopthSie3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D&md5=7a2f9697b13b8e76de0e7dc5074ab229</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0021889808042726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889808042726%26sid%3Dliteratum%253Aachs%26aulast%3DDolomanov%26aufirst%3DO.%2BV.%26aulast%3DBourhis%26aufirst%3DL.%2BJ.%26aulast%3DGildea%26aufirst%3DR.%2BJ.%26aulast%3DHoward%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DPuschmann%26aufirst%3DH.%26atitle%3DOLEX2%253A%2520A%2520Complete%2520Structure%2520Solution%252C%2520Refinement%2520and%2520Analysis%2520Program%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2009%26volume%3D42%26spage%3D339%26epage%3D341%26doi%3D10.1107%2FS0021889808042726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">A Short History of SHELX</span>. <i>Acta Crystallogr., Sect. A: Found. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>A64</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/S0108767307043930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1107%2FS0108767307043930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=A64&publication_year=2008&pages=112-122&author=G.+M.+Sheldrick&title=A+Short+History+of+SHELX&doi=10.1107%2FS0108767307043930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of SHELX</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section A: Foundations of Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACACEQ</span>;
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An account is given of the development of the SHELX system of computer programs from SHELX-76 to the present day.  In addn. to identifying useful innovations that have come into general use through their implementation in SHELX, a crit. anal. is presented of the less-successful features, missed opportunities and desirable improvements for future releases of the software.  An attempt is made to understand how a program originally designed for photog. intensity data, punched cards and computers over 10000 times slower than an av. modern personal computer has managed to survive for so long.  SHELXL is the most widely used program for small-mol. refinement and SHELXS and SHELXD are often employed for structure soln. despite the availability of objectively superior programs.  SHELXL also finds a niche for the refinement of macromols. against high-resoln. or twinned data; SHELXPRO acts as an interface for macromol. applications.  SHELXC, SHELXD and SHELXE are proving useful for the exptl. phasing of macromols., esp. because they are fast and robust and so are often employed in pipelines for high-throughput phasing.  This paper could serve as a general literature citation when one or more of the open-source SHELX programs (and the Bruker AXS version SHELXTL) are employed in the course of a crystal-structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLPYyJyJ2RbVg90H21EOLACvtfcHk0liAopthSie3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO&md5=8f91f10be4a9df74b2a9dad522c71e6e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0108767307043930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767307043930%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DA%2520Short%2520History%2520of%2520SHELX%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D2008%26volume%3DA64%26spage%3D112%26epage%3D122%26doi%3D10.1107%2FS0108767307043930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure Refinement with SHELXL</span>. <i>Acta Crystallogr., Sect. C: Struct. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>C71</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1107/S2053229614024218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1107%2FS2053229614024218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=C71&publication_year=2015&pages=3-8&author=G.+M.+Sheldrick&title=Crystal+Structure+Refinement+with+SHELXL&doi=10.1107%2FS2053229614024218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS2053229614024218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053229614024218%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DCrystal%2520Structure%2520Refinement%2520with%2520SHELXL%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520C%253A%2520Struct.%2520Chem.%26date%3D2015%26volume%3DC71%26spage%3D3%26epage%3D8%26doi%3D10.1107%2FS2053229614024218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Niklas M. Tormählen, Mariella Martorelli, Annette Kuhn, Florian Maier, Jamil Guezguez, Michael Burnet, Wolfgang Albrecht, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Pierre Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01773%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BHighly%252BSelective%252BBrain%252BPenetrant%252Bp38%2525CE%2525B1%252BMitogen-Activated%252BProtein%252BKinase%252BInhibitors%26aulast%3DTorm%25C3%25A4hlen%26aufirst%3DNiklas%2BM.%26date%3D2021%26date%3D2020%26date%3D09102020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silke  Miller</span>, <span class="hlFld-ContribAuthor ">Maria-Jesus  Blanco</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 871-886. <a href="https://doi.org/10.1039/D1MD00036E" title="DOI URL">https://doi.org/10.1039/D1MD00036E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00036E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00036E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSmall%252Bmolecule%252Btherapeutics%252Bfor%252Bneuroinflammation-mediated%252Bneurodegenerative%252Bdisorders%26aulast%3DMiller%26aufirst%3DSilke%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D6%26spage%3D871%26epage%3D886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samantha E.  Stilley</span>, <span class="hlFld-ContribAuthor ">Randy D.  Blakely</span>. </span><span class="cited-content_cbyCitation_article-title">Rare Opportunities for Insights Into Serotonergic Contributions to Brain and Bowel Disorders: Studies of the SERT Ala56 Mouse. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular Neuroscience</span><span> <strong>2021,</strong> <em>15 </em><a href="https://doi.org/10.3389/fncel.2021.677563" title="DOI URL">https://doi.org/10.3389/fncel.2021.677563</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fncel.2021.677563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffncel.2021.677563%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520Neuroscience%26atitle%3DRare%252BOpportunities%252Bfor%252BInsights%252BInto%252BSerotonergic%252BContributions%252Bto%252BBrain%252Band%252BBowel%252BDisorders%25253A%252BStudies%252Bof%252Bthe%252BSERT%252BAla56%252BMouse%26aulast%3DStilley%26aufirst%3DSamantha%2BE.%26date%3D2021%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Xu</span>, <span class="hlFld-ContribAuthor ">Kaiwu  He</span>, <span class="hlFld-ContribAuthor ">Kaiqin  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Yang</span>, <span class="hlFld-ContribAuthor ">Lulin  Nie</span>, <span class="hlFld-ContribAuthor ">Ding  Dan</span>, <span class="hlFld-ContribAuthor ">Jianjun  Liu</span>, <span class="hlFld-ContribAuthor ">Chang-E.  Zhang</span>, <span class="hlFld-ContribAuthor ">Xifei  Yang</span>, . </span><span class="cited-content_cbyCitation_article-title">Low-Dose Copper Exposure Exacerbates Depression-Like Behavior in ApoE4 Transgenic Mice. </span><span class="cited-content_cbyCitation_journal-name">Oxidative Medicine and Cellular Longevity</span><span> <strong>2021,</strong> <em>2021 </em>, 1-20. <a href="https://doi.org/10.1155/2021/6634181" title="DOI URL">https://doi.org/10.1155/2021/6634181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2021/6634181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2021%2F6634181%26sid%3Dliteratum%253Aachs%26jtitle%3DOxidative%2520Medicine%2520and%2520Cellular%2520Longevity%26atitle%3DLow-Dose%252BCopper%252BExposure%252BExacerbates%252BDepression-Like%252BBehavior%252Bin%252BApoE4%252BTransgenic%252BMice%26aulast%3DXu%26aufirst%3DJia%26date%3D2021%26volume%3D2021%26spage%3D1%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Seyyedmohsen  Hosseinibarkooie</span>, <span class="hlFld-ContribAuthor ">Adam L.  Borne</span>, <span class="hlFld-ContribAuthor ">Mitchell E.  Granade</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Brulet</span>, <span class="hlFld-ContribAuthor ">Thurl E.  Harris</span>, <span class="hlFld-ContribAuthor ">Heather A.  Ferris</span>, <span class="hlFld-ContribAuthor ">Ku-Lung  Hsu</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoproteomic profiling of kinases in live cells using electrophilic sulfonyl triazole probes. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (9)
                                     , 3295-3307. <a href="https://doi.org/10.1039/D0SC06623K" title="DOI URL">https://doi.org/10.1039/D0SC06623K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC06623K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC06623K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DChemoproteomic%252Bprofiling%252Bof%252Bkinases%252Bin%252Blive%252Bcells%252Busing%252Belectrophilic%252Bsulfonyl%252Btriazole%252Bprobes%26aulast%3DHuang%26aufirst%3DTao%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D9%26spage%3D3295%26epage%3D3307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moustafa M.  Madkour</span>, <span class="hlFld-ContribAuthor ">Hanan S.  Anbar</span>, <span class="hlFld-ContribAuthor ">Mohammed I.  El-Gamal</span>. </span><span class="cited-content_cbyCitation_article-title">Current status and future prospects of p38α/MAPK14 kinase and its inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113216. <a href="https://doi.org/10.1016/j.ejmech.2021.113216" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113216%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Bstatus%252Band%252Bfuture%252Bprospects%252Bof%252Bp38%2525CE%2525B1%25252FMAPK14%252Bkinase%252Band%252Bits%252Binhibitors%26aulast%3DMadkour%26aufirst%3DMoustafa%2BM.%26date%3D2021%26volume%3D213%26spage%3D113216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linda J.  Van Eldik</span>, <span class="hlFld-ContribAuthor ">Lumy  Sawaki</span>, <span class="hlFld-ContribAuthor ">Karen  Bowen</span>, <span class="hlFld-ContribAuthor ">Daniel T.  Laskowitz</span>, <span class="hlFld-ContribAuthor ">Robert J.  Noveck</span>, <span class="hlFld-ContribAuthor ">Byron  Hauser</span>, <span class="hlFld-ContribAuthor ">Lynn  Jordan</span>, <span class="hlFld-ContribAuthor ">Tracy G.  Spears</span>, <span class="hlFld-ContribAuthor ">Huali  Wu</span>, <span class="hlFld-ContribAuthor ">Kevin  Watt</span>, <span class="hlFld-ContribAuthor ">Shruti  Raja</span>, <span class="hlFld-ContribAuthor ">Saktimayee M.  Roy</span>, <span class="hlFld-ContribAuthor ">D. Martin  Watterson</span>, <span class="hlFld-ContribAuthor ">Jeffrey T.  Guptill</span>. </span><span class="cited-content_cbyCitation_article-title">First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 131-143. <a href="https://doi.org/10.1002/cpdd.795" title="DOI URL">https://doi.org/10.1002/cpdd.795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.795%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DFirst%2525E2%252580%252590in%2525E2%252580%252590Human%252BStudies%252Bof%252BMW01%2525E2%252580%2525906%2525E2%252580%252590189WH%25252C%252Ba%252BBrain%2525E2%252580%252590Penetrant%25252C%252BAntineuroinflammatory%252BSmall%2525E2%252580%252590Molecule%252BDrug%252BCandidate%25253A%252BPhase%252B1%252BSafety%25252C%252BTolerability%25252C%252BPharmacokinetic%25252C%252Band%252BPharmacodynamic%252BStudies%252Bin%252BHealthy%252BAdult%252BVolunteers%26aulast%3DVan%2BEldik%26aufirst%3DLinda%2BJ.%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D2%26spage%3D131%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ursula A.  Germann</span>, <span class="hlFld-ContribAuthor ">John J.  Alam</span>. </span><span class="cited-content_cbyCitation_article-title">P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (15)
                                     , 5485. <a href="https://doi.org/10.3390/ijms21155485" title="DOI URL">https://doi.org/10.3390/ijms21155485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21155485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21155485%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DP38%2525CE%2525B1%252BMAPK%252BSignaling%2525E2%252580%252594A%252BRobust%252BTherapeutic%252BTarget%252Bfor%252BRab5-Mediated%252BNeurodegenerative%252BDisease%26aulast%3DGermann%26aufirst%3DUrsula%2BA.%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D15%26spage%3D5485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Falcicchia</span>, <span class="hlFld-ContribAuthor ">Francesca  Tozzi</span>, <span class="hlFld-ContribAuthor ">Ottavio  Arancio</span>, <span class="hlFld-ContribAuthor ">Daniel Martin  Watterson</span>, <span class="hlFld-ContribAuthor ">Nicola  Origlia</span>. </span><span class="cited-content_cbyCitation_article-title">Involvement of p38 MAPK in Synaptic Function and Dysfunction. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (16)
                                     , 5624. <a href="https://doi.org/10.3390/ijms21165624" title="DOI URL">https://doi.org/10.3390/ijms21165624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21165624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21165624%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DInvolvement%252Bof%252Bp38%252BMAPK%252Bin%252BSynaptic%252BFunction%252Band%252BDysfunction%26aulast%3DFalcicchia%26aufirst%3DChiara%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D16%26spage%3D5624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nur Syatila  Ab Ghani</span>, <span class="hlFld-ContribAuthor ">Reeki  Emrizal</span>, <span class="hlFld-ContribAuthor ">Haslina  Makmur</span>, <span class="hlFld-ContribAuthor ">Mohd  Firdaus-Raih</span>. </span><span class="cited-content_cbyCitation_article-title">Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19. </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2020,</strong> <em>18 </em>, 2931-2944. <a href="https://doi.org/10.1016/j.csbj.2020.10.013" title="DOI URL">https://doi.org/10.1016/j.csbj.2020.10.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2020.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2020.10.013%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DSide%252Bchain%252Bsimilarity%252Bcomparisons%252Bfor%252Bintegrated%252Bdrug%252Brepositioning%252Band%252Bpotential%252Btoxicity%252Bassessments%252Bin%252Bepidemic%252Bresponse%252Bscenarios%25253A%252BThe%252Bcase%252Bfor%252BCOVID-19%26aulast%3DAb%2BGhani%26aufirst%3DNur%2BSyatila%26date%3D2020%26volume%3D18%26spage%3D2931%26epage%3D2944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian M.  Simon</span>, <span class="hlFld-ContribAuthor ">Meaghan  Van Alstyne</span>, <span class="hlFld-ContribAuthor ">Francesco  Lotti</span>, <span class="hlFld-ContribAuthor ">Elena  Bianchetti</span>, <span class="hlFld-ContribAuthor ">Sarah  Tisdale</span>, <span class="hlFld-ContribAuthor ">D. Martin  Watterson</span>, <span class="hlFld-ContribAuthor ">George Z.  Mentis</span>, <span class="hlFld-ContribAuthor ">Livio  Pellizzoni</span>. </span><span class="cited-content_cbyCitation_article-title">Stasimon Contributes to the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 3885-3901.e5. <a href="https://doi.org/10.1016/j.celrep.2019.11.058" title="DOI URL">https://doi.org/10.1016/j.celrep.2019.11.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.celrep.2019.11.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.celrep.2019.11.058%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%26atitle%3DStasimon%252BContributes%252Bto%252Bthe%252BLoss%252Bof%252BSensory%252BSynapses%252Band%252BMotor%252BNeuron%252BDeath%252Bin%252Ba%252BMouse%252BModel%252Bof%252BSpinal%252BMuscular%252BAtrophy%26aulast%3DSimon%26aufirst%3DChristian%2BM.%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D3885%26epage%3D3901.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the human p38αMAPK:<b>11</b> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C">4R3C</a>). The protein is shown as a gray surface representation, and compound <b>11</b> is shown in a stick representation with the atoms colored white for carbon and blue for nitrogen. The mesh over compound <b>11</b> reflects the refined experimental electron density for compound <b>11</b>. (A) Compound <b>11</b> binds within the active site cleft, located between the bilobed catalytic domain, and has interactions with the connecting hinge region and a proximal hydrophobic pocket. (B) The compound <b>11</b> pyridine ring nitrogen forms a hydrogen bond interaction with the amide backbone at amino acids Leu108 and Met109, while the vicinal 2-naphthyl substituent fills the proximal hydrophobic pocket that adds to kinome selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Hit design via fragment expansion. Diversification of the inactive fragment compound <b>1</b> by amination yields the active hit compound <b>3</b>. The crystal structure of the p38αMAPK:<b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a>) identifies key molecular recognition features that are retained in the p38αMAPK:<b>3</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a>). The key features include the position and net charge of the pyridine ring nitrogen that allows H-bonding with the peptide backbone of the kinase hinge region and the occupancy of the localized hydrophobic pocket by the vicinal phenyl substituent. The representation and orientation of structures shown are as in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome target selectivity of hit compound <b>3</b> vs off-target kinases of widely used p38MAPK inhibitors. Red circles denote inhibition at specific kinases with IC<sub>50</sub> < 1 μM. (A) Kinase inhibition profile for the widely used p38αMAPK inhibitors VX-745, BIRB-796, and SB203580.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Crossover kinases with IC<sub>50</sub> < 1 μM for VX-745 include ABL1, ABL2, p38β, PDGFRβ, SRC; for BIRB-796 include BLK, CDK5, CDK8, DDR1, DDR2, EPHA3, EPHA7, EPHA8, EPHB2, p38β p38γ, FLT1, FRK, NTRK1, JNK1, JNK2, JNK3, KIT, MAP4K4, MRCKβ, PTK2β, RET, SLK, STK10, TIE1, TIE2, TNIK, TRKB, TRKC, ZAK; and for SB203580 include BRAF, CIT, CK1δ, CK1ε, DMPK, GAK, JNK2, JNK3, NLK, p38β, RIPK2, STK36, TNIK. (B) Kinase targets (IC<sub>50</sub> < 1 μM) for compound <b>3</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Table 4S</a>). Crossover kinases with IC<sub>50</sub> < 1 μM for compound <b>3</b> include CK1α, CK1δ, CK1ε, PKD3, RIPK2, and TNIK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinome selectivity of lead compound <b>9</b> and candidate compounds <b>10</b> and <b>11</b>. (A) Progression from compound <b>3</b> to compound <b>9</b> improved kinome selectivity to p38αMAPK, p38βMAPK, and atypical p38MAPK (NLK). In parallel with kinome selectivity improvement, crossover activity in GPCR agonist and antagonist cell based screens was removed as was in vivo dose limiting toxicity. (B) Refinement to compounds <b>10</b> and <b>11</b> biased inhibition toward p38αMAPK with retention of overall kinome selectivity, absence of GPCR agonist or antagonist activity, and absence of dose limiting toxicity. Red circles reflect inhibition at specific kinases with IC<sub>50</sub> < 1 μM.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of the p38αMAPK:<b>9</b> and p38αMAPK:<b>10</b> complexes. Shown are the representation and the orientation of (A) compound <b>9</b> and (B) compound <b>10</b> in the kinase active site. Perspective is the same as for compound <b>11</b> in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B. The hydrogen bond interaction of the pyridine ring nitrogen with the amide backbone of the kinase is retained in all structures, and the vicinal naphthyl groups of compounds <b>9</b>–<b>11</b> occupy the proximal hydrophobic pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Production scheme for compound <b>11</b>. The regulatory starting material (RSM) was prepared as previously described.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The intermediate compound was prepared by chlorination of the arylpyridazinone by POCl<sub>3</sub> in acetonitrile (ACN).<a onclick="showRef(event, 'ref13 ref14 ref22'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref22">(13,14,22)</a> The product substance (API) was generated by treatment with 1-methylpiperazine in ethanol. The summary chemical and physical properties, including crystal structure (CCDC deposit numbers 1851508 and 1851509), are in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf" class="ext-link">Tables 8S and 9S</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Exposure of compound <b>11</b> in plasma and brain after oral administration. Oral gavage administration results in comparable profiles for plasma (A) and brain (B). Oral doses (mg/kg): 1.25 (circles), 2.5 (squares), 5 (triangles), 10 (diamonds). Sampling time points (h): 0.25, 0.5, 1, 3, 6, 8, 12. Drug concentrations in biological matrices were determined by LC–MS/MS as described in <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>11</b> treatment rescues tau-induced memory impairment. The effects of compound <b>11</b> administration on hippocampus-dependent reference memory in the radial arm water maze (RAWM) and contextual fear memory in the contextual fear conditioning (CFC) assay were tested. (A) Human tau oligomer infusion (white triangles) into mice brains creates short-term memory impairment as shown by the significantly greater numbers of errors in the RAWM test compared to control, vehicle-infused mice (black circles) (two-way ANOVA, <i>p</i> < 0.01). Compound <b>11</b> administration (light gray diamonds) to the tau-infused animals (5 mg/kg ip, 20 min prior to start of testing) attenuates memory impairment (<i>p</i> < 0.05). Compound <b>11</b> administration in control, vehicle-infused mice (dark gray squares), had no effect. (B) Fear conditioning was assessed by exposing mice to a mild shock and then reassessed 24 h later to gauge “freezing” behavior. Tau-infused mice (white bar) experience reduced rates of freezing relative to control mice (“vehicle”; black bar) or control mice administered compound <b>11</b> (dark gray bar). Compound <b>11</b> administration in tau-infused mice (light gray bar) significantly increases freezing rates, demonstrating protection against tau-related memory impairment (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>11</b> treatment rescues cognitive deficits and cortex size in tau transgenic animal model. (A) Compound <b>11</b> treatment of rTg4510 mice (white triangles) results in a reduction in errors in the RAWM cognitive function assay compared to vehicle-treated rTg4510 animals (gray squares). Outcomes for compound <b>11</b> treated mice are comparable to disease state control mice (black circles; doxy-treated rTg4510 mice). (B) Contextual fear conditioning shows that compound <b>11</b> treatment (white bar) rescues the freezing deficit seen in rTg4510 mice treated with vehicle (gray bar), reaching levels similar to the control doxy-treated rTg4510 animals (black bar). (C) Vehicle-treated rTg4510 mice (gray bar) show reduced cerebral cortex size compared to control doxy-treated mice (black bar), and compound <b>11</b> treatment of rTg4510 mice (white bar) prevents the cortical tissue loss (<i>t</i> test: <i>p</i> < 0.05 vs Tg4510 vehicle). (D) Reductions in hippocampal size also manifest in the rTg4510 mice (gray bar) compared to the doxy mice (black bar). Compound <b>11</b> treatment of the rTg4510 mice (white bar) shows a trend toward rescuing the size deficit but does not reach statistical significance (<i>p</i> = 0.104 comparing compound <b>11</b>-treated rTg4510 mice vs vehicle treated rTg4510 mice).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>3</b>–<b>8</b>, <b>11</b>, and <b>17</b>–<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-butanol/ethanol, reflux, 15–48 h at 110–130 °C.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/medium/jm-2019-00058n_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>9</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-11/acs.jmedchem.9b00058/20190607/images/large/jm-2019-00058n_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00058&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-butanol, R<sup>3</sup>-amiine, 120 °C; (b) R<sup>6</sup>-boronic acid, DME/water, Na<sub>2</sub>CO<sub>3</sub>, tetrakis(triphenylphosphine)palladium(0), 110 °C .</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barres, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B.</span></span> <span> </span><span class="NLM_article-title">Do Glia Drive Synaptic and Cognitive Impairment in Disease?</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1038/nn.4142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnn.4142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=26505565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=1539-1545&author=W.+S.+Chungauthor=C.+A.+Welshauthor=B.+A.+Barresauthor=B.+Stevens&title=Do+Glia+Drive+Synaptic+and+Cognitive+Impairment+in+Disease%3F&doi=10.1038%2Fnn.4142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Do glia drive synaptic and cognitive impairment in disease?</span></div><div class="casAuthors">Chung, Won-Suk; Welsh, Christina A.; Barres, Ben A.; Stevens, Beth</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1539-1545</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Synaptic dysfunction is a hallmark of many neurodegenerative and psychiatric brain disorders, yet we know little about the mechanisms that underlie synaptic vulnerability.  Although neuroinflammation and reactive gliosis are prominent in virtually every CNS disease, glia are largely viewed as passive responders to neuronal damage rather than drivers of synaptic dysfunction.  This perspective is changing with the growing realization that glia actively signal with neurons and influence synaptic development, transmission and plasticity through an array of secreted and contact-dependent signals.  We propose that disruptions in neuron-glia signaling contribute to synaptic and cognitive impairment in disease.  Illuminating the mechanisms by which glia influence synapse function may lead to the development of new therapies and biomarkers for synaptic dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkpLYG_8HG6rVg90H21EOLACvtfcHk0ljav73yzE-p-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsrjL&md5=639d69e48e525d53d6b4bad3ecd81786</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnn.4142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.4142%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DW.%2BS.%26aulast%3DWelsh%26aufirst%3DC.%2BA.%26aulast%3DBarres%26aufirst%3DB.%2BA.%26aulast%3DStevens%26aufirst%3DB.%26atitle%3DDo%2520Glia%2520Drive%2520Synaptic%2520and%2520Cognitive%2520Impairment%2520in%2520Disease%253F%26jtitle%3DNat.%2520Neurosci.%26date%3D2015%26volume%3D18%26spage%3D1539%26epage%3D1545%26doi%3D10.1038%2Fnn.4142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudy, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsberger, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. N.</span></span> <span> </span><span class="NLM_article-title">The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease</span>. <i>Aging Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.14336/AD.2014.0423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.14336%2FAD.2014.0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=25821641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnpt1WrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=131-148&author=C.+C.+Rudyauthor=H.+C.+Hunsbergerauthor=D.+S.+Weitznerauthor=M.+N.+Reed&title=The+Role+of+the+Tripartite+Glutamatergic+Synapse+in+the+Pathophysiology+of+Alzheimer%E2%80%99s+Disease&doi=10.14336%2FAD.2014.0423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease</span></div><div class="casAuthors">Rudy Carolyn C; Hunsberger Holly C; Weitzner Daniel S; Reed Miranda N</div><div class="citationInfo"><span class="NLM_cas:title">Aging and disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-48</span>
        ISSN:<span class="NLM_cas:issn">2152-5250</span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is the most common form of dementia in individuals over 65 years of age and is characterized by accumulation of beta-amyloid (Aβ) and tau.  Both Aβ and tau alter synaptic plasticity, leading to synapse loss, neural network dysfunction, and eventually neuron loss.  However, the exact mechanism by which these proteins cause neurodegeneration is still not clear.  A growing body of evidence suggests perturbations in the glutamatergic tripartite synapse, comprised of a presynaptic terminal, a postsynaptic spine, and an astrocytic process, may underlie the pathogenic mechanisms of AD.  Glutamate is the primary excitatory neurotransmitter in the brain and plays an important role in learning and memory, but alterations in glutamatergic signaling can lead to excitotoxicity.  This review discusses the ways in which both beta-amyloid (Aβ) and tau act alone and in concert to perturb synaptic functioning of the tripartite synapse, including alterations in glutamate release, astrocytic uptake, and receptor signaling.  Particular emphasis is given to the role of N-methyl-D-aspartate (NMDA) as a possible convergence point for Aβ and tau toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRm5-JqzaQwHP6AExegM5LLfW6udTcc2eaACURn5qOwP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnpt1WrtQ%253D%253D&md5=daeca277592e2a6349610b8c0ca9442e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.14336%2FAD.2014.0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14336%252FAD.2014.0423%26sid%3Dliteratum%253Aachs%26aulast%3DRudy%26aufirst%3DC.%2BC.%26aulast%3DHunsberger%26aufirst%3DH.%2BC.%26aulast%3DWeitzner%26aufirst%3DD.%2BS.%26aulast%3DReed%26aufirst%3DM.%2BN.%26atitle%3DThe%2520Role%2520of%2520the%2520Tripartite%2520Glutamatergic%2520Synapse%2520in%2520the%2520Pathophysiology%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAging%2520Dis.%26date%3D2015%26volume%3D6%26spage%3D131%26epage%3D148%26doi%3D10.14336%2FAD.2014.0423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huentelman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siniard, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Both, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richholt, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balak, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigio, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyer, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesulam, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogalski, E. J.</span></span> <span> </span><span class="NLM_article-title">Associations of MAP2K3 Gene Variants with Superior Memory in SuperAgers</span>. <i>Front. Aging Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">155</span>, <span class="refDoi"> DOI: 10.3389/fnagi.2018.00155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.3389%2Ffnagi.2018.00155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=29896098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbms1ygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=155&author=M.+J.+Huentelmanauthor=I.+S.+Pirasauthor=A.+L.+Siniardauthor=M.+D.+De+Bothauthor=R.+F.+Richholtauthor=C.+D.+Balakauthor=P.+Jamshidiauthor=E.+H.+Bigioauthor=S.+Weintraubauthor=E.+T.+Loyerauthor=M.+M.+Mesulamauthor=C.+Geulaauthor=E.+J.+Rogalski&title=Associations+of+MAP2K3+Gene+Variants+with+Superior+Memory+in+SuperAgers&doi=10.3389%2Ffnagi.2018.00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers</span></div><div class="casAuthors">Huentelman Matthew J; Piras Ignazio S; Siniard Ashley L; De Both Matthew D; Richholt Ryan F; Balak Chris D; Jamshidi Pouya; Bigio Eileen H; Weintraub Sandra; Loyer Emmaleigh T; Mesulam M-Marsel; Geula Changiz; Rogalski Emily J; Bigio Eileen H; Weintraub Sandra; Rogalski Emily J; Mesulam M-Marsel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in aging neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155</span>
        ISSN:<span class="NLM_cas:issn">1663-4365</span>.
    </div><div class="casAbstract">Introduction: SuperAgers are adults age 80+ with episodic memory performance that is at least as good as that of average middle-aged adults.  Understanding the biological determinants of SuperAging may have relevance to preventing age-related cognitive decline and dementia.  This study aimed to identify associations between genetic variations and the SuperAging phenotype using Whole Exome Sequencing (WES).  Methods: Sequence Kernel Association Combined (SKAT-C) test was conducted at the gene level including both rare and common variants in 56 SuperAgers and 22 cognitively-average controls from the Alzheimer's disease Neuroimaging Initiative (ADNI).  Results: The SuperAging phenotype was associated with variants in the Mitogen-Activated Protein Kinase Kinase 3 (MAP2K3) gene.  Three single nucleotide polymorphisms (SNPs) contributed to the significance (rs2363221 [intron 1], rs2230435 [exon 5], rs736103 [intron 7]).  Conclusions: MAP2K3 resides in a biological pathway linked to memory.  It is in a signaling cascade associated with beta-amyloid mediated apoptosis and has enriched expression in microglia.  This preliminary work suggests MAP2K3 may represent a novel therapeutic target for age-related memory decline and perhaps Alzheimer's disease (AD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTai27mQTtuYOR_TJajKxJDfW6udTcc2eahMU_vpBi_dbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbms1ygug%253D%253D&md5=646b4c020600ee22145d13cbeb444bd5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffnagi.2018.00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnagi.2018.00155%26sid%3Dliteratum%253Aachs%26aulast%3DHuentelman%26aufirst%3DM.%2BJ.%26aulast%3DPiras%26aufirst%3DI.%2BS.%26aulast%3DSiniard%26aufirst%3DA.%2BL.%26aulast%3DDe%2BBoth%26aufirst%3DM.%2BD.%26aulast%3DRichholt%26aufirst%3DR.%2BF.%26aulast%3DBalak%26aufirst%3DC.%2BD.%26aulast%3DJamshidi%26aufirst%3DP.%26aulast%3DBigio%26aufirst%3DE.%2BH.%26aulast%3DWeintraub%26aufirst%3DS.%26aulast%3DLoyer%26aufirst%3DE.%2BT.%26aulast%3DMesulam%26aufirst%3DM.%2BM.%26aulast%3DGeula%26aufirst%3DC.%26aulast%3DRogalski%26aufirst%3DE.%2BJ.%26atitle%3DAssociations%2520of%2520MAP2K3%2520Gene%2520Variants%2520with%2520Superior%2520Memory%2520in%2520SuperAgers%26jtitle%3DFront.%2520Aging%2520Neurosci.%26date%3D2018%26volume%3D10%26spage%3D155%26doi%3D10.3389%2Ffnagi.2018.00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski-Kurdziel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra-VanderWeele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">p38α MAPK Signaling Drives Pharmacologically Reversible Brain and Gastrointestinal Phenotypes in the SERT Ala56 Mouse</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">E10245</span>– <span class="NLM_lpage">E10254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1809137115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1073%2Fpnas.1809137115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=30297392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10245-E10254&issue=43&author=M.+J.+Robsonauthor=M.+A.+Quinlanauthor=K.+G.+Margolisauthor=P.+A.+Gajewski-Kurdzielauthor=J.+Veenstra-VanderWeeleauthor=M.+D.+Gershonauthor=D.+M.+Wattersonauthor=R.+D.+Blakely&title=p38%CE%B1+MAPK+Signaling+Drives+Pharmacologically+Reversible+Brain+and+Gastrointestinal+Phenotypes+in+the+SERT+Ala56+Mouse&doi=10.1073%2Fpnas.1809137115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse</span></div><div class="casAuthors">Robson, Matthew J.; Quinlan, Meagan A.; Margolis, Kara Gross; Gajewski-Kurdziel, Paula A.; Veenstra-VanderWeele, Jeremy; Gershon, Michael D.; Watterson, D. Martin; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10245-E10254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a common neurobehavioral disorder with limited treatment options.  Activation of p38 MAPK signaling networks has been identified in ASD, and p38 MAPK signaling elevates serotonin (5-HT) transporter (SERT) activity, effects mimicked by multiple, hyperfunctional SERT coding variants identified in ASD subjects.  Mice expressing the most common of these variants (SERT Ala56) exhibit hyperserotonemia, a biomarker obsd. in ASD subjects, as well as p38 MAPK-dependent SERT hyperphosphorylation, elevated hippocampal 5-HT clearance, hypersensitivity of CNS 5-HT1A and 5-HT2A/2C receptors, and behavioral and gastrointestinal perturbations reminiscent of ASD.  As the α-isoform of p38 MAPK drives SERT activation, we tested the hypothesis that CNS-penetrant, α-isoform-specific p38 MAPK inhibitors might normalize SERT Ala56 phenotypes.  Strikingly, 1-wk treatment of adult SERT Ala56 mice with MW150, a selective p38α MAPK inhibitor, normalized hippocampal 5-HT clearance, CNS 5-HT1A and 5-HT2A/2C receptor sensitivities, social interactions, and colonic motility.  Conditional elimination of p389α MAPK in 5-HT neurons of SERT Ala56 mice restored 5-HT1A and 5-HT2A/2C receptor sensitivities as well as social interactions, mirroring effects of MW150.  Our findings support ongoing p38α MAPK activity as an important determinant of the physiol. and behavioral perturbations of SERT Ala56 mice and, more broadly, supports consideration of p38α MAPK inhibition as a potential treatment for core and comorbid phenotypes present in ASD subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpZykHY5klbVg90H21EOLACvtfcHk0lgASH8OXHSNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N&md5=ea39d3218225fab9b9ef7a1465a80887</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1809137115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1809137115%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DQuinlan%26aufirst%3DM.%2BA.%26aulast%3DMargolis%26aufirst%3DK.%2BG.%26aulast%3DGajewski-Kurdziel%26aufirst%3DP.%2BA.%26aulast%3DVeenstra-VanderWeele%26aufirst%3DJ.%26aulast%3DGershon%26aufirst%3DM.%2BD.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3Dp38%25CE%25B1%2520MAPK%2520Signaling%2520Drives%2520Pharmacologically%2520Reversible%2520Brain%2520and%2520Gastrointestinal%2520Phenotypes%2520in%2520the%2520SERT%2520Ala56%2520Mouse%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D43%26spage%3DE10245%26epage%3DE10254%26doi%3D10.1073%2Fpnas.1809137115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, X. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, G.</span></span> <span> </span><span class="NLM_article-title">p38 MAP Kinase is Activated at Early Stages in Alzheimer’s Disease Brain</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1016/S0014-4886(03)00180-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2FS0014-4886%2803%2900180-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=14552880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2003&pages=394-405&author=A.+Sunauthor=M.+Liuauthor=X.+V.+Nguyenauthor=G.+Bing&title=p38+MAP+Kinase+is+Activated+at+Early+Stages+in+Alzheimer%E2%80%99s+Disease+Brain&doi=10.1016%2FS0014-4886%2803%2900180-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinase is activated at early stages in Alzheimer's disease brain</span></div><div class="casAuthors">Sun, Anyang; Liu, Mei; Nguyen, Xuan V.; Bing, Guoying</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">394-405</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The regional, cellular, and subcellular localization of phosphorylated p38 MAPK (pp38) was examd. by immunocytochem., immuofluorescent multiple labeling, and immunoblotting of exts. as well as immunoppts. of human postmortem tissue from control and Alzheimer's disease (AD) cases at different Braak stages.  "Early AD" cases (Braak stages IV-V) and a subset of Braak stage VI cases have high levels of pp38 immunoreactivity, with the most dense immunoreactivity located in CA2 and subiculum followed by CA1 in the hippocampus.  On the contrary, very little pp38 was detected in age-matched controls (Braak stages 0-II).  More importantly, as revealed by various multiple labeling expts., pp38 immunoreactivity is mainly located in neurons bearing early neurofibrillary pathol., but not in typically fibrillar tangles that are densely stained by thioflavin-S.  Most pp38-pos. neurons only contain a small amt. of phospho-tau.  Addnl., pp38 immunoreactivity was not assocd. with senile plaques.  At the subcellular level, pp38-immunoreactive granules are usually larger than the granules stained with the lysosomal marker cathepsin D.  Immunoblotting with different extn. buffers and immunopptn. indicate that pp38 does not or only loosely binds to phospho-tau.  Taken together, this study demonstrates that p38 MAPK is activated at early stages of neurofibrillary degeneration in AD hippocampus.  The p38 activation may also be linked to neurodegeneration through mechanisms other than neurofibrillary tangle formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxxwaFL8EObVg90H21EOLACvtfcHk0lgASH8OXHSNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D&md5=9823c9aa4ce32ba4b9c68e005b198593</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0014-4886%2803%2900180-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4886%252803%252900180-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DX.%2BV.%26aulast%3DBing%26aufirst%3DG.%26atitle%3Dp38%2520MAP%2520Kinase%2520is%2520Activated%2520at%2520Early%2520Stages%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Brain%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D183%26spage%3D394%26epage%3D405%26doi%3D10.1016%2FS0014-4886%2803%2900180-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delahanty, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folstein, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">Allelic Heterogeneity at the Serotonin Transporter Locus (SLC6A4) Confers Susceptibility to Autism and Rigid-Compulsive Behaviors</span>. <i>Am. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1086/432648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1086%2F432648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=15995945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms12jurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=265-279&author=J.+S.+Sutcliffeauthor=R.+J.+Delahantyauthor=H.+C.+Prasadauthor=J.+L.+McCauleyauthor=Q.+Hanauthor=L.+Jiangauthor=C.+Liauthor=S.+E.+Folsteinauthor=R.+D.+Blakely&title=Allelic+Heterogeneity+at+the+Serotonin+Transporter+Locus+%28SLC6A4%29+Confers+Susceptibility+to+Autism+and+Rigid-Compulsive+Behaviors&doi=10.1086%2F432648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors</span></div><div class="casAuthors">Sutcliffe, James S.; Delahanty, Ryan J.; Prasad, Harish C.; McCauley, Jacob L.; Han, Qiao; Jiang, Lan; Li, Chun; Folstein, Susan E.; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-279</span>CODEN:
                <span class="NLM_cas:coden">AJHGAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9297</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Autism is a spectrum of neurodevelopmental disorders with a primarily genetic etiol. exhibiting deficits in (1) development of language and (2) social relationships and (3) patterns of repetitive, restricted behaviors or interests and resistance to change.  Elevated platelet serotonin (5-HT) in 20%-25% of cases and efficacy of selective 5-HT reuptake inhibitors (SSRIs) in treating anxiety, depression, and repetitive behaviors points to the 5-HT transporter (5-HTT; SERT) as a strong candidate gene.  Assocn. studies involving the functional insertion/deletion polymorphism in the promoter (5-HTTLPR) and a polymorphism in intron 2 are inconclusive, possibly because of phenotypic heterogeneity.  Nonetheless, mounting evidence for genetic linkage of autism to the chromosome 17q11.2 region that harbors the SERT locus (SLC6A4) supports a genetic effect at or near this gene.  We confirm recent reports of sex-biased genetic effects in 17q by showing highly significant linkage driven by families with only affected males.  Assocn. with common alleles fails to explain obsd. linkage; therefore, we hypothesized that preferential transmission of multiple alleles does explain it.  From 120 families, most contributing to linkage at 17q11.2, we found four coding substitutions at highly conserved positions and 15 other variants in 5' noncoding and other intronic regions transmitted in families exhibiting increased rigid-compulsive behaviors.  In the aggregate, these variants show significant linkage to and assocn. with autism.  Our data provide strong support for a collection of multiple, often rare, alleles at SLC6A4 as imposing risk of autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2we43zGjOjrVg90H21EOLACvtfcHk0ljBpLwfXmYFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms12jurc%253D&md5=763cce96557c332d5a8b4e4900bd529f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1086%2F432648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F432648%26sid%3Dliteratum%253Aachs%26aulast%3DSutcliffe%26aufirst%3DJ.%2BS.%26aulast%3DDelahanty%26aufirst%3DR.%2BJ.%26aulast%3DPrasad%26aufirst%3DH.%2BC.%26aulast%3DMcCauley%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DFolstein%26aufirst%3DS.%2BE.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3DAllelic%2520Heterogeneity%2520at%2520the%2520Serotonin%2520Transporter%2520Locus%2520%2528SLC6A4%2529%2520Confers%2520Susceptibility%2520to%2520Autism%2520and%2520Rigid-Compulsive%2520Behaviors%26jtitle%3DAm.%2520J.%2520Hum.%2520Genet.%26date%3D2005%26volume%3D77%26spage%3D265%26epage%3D279%26doi%3D10.1086%2F432648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleasby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seavers, L. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel p38h MAP Kinase Inhibitors Using Fragment-Based Lead Generation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1021/jm049575n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049575n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=414-426&author=A.+L.+Gillauthor=M.+Fredericksonauthor=A.+Cleasbyauthor=S.+J.+Woodheadauthor=M.+G.+Carrauthor=A.+J.+Woodheadauthor=M.+T.+Walkerauthor=M.+S.+Congreveauthor=L.+A.+Devineauthor=D.+Tisiauthor=M.+O%E2%80%99Reillyauthor=L.+C.+A.+Seaversauthor=D.+J.+Davisauthor=J.+Curryauthor=R.+Anthonyauthor=A.+Padovaauthor=C.+W.+Murrayauthor=R.+A.+Carrauthor=H.+Jhoti&title=Identification+of+Novel+p38h+MAP+Kinase+Inhibitors+Using+Fragment-Based+Lead+Generation&doi=10.1021%2Fjm049575n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation</span></div><div class="casAuthors">Gill, Adrian L.; Frederickson, Martyn; Cleasby, Anne; Woodhead, Steven J.; Carr, Maria G.; Woodhead, Andrew J.; Walker, Margaret T.; Congreve, Miles S.; Devine, Lindsay A.; Tisi, Dominic; O'Reilly, Marc; Seavers, Lisa C. A.; Davis, Deborah J.; Curry, Jayne; Anthony, Rachel; Padova, Alessandro; Murray, Christopher W.; Carr, Robin A. E.; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">414-426</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the structure-guided optimization of the mol. fragments 2-amino-3-benzyloxypyridine 1 (IC50 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC50 35 μM) identified using X-ray crystallog. screening of p38α MAP kinase.  Using two sep. case studies, the article focuses on the key compds. synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate significant increases in activity.  We describe the process of compd. elaboration either through the growing out from fragments into adjacent pockets or through the conjoining of overlapping fragments and demonstrate that we have exploited the mobile conserved activation loop, consisting in part of Asp168-Phe169-Gly170 (DFG), to generate significant improvements in potency and kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOROTrqNSv97Vg90H21EOLACvtfcHk0ljBpLwfXmYFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nJ&md5=a128859d7f3725f2672512331b6bdc83</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm049575n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049575n%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DCongreve%26aufirst%3DM.%2BS.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%2BA.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DAnthony%26aufirst%3DR.%26aulast%3DPadova%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%2BA.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520Novel%2520p38h%2520MAP%2520Kinase%2520Inhibitors%2520Using%2520Fragment-Based%2520Lead%2520Generation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D414%26epage%3D426%26doi%3D10.1021%2Fjm049575n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleasby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickle, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Lead Discovery Using X-ray Crystallography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1021/jm0495778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0495778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=403-413&author=M.+J.+Hartshornauthor=C.+W.+Murrayauthor=A.+Cleasbyauthor=M.+Fredericksonauthor=I.+J.+Tickleauthor=H.+Jhoti&title=Fragment-Based+Lead+Discovery+Using+X-ray+Crystallography&doi=10.1021%2Fjm0495778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Lead Discovery Using X-ray Crystallography</span></div><div class="casAuthors">Hartshorn, Michael J.; Murray, Christopher W.; Cleasby, Anne; Frederickson, Martyn; Tickle, Ian J.; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">403-413</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment screening offers an alternative to traditional screening for discovering new leads in drug discovery programs.  This paper describes a fragment screening methodol. based on high throughput x-ray crystallog.  The method is illustrated against five proteins (p38 MAP kinase, CDK2, thrombin, RNase A, and PTP1B).  The fragments identified have weak potency (>100 μM) but are efficient binders relative to their size and may therefore represent suitable starting points for evolution to good quality lead compds.  The examples illustrate that a range of mol. interactions (i.e., lipophilic, charge-charge, neutral hydrogen bonds) can drive fragment binding and also that fragments can induce protein movement.  The authors believe that the method has great potential for the discovery of novel lead compds. against a range of targets, and the companion paper illustrates how lead compds. have been identified for p38 MAP kinase starting from fragments such as those described in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeepqN9_V8prVg90H21EOLACvtfcHk0ljBpLwfXmYFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7nK&md5=41f6e394812669bde519ab7366fea9d6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm0495778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0495778%26sid%3Dliteratum%253Aachs%26aulast%3DHartshorn%26aufirst%3DM.%2BJ.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DFragment-Based%2520Lead%2520Discovery%2520Using%2520X-ray%2520Crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D403%26epage%3D413%26doi%3D10.1021%2Fjm0495778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elayan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagadeesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laniyonu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Secondary Pharmacology Data to Assess Potential Off-Target Activity of New Drugs: A Regulatory Perspective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1038/nrd3845-c1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnrd3845-c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=25792260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=294-296&author=T.+Papoianauthor=H.-J.+Chiuauthor=I.+Elayanauthor=G.+Jagadeeshauthor=I.+Khanauthor=A.+A.+Laniyonuauthor=C.+X.+Liauthor=M.+Saulnierauthor=N.+Simpsonauthor=B.+Yang&title=Secondary+Pharmacology+Data+to+Assess+Potential+Off-Target+Activity+of+New+Drugs%3A+A+Regulatory+Perspective&doi=10.1038%2Fnrd3845-c1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective</span></div><div class="casAuthors">Papoian, Thomas; Chiu, Haw-Jyh; Elayan, Ikram; Jagadeesh, Gowraganahalli; Khan, Imran; Laniyonu, Adebayo A.; Li, Cindy Xinguang; Saulnier, Muriel; Simpson, Natalie; Yang, Baichun</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">294</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Useful aspects of submitted secondary pharmacol. data.  Detailed aspects of secondary pharmacol. data that are considered to be useful during regulatory safety assessments are summarized in Table 1.  Incorporation of these aspects into secondary pharmacol. study reports not only enhances the quality and regulatory utility of the reports but also decreases uncertainty in decision making owing to misinterpretation of data.  Regulatory assessment of in vitro secondary pharmacol. data.  Various protocols for secondary pharmacol. studies are commonly available and generally consist of binding assays, functional assays and enzyme assays, all of which provide important information regarding the pharmacol. activity of a drug and possible unanticipated side effects that may be seen in humans.  When the data suggest possible off-target activity, the extent of that risk under clin. relevant conditions and drug exposures is carefully assessed, and safety recommendations are made for the proposed clin. studies or addnl. non-clin. studies are requested to help to better understand or reduce the risk.  In our experience, the panels of targets that are employed vary widely and are often selected without justification or a description of their relevance to human safety.  In such cases, a repeat of the study may be recommended using a more appropriate selection of clin. relevant targets.  It is useful to det. whether a drug shares similar off-target activity with other drugs in the class - for example, the sedative and anticholinergic properties of certain histamine H1 receptor antagonists - so that such side effects in humans can be better anticipated and monitored.  Similarly, target panel selection may also include consideration of whether the intended drug target has structural or functional similarity to a related but unintended target.  If such a relationship is found, then clin. consequences of affecting those targets are considered.  Drugs may also possess specificity for, or a mechanism of action linked to, selected targets from a large family of related targets that have structural or functional similarity (for example, the ATP-binding site of protein tyrosine kinases).  In such cases, a broad panel screen of all closely related family members may be useful in distinguishing intended pharmacol. effects from unintended effects.  It is important to understand how findings relate to those obsd. with other members of the drug class or for a certain mechanism of action.  If the findings are similar, then the clin. risk may be considered to be similar as well.  If they are different, however, then further evaluation, such as follow-up in vitro or animal studies focusing on the different targets affected, may be recommended to better define the risk.  Correlations between pos. secondary pharmacol. results and results seen in animals may be used to det. whether in vitro activity translates to possible human risk under therapeutic conditions.  It is important to note that in vitro panels generally use human-specific targets, and in vitro results may not always correlate with those obsd. in animals.  Correlations between in vitro half-maximal inhibitory concn. (IC50) or inhibition const. (Ki) values with in vivo plasma drug levels are also used to assess possible effects at therapeutic exposures.  The closer the IC50 or Ki values are to plasma drug levels, the more likely the clin. effect.  Also considered in this context are local tissue drug concns. at the site of action that may be higher than circulating levels.  Use of focused profiling may be recommended to address specific issues of concern, such as the safety of active drug metabolites or unique major human metabolites not formed in animals but found during subsequent clin. testing.  Even if a compd. produces a pos. in vitro result at therapeutically relevant concns., certain risk-benefit considerations for particular patient populations are taken into account, such as the seriousness of the therapeutic indication and whether potential adverse effects are considered to be reversible.  Case examples of regulatory actions based on pos. off-target activity are provided in Table 2 and include endocrine disruptors, peroxisome proliferator-activated receptor-γ agonists, cardiac (voltage-gated) ion channel protein antagonists, 5-HT2B (serotonin) receptor agonists, ligand-gated ion channel protein (for example, N-methyl-d-aspartate receptor) antagonists and drugs with potential for abuse.  Although not exhaustive, these examples highlight current experience with certain classes and actions of drugs that have resulted in specific regulatory actions based on their potential risk for human safety.  Timing of secondary pharmacol. data submission.  For proper safety assessment, it is advantageous for secondary pharmacol. data to be available with the initial submission to support first-in-human (Phase I) clin. trials.  Such data can also be used to help to interpret clin. findings or adverse drug reactions that occur as drug development proceeds into later phases of clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD40Aby38TPrVg90H21EOLACvtfcHk0li68bfIztNAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D&md5=69b08c957679ef003271b07fef0d4de5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845-c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845-c1%26sid%3Dliteratum%253Aachs%26aulast%3DPapoian%26aufirst%3DT.%26aulast%3DChiu%26aufirst%3DH.-J.%26aulast%3DElayan%26aufirst%3DI.%26aulast%3DJagadeesh%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DLaniyonu%26aufirst%3DA.%2BA.%26aulast%3DLi%26aufirst%3DC.%2BX.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DSecondary%2520Pharmacology%2520Data%2520to%2520Assess%2520Potential%2520Off-Target%2520Activity%2520of%2520New%2520Drugs%253A%2520A%2520Regulatory%2520Perspective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D294%26epage%3D296%26doi%3D10.1038%2Fnrd3845-c1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagadeesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laniyonu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarfman, A.</span></span> <span> </span><span class="NLM_article-title">Regulatory Forum Review: Utility of In Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1177/0192623317690609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1177%2F0192623317690609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=28421966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1Cmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=381-388&author=T.+Papoianauthor=G.+Jagadeeshauthor=M.+Saulnierauthor=N.+Simpsonauthor=A.+Ravindranauthor=B.+Yangauthor=A.+A.+Laniyonuauthor=I.+Khanauthor=A.+Szarfman&title=Regulatory+Forum+Review%3A+Utility+of+In+Vitro+Secondary+Pharmacology+Data+to+Assess+Risk+of+Drug-induced+Valvular+Heart+Disease+in+Humans%3A+Regulatory+Considerations&doi=10.1177%2F0192623317690609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations</span></div><div class="casAuthors">Papoian, Thomas; Jagadeesh, Gowraganahalli; Saulnier, Muriel; Simpson, Natalie; Ravindran, Arippa; Yang, Baichun; Laniyonu, Adebayo A.; Khan, Imran; Szarfman, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Drug-induced valvular heart disease (VHD) is a serious side effect linked to long-term treatment with 5-hydroxytryptamine (serotonin) receptor 2B (5-HT2B) agonists.  Safety assessment for off-target pharmacodynamic activity is a common approach used to screen drugs for this undesired property.  Such studies include in vitro assays to det. whether the drug is a 5-HT2B agonist, a necessary pharmacol. property for development of VHD.  Measures of in vitro binding affinity (IC50, Ki) or cellular functional activity (EC50) are often compared to max. therapeutic free plasma drug levels (fCmax) from which safety margins (SMs) can be derived.  However, there is no clear consensus on what constitutes an appropriate SM under various therapeutic conditions of use.  The strengths and limitations of SM detns. and current risk assessment methodol. are reviewed and evaluated.  It is concluded that the use of SMs based on Ki values, or those relative to serotonin (5-HT), appears to be a better predictor than the use of EC50 or EC50/human fCmax values for detg. whether known 5-HT2B agonists have resulted in VHD.  It is hoped that such a discussion will improve efforts to reduce this preventable serious drug-induced toxicity from occurring and lead to more informed risk assessment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbpv1RzQwmQLVg90H21EOLACvtfcHk0li68bfIztNAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1Cmsw%253D%253D&md5=99179d2659014ce01ac730052aee76f0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F0192623317690609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623317690609%26sid%3Dliteratum%253Aachs%26aulast%3DPapoian%26aufirst%3DT.%26aulast%3DJagadeesh%26aufirst%3DG.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DRavindran%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DLaniyonu%26aufirst%3DA.%2BA.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DSzarfman%26aufirst%3DA.%26atitle%3DRegulatory%2520Forum%2520Review%253A%2520Utility%2520of%2520In%2520Vitro%2520Secondary%2520Pharmacology%2520Data%2520to%2520Assess%2520Risk%2520of%2520Drug-induced%2520Valvular%2520Heart%2520Disease%2520in%2520Humans%253A%2520Regulatory%2520Considerations%26jtitle%3DToxicol.%2520Pathol.%26date%3D2017%26volume%3D45%26spage%3D381%26epage%3D388%26doi%3D10.1177%2F0192623317690609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of <i>In Vitro</i>Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+In+VitroPharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0li68bfIztNAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520In%2520VitroPharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranaivo, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">A Novel p38 MAPK Inhibitor Suppresses Brain Proinflammatory Cytokine Up-Regulation and Attenuates Synaptic Dysfunction and Behavioral Deficits in an Alzheimer’s Disease Mouse Model</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-4-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2F1742-2094-4-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=17784957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=21&author=L.+Munozauthor=H.+R.+Ranaivoauthor=S.+M.+Royauthor=W.+Huauthor=J.+M.+Craftauthor=L.+K.+McNamaraauthor=L.+W.+Chicoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=A+Novel+p38+MAPK+Inhibitor+Suppresses+Brain+Proinflammatory+Cytokine+Up-Regulation+and+Attenuates+Synaptic+Dysfunction+and+Behavioral+Deficits+in+an+Alzheimer%E2%80%99s+Disease+Mouse+Model&doi=10.1186%2F1742-2094-4-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model</span></div><div class="casAuthors">Munoz Lenka; Ralay Ranaivo Hantamalala; Roy Saktimayee M; Hu Wenhui; Craft Jeffrey M; McNamara Laurie K; Chico Laura Wing; Van Eldik Linda J; Watterson D Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  An accumulating body of evidence is consistent with the hypothesis that excessive or prolonged increases in proinflammatory cytokine production by activated glia is a contributor to the progression of pathophysiology that is causally linked to synaptic dysfunction and hippocampal behavior deficits in neurodegenerative diseases such as Alzheimer's disease (AD).  This raises the opportunity for the development of new classes of potentially disease-modifying therapeutics.  A logical candidate CNS target is p38 alpha MAPK, a well-established drug discovery molecular target for altering proinflammatory cytokine cascades in peripheral tissue disorders.  Activated p38 MAPK is seen in human AD brain tissue and in AD-relevant animal models, and cell culture studies strongly implicate p38 MAPK in the increased production of proinflammatory cytokines by glia activated with human amyloid-beta (A beta) and other disease-relevant stressors.  However, the vast majority of small molecule drugs do not have sufficient penetrance of the blood-brain barrier to allow their use as in vivo research tools or as therapeutics for neurodegenerative disorders.  The goal of this study was to test the hypothesis that brain p38 alpha MAPK is a potential in vivo target for orally bioavailable, small molecules capable of suppressing excessive cytokine production by activated glia back towards homeostasis, allowing an improvement in neurologic outcomes.  METHODS:  A novel synthetic small molecule based on a molecular scaffold used previously was designed, synthesized, and subjected to analyses to demonstrate its potential in vivo bioavailability, metabolic stability, safety and brain uptake.  Testing for in vivo efficacy used an AD-relevant mouse model.  RESULTS:  A novel, CNS-penetrant, non-toxic, orally bioavailable, small molecule inhibitor of p38 alpha MAPK (MW01-2-069A-SRM) was developed.  Oral administration of the compound at a low dose (2.5 mg/kg) resulted in attenuation of excessive proinflammatory cytokine production in the hippocampus back towards normal in the animal model.  Animals with attenuated cytokine production had reductions in synaptic dysfunction and hippocampus-dependent behavioral deficits.  CONCLUSION:  The p38 alpha MAPK pathway is quantitatively important in the A beta-induced production of proinflammatory cytokines in hippocampus, and brain p38 alpha MAPK is a viable molecular target for future development of potential disease-modifying therapeutics in AD and related neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsGGsjPM4Dps25P7XSLhESfW6udTcc2eblqE24wCQHg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D&md5=e7768f444f68015f134d42880ed01f3b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-4-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-4-21%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DRanaivo%26aufirst%3DH.%2BR.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DCraft%26aufirst%3DJ.%2BM.%26aulast%3DMcNamara%26aufirst%3DL.%2BK.%26aulast%3DChico%26aufirst%3DL.%2BW.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DA%2520Novel%2520p38%2520MAPK%2520Inhibitor%2520Suppresses%2520Brain%2520Proinflammatory%2520Cytokine%2520Up-Regulation%2520and%2520Attenuates%2520Synaptic%2520Dysfunction%2520and%2520Behavioral%2520Deficits%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mouse%2520Model%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2007%26volume%3D4%26spage%3D21%26doi%3D10.1186%2F1742-2094-4-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schavocky, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradaric, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Development of Novel <i>In Vivo</i> Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e66226</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0066226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1371%2Fjournal.pone.0066226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23840427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSlt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=D.+M.+Wattersonauthor=V.+L.+Grum-Tokarsauthor=S.+M.+Royauthor=J.+P.+Schavockyauthor=B.+D.+Bradaricauthor=A.+D.+Bachstetterauthor=B.+Xingauthor=E.+Dimayugaauthor=F.+Saeedauthor=H.+Zhangauthor=A.+Staniszewskiauthor=J.+C.+Pelletierauthor=G.+Minasovauthor=W.+F.+Andersonauthor=O.+Arancioauthor=L.+J.+Van+Eldik&title=Development+of+Novel+In+Vivo+Chemical+Probes+to+Address+CNS+Protein+Kinase+Involvement+in+Synaptic+Dysfunction&doi=10.1371%2Fjournal.pone.0066226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel in vivo chemical probes to address CNS protein kinase involvement in synaptic dysfunction</span></div><div class="casAuthors">Watterson, D. Martin; Grum-Tokars, Valerie L.; Roy, Saktimayee M.; Schavocky, James P.; Bradaric, Brinda Desai; Bachstetter, Adam D.; Xing, Bin; Dimayuga, Edgardo; Saeed, Faisal; Zhang, Hong; Staniszewski, Agnieszka; Pelletier, Jeffrey C.; Minasov, George; Anderson, Wayne F.; Arancio, Ottavio; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e66226</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Serine-threonine protein kinases are crit. to CNS function, yet there is a dearth of highly selective, CNS-active kinase inhibitors for in vivo investigations.  Further, prevailing assumptions raise concerns about whether single kinase inhibitors can show in vivo efficacy for CNS pathologies and debates over viable approaches to the development of safe and efficacious kinase inhibitors are unsettled.  It is crit., therefore, that these scientific challenges be addressed in order to test hypotheses about protein kinases in neuropathol. progression and the potential for in vivo modulation of their catalytic activity.  Identification of mol. targets whose in vivo modulation can attenuate synaptic dysfunction would provide a foundation for future disease-modifying therapeutic development as well as insight into cellular mechanisms.  Clin. and preclin. studies suggest a crit. link between synaptic dysfunction in neurodegenerative disorders and the activation of p38αMAPK mediated signaling cascades.  Activation in both neurons and glia also offers the unusual potential to generate enhanced responses through targeting a single kinase in two distinct cell types involved in pathol. progression.  However, target validation has been limited by lack of highly selective inhibitors amenable to in vivo use in the CNS.  Therefore, the authors employed high-resoln. co-crystallog. and pharmacoinformatics to design and develop a novel synthetic, active site targeted, CNS-active, p38αMAPK inhibitor (MW108).  Selectivity was demonstrated by large-scale kinome screens, functional GPCR agonist and antagonist analyses of off-target potential, and evaluation of cellular target engagement.  In vitro and in vivo assays demonstrated that MW108 ameliorates beta-amyloid induced synaptic and cognitive dysfunction.  A serendipitous discovery during co-crystallog. analyses revised prevailing models about active site targeting of inhibitors, providing insights that will facilitate future kinase inhibitor design.  Overall, the authors' studies deliver highly selective in-vivo probes appropriate for CNS investigations and demonstrate that modulation of p38αMAPK activity can attenuate synaptic dysfunction.  The title compds. thus formed included a (naphthalenyl)(pyridinyl)pyridazinamine deriv. (I).  The synthesis of the target compds. was achieved by a coupling reaction of (chloro)(pyridinyl)pyridazinamine with (naphthalene)boronic acid derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiciSYOCxFa7Vg90H21EOLACvtfcHk0lgPaJvT7MOHmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSlt7jI&md5=7c8b917f6e4fec0276073bcfd9e8ec74</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0066226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0066226%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DGrum-Tokars%26aufirst%3DV.%2BL.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DSchavocky%26aufirst%3DJ.%2BP.%26aulast%3DBradaric%26aufirst%3DB.%2BD.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DXing%26aufirst%3DB.%26aulast%3DDimayuga%26aufirst%3DE.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DDevelopment%2520of%2520Novel%2520In%2520Vivo%2520Chemical%2520Probes%2520to%2520Address%2520CNS%2520Protein%2520Kinase%2520Involvement%2520in%2520Synaptic%2520Dysfunction%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0066226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schavocky, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor that Attenuates Disease Progression in Alzheimer’s Disease Mouse Models</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=666-680&author=S.+M.+Royauthor=V.+L.+Grum-Tokarsauthor=J.+P.+Schavockyauthor=F.+Saeedauthor=A.+Staniszewskiauthor=A.+F.+Teichauthor=O.+Arancioauthor=A.+D.+Bachstetterauthor=S.+J.+Websterauthor=L.+J.+Van+Eldikauthor=G.+Minasovauthor=W.+F.+Andersonauthor=J.+C.+Pelletierauthor=D.+M.+Watterson&title=Targeting+Human+Central+Nervous+System+Protein+Kinases%3A+An+Isoform+Selective+p38%CE%B1MAPK+Inhibitor+that+Attenuates+Disease+Progression+in+Alzheimer%E2%80%99s+Disease+Mouse+Models&doi=10.1021%2Facschemneuro.5b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models</span></div><div class="casAuthors">Roy, Saktimayee M.; Grum-Tokars, Valerie L.; Schavocky, James P.; Saeed, Faisal; Staniszewski, Agnieszka; Teich, Andrew F.; Arancio, Ottavio; Bachstetter, Adam D.; Webster, Scott J.; Van Eldik, Linda J.; Minasov, George; Anderson, Wayne F.; Pelletier, Jeffrey C.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">666-680</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncol. indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications.  Stress kinases are of special interest in neurol. and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility.  Clin. and preclin. evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurol. indications.  Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacol. features.  Synaptic dysfunction disorders offer a potential for enhanced pharmacol. efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiol. axis, to be modulated.  We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models.  A synthetic scheme for biocompatible product and pos. outcomes from pharmacol. screens are presented.  The high-resoln. crystallog. structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity.  As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-xfPVSbGEOrVg90H21EOLACvtfcHk0lgPaJvT7MOHmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D&md5=defac1ac010ab8a139647844153c7b86</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00002%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DGrum-Tokars%26aufirst%3DV.%2BL.%26aulast%3DSchavocky%26aufirst%3DJ.%2BP.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DWebster%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520Human%2520Central%2520Nervous%2520System%2520Protein%2520Kinases%253A%2520An%2520Isoform%2520Selective%2520p38%25CE%25B1MAPK%2520Inhibitor%2520that%2520Attenuates%2520Disease%2520Progression%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mouse%2520Models%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D666%26epage%3D680%26doi%3D10.1021%2Facschemneuro.5b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Späni, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Retention of Normal Glia Function by an Isoform-Selective Protein Kinase Inhibitor Drug Candidate that Modulates Cytokine Production and Cognitive Outcomes</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">75</span>, <span class="refDoi"> DOI: 10.1186/s12974-017-0845-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2Fs12974-017-0845-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=28381303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=75&author=Z.+Zhouauthor=A.+D.+Bachstetterauthor=C.+B.+Sp%C3%A4niauthor=S.+M.+Royauthor=D.+M.+Wattersonauthor=L.+J.+Van+Eldik&title=Retention+of+Normal+Glia+Function+by+an+Isoform-Selective+Protein+Kinase+Inhibitor+Drug+Candidate+that+Modulates+Cytokine+Production+and+Cognitive+Outcomes&doi=10.1186%2Fs12974-017-0845-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes</span></div><div class="casAuthors">Zhou, Zhengqiu; Bachstetter, Adam D.; Spani, Claudia B.; Roy, Saktimayee M.; Watterson, D. Martin; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75/1-75/12</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Brain p38α mitogen-activated protein kinase (MAPK), a potential therapeutic target for cognitive dysfunction based on the neuroinflammation-synaptic dysfunction cycle of pathophysiol. progression, offers an innovative pharmacol. strategy via inhibiting the same activated target in both glia and neurons, thereby enhancing the possibility for efficacy.  The highly selective, brain-penetrant p38αMAPK inhibitor MW150 attenuates cognitive dysfunction in two distinct Alzheimer's disease (AD)-relevant models and avoids the problems encountered with previous mixed-kinase inhibitor drug candidates.  Therefore, it is essential that the glial effects of this CNS-active kinase inhibitor be addressed in order to anticipate future use in clin. investigations.  Methods: We explored the effects of MW150 on glial biol. in the AD-relevant APP/PS1 knock-in (KI) mouse model where we previously showed efficacy in suppression of hippocampal-dependent associative and spatial memory deficits.  MW150 (2.5 mg/kg/day) was administered daily to 11-12-mo-old KI mice for 14 days, and levels of proinflammatory cytokines IL-1β, TNFα, and IL-6 measured in homogenates of mouse cortex using ELISA.  Glial markers IBA1, CD45, CD68, and GFAP were assessed by immunohistochem.  Microglia and amyloid plaques were quantified by immunofluorescence staining followed by confocal imaging.  Levels of sol. and insol. of Aβ40 and Aβ42 were measured by ELISA.  The studies of in vivo pharmacodynamic effects on markers of neuroinflammation were complemented by mechanistic studies in the murine microglia BV2 cell line, using live cell imaging techniques to monitor proliferation, migration, and phagocytosis activities.  Results: Intervention with MW150 in KI mice during the established therapeutic time window attenuated the increased levels of IL-1β and TNFα but not IL-6.  MW150 treatment also increased the IBA1+ microglia within a 15 μm radius of the amyloid plaques, without significantly affecting overall microglia or plaque vol.  Levels of IBA1, CD45, CD68, GFAP, and Aβ40 and Aβ42 were not affected by MW150 treatment.  MW150 did not significantly alter microglial migration, proliferation, or phagocytosis in BV2 cells.  Conclusions: Our results demonstrate that MW150 at an efficacious dose can selectively modulate neuroinflammatory responses assocd. with pathol. progression without pan-suppression of normal physiol. functions of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq16MlfxcvdbVg90H21EOLACvtfcHk0lj93u6JwweoCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK&md5=9137eff52c9715df75ca1ea1ac2a3656</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1186%2Fs12974-017-0845-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-017-0845-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DSp%25C3%25A4ni%26aufirst%3DC.%2BB.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DRetention%2520of%2520Normal%2520Glia%2520Function%2520by%2520an%2520Isoform-Selective%2520Protein%2520Kinase%2520Inhibitor%2520Drug%2520Candidate%2520that%2520Modulates%2520Cytokine%2520Production%2520and%2520Cognitive%2520Outcomes%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2017%26volume%3D14%26spage%3D75%26doi%3D10.1186%2Fs12974-017-0845-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Target Engagement Analysis and Link to Pharmacodynamic Endpoint for a Novel Class of CNS-Penetrant and Efficacious p38α MAPK Inhibitors</span>. <i>J. Neuroimmune Pharmcol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1007/s11481-014-9543-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1007%2Fs11481-014-9543-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=24789302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC2cnoslOjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=454-460&author=A.+D.+Bachstetterauthor=D.+M.+Wattersonauthor=L.+J.+Van+Eldik&title=Target+Engagement+Analysis+and+Link+to+Pharmacodynamic+Endpoint+for+a+Novel+Class+of+CNS-Penetrant+and+Efficacious+p38%CE%B1+MAPK+Inhibitors&doi=10.1007%2Fs11481-014-9543-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors</span></div><div class="casAuthors">Bachstetter Adam D; Watterson D Martin; Van Eldik Linda J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">454-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The protein kinase, p38α MAPK, is a key intracellular transducer of stressor-induced neuroinflammatory responses and, as such, is of high interest as a potential therapeutic target.  We recently reported the synthesis and evaluation of first-in-class CNS-penetrant and highly specific p38 MAPK inhibitors that avoid target crossover issues seen in popular small molecule p38 MAPK inhibitors used in hundreds of previous reports.  The novel p38 MAPK inhibitors, represented in this study by MW181, are efficacious in vivo.  Pharmacodynamic actions include attenuation of stressor-induced increases in brain proinflammatory cytokine levels.  We report here more detailed analyses of MW181 target engagement and specific linkage to the downstream increase in glia proinflammatory cytokine production.  In vivo validation included demonstration that oral administration of MW181 suppresses lipopolysaccharide-induced increases in mouse brain IL-1β, TNFα, IL-6, IL-10, and CXCL1 but not in a drug-resistant p38α MAPK mutant mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWolJymxo2JeWhZTslLrfffW6udTcc2ebSfvbk8G4kcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnoslOjtg%253D%253D&md5=720ce3aa521c0535df86081dc31d9b46</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs11481-014-9543-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11481-014-9543-3%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DTarget%2520Engagement%2520Analysis%2520and%2520Link%2520to%2520Pharmacodynamic%2520Endpoint%2520for%2520a%2520Novel%2520Class%2520of%2520CNS-Penetrant%2520and%2520Efficacious%2520p38%25CE%25B1%2520MAPK%2520Inhibitors%26jtitle%3DJ.%2520Neuroimmune%2520Pharmcol.%26date%3D2014%26volume%3D9%26spage%3D454%26epage%3D460%26doi%3D10.1007%2Fs11481-014-9543-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maphis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokiko-Cochran, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhaskar, K.</span></span> <span> </span><span class="NLM_article-title">Selective Suppression of the α Isoform of p38 MAPK Rescues Late-Stage Tau Pathology</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">54</span>, <span class="refDoi"> DOI: 10.1186/s13195-016-0221-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2Fs13195-016-0221-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=54&author=N.+Maphisauthor=S.+Jiangauthor=G.+Xuauthor=O.+N.+Kokiko-Cochranauthor=S.+M.+Royauthor=L.+J.+Van+Eldikauthor=D.+M.+Wattersonauthor=B.+T.+Lambauthor=K.+Bhaskar&title=Selective+Suppression+of+the+%CE%B1+Isoform+of+p38+MAPK+Rescues+Late-Stage+Tau+Pathology&doi=10.1186%2Fs13195-016-0221-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology</span></div><div class="casAuthors">Maphis, Nicole; Jiang, Shanya; Xu, Guixiang; Kokiko-Cochran, Olga N.; Roy, Saktimayee M.; Van Eldik, Linda J.; Watterson, Martin D.; Lamb, Bruce T.; Kiran, Bhaskar</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54/1-54/15</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Hyperphosphorylation and aggregation of tau protein are the pathol. hallmarks of Alzheimer's disease and related tauopathies.  We previously demonstrated that the microglial activation induces tau hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK) in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1.  Method: We report an isoform-selective, brain-permeable, and orally bioavailable small mol. inhibitor of p38α MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice.  Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the max. effect peaking at 60-90 min after stimulation.  Second, treatment of old (∼20 mo of age) hTau mice with MW181 (1 mg/kg body wt.; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-administered hTau mice.  This also resulted in a significant redn. in AT180 (pT231) site tau phosphorylation and Sarkosyl-insol. tau aggregates.  Third, MW181 treatment significantly increased synaptophysin protein expression and resulted in improved working memory.  Fourth, MW181 administration reduced phosphorylated MAPK-activated protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates of p38α MAPK.  Finally, MW181 reduced the expression of interferon-γ and interleukin-1β.  Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS6AXNcANBc7Vg90H21EOLACvtfcHk0lj93u6JwweoCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFait7o%253D&md5=3acd2f928ea95f5089eb1bad61a5cb2c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs13195-016-0221-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-016-0221-y%26sid%3Dliteratum%253Aachs%26aulast%3DMaphis%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DKokiko-Cochran%26aufirst%3DO.%2BN.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DLamb%26aufirst%3DB.%2BT.%26aulast%3DBhaskar%26aufirst%3DK.%26atitle%3DSelective%2520Suppression%2520of%2520the%2520%25CE%25B1%2520Isoform%2520of%2520p38%2520MAPK%2520Rescues%2520Late-Stage%2520Tau%2520Pathology%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2016%26volume%3D8%26spage%3D54%26doi%3D10.1186%2Fs13195-016-0221-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morfini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavassoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigino, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, S. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves Activation of p38 MAP Kinase</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e65235</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0065235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1371%2Fjournal.pone.0065235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23776455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVejsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=G.+A.+Morfiniauthor=D.+A.+Boscoauthor=H.+Brownauthor=R.+Gattoauthor=A.+Kaminskaauthor=Y.+Songauthor=L.+Mollaauthor=L.+Bakerauthor=M.+N.+Marangoniauthor=S.+Berthauthor=E.+Tavassoliauthor=C.+Bagnatoauthor=A.+Tiwariauthor=L.+J.+Haywardauthor=G.+F.+Piginoauthor=D.+M.+Wattersonauthor=C.-F.+Huangauthor=G.+Bankerauthor=R.+H.+Brownauthor=S.+T.+Brady&title=Inhibition+of+Fast+Axonal+Transport+by+Pathogenic+SOD1+Involves+Activation+of+p38+MAP+Kinase&doi=10.1371%2Fjournal.pone.0065235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase</span></div><div class="casAuthors">Morfini, Gerardo A.; Bosco, Daryl A.; Brown, Hannah; Gatto, Rodolfo; Kaminska, Agnieszka; Song, Yuyu; Molla, Linda; Baker, Lisa; Marangoni, M. Natalia; Berth, Sarah; Tavassoli, Ehsan; Bagnato, Carolina; Tiwari, Ashutosh; Hayward, Lawrence J.; Pigino, Gustavo F.; Watterson, D. Martin; Huang, Chun-Fang; Banker, Gary; Brown, Robert H., Jr.; Brady, Scott T.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e65235</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dying-back degeneration of motor neuron axons represents an established feature of familial amyotrophic lateral sclerosis (FALS) assocd. with superoxide dismutase 1 (SOD1) mutations, but axon-autonomous effects of pathogenic SOD1 remained undefined.  Characteristics of motor neurons affected in FALS include abnormal kinase activation, aberrant neurofilament phosphorylation, and fast axonal transport (FAT) deficits, but functional relationships among these pathogenic events were unclear.  Expts. in isolated squid axoplasm reveal that FALS-related SOD1 mutant polypeptides inhibit FAT through a mechanism involving a p38 mitogen activated protein kinase pathway.  Mutant SOD1 activated neuronal p38 in mouse spinal cord, neuroblastoma cells and squid axoplasm.  Active p38 MAP kinase phosphorylated kinesin-1, and this phosphorylation event inhibited kinesin-1.  Finally, vesicle motility assays revealed previously unrecognized, isoform-specific effects of p38 on FAT.  Axon-autonomous activation of the p38 pathway represents a novel gain of toxic function for FALS-linked SOD1 proteins consistent with the dying-back pattern of neurodegeneration characteristic of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirO1D7q7G5bVg90H21EOLACvtfcHk0lgUUx39gywLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVejsLnN&md5=33d6944dc106100da9eedd3d999ad5f7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0065235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0065235%26sid%3Dliteratum%253Aachs%26aulast%3DMorfini%26aufirst%3DG.%2BA.%26aulast%3DBosco%26aufirst%3DD.%2BA.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DGatto%26aufirst%3DR.%26aulast%3DKaminska%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DMolla%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DL.%26aulast%3DMarangoni%26aufirst%3DM.%2BN.%26aulast%3DBerth%26aufirst%3DS.%26aulast%3DTavassoli%26aufirst%3DE.%26aulast%3DBagnato%26aufirst%3DC.%26aulast%3DTiwari%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DL.%2BJ.%26aulast%3DPigino%26aufirst%3DG.%2BF.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DHuang%26aufirst%3DC.-F.%26aulast%3DBanker%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DR.%2BH.%26aulast%3DBrady%26aufirst%3DS.%2BT.%26atitle%3DInhibition%2520of%2520Fast%2520Axonal%2520Transport%2520by%2520Pathogenic%2520SOD1%2520Involves%2520Activation%2520of%2520p38%2520MAP%2520Kinase%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0065235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Origlia, N.</span></span> <span> </span><span class="NLM_article-title">An Isoform-Selective p38α Mitogen-Activated Protein Kinase Inhibitor Rescues Early Entorhinal Cortex Dysfunctions in a Mouse Model of Alzheimer’s Disease</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2Fj.neurobiolaging.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=30007168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=86-91&author=G.+Rutiglianoauthor=M.+Staziauthor=O.+Arancioauthor=D.+M.+Wattersonauthor=N.+Origlia&title=An+Isoform-Selective+p38%CE%B1+Mitogen-Activated+Protein+Kinase+Inhibitor+Rescues+Early+Entorhinal+Cortex+Dysfunctions+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.neurobiolaging.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Rutigliano, Grazia; Stazi, Martina; Arancio, Ottavio; Watterson, D. Martin; Origlia, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-91</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuroinflammation is a fundamental mechanism in Alzheimer's disease (AD) progression.  The stress-induced activation of the p38α mitogen-activated protein kinase (MAPK) leads to increased prodn. of proinflammatory cytokines and neurodegeneration.  We investigated the effects of an isoform selective p38α MAPK inhibitor, MW01-18-150SRM (MW150), administered at 2.5 mg/kg/d (i.p.; 14 days) on early entorhinal cortex (EC) alterations in an AD mouse model carrying human mutations of the amyloid precursor protein (mhAPP).  We used electrophysiol. analyses with long-term potentiation induction in EC-contg. brain slices and EC-relevant associative memory tasks.  We found that MW150 was capable of rescuing long-term potentiation in 2-mo old mhAPP mice.  Acute delivery of MW150 to brain slices was similarly effective in rescuing long-term potentiation, with a comparable efficacy to that of the widely used multikinase inhibitor SB203580.  MW150-treated mhAPP mice demonstrated improved ability to discriminate novel assocns. between objects and their position/context.  Our findings suggest that the selective inhibition of the stress-activated p38α MAPK with MW150 can attenuate the EC dysfunctions assocd. with neuroinflammation in an early stage of AD progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-g02KszQjrrVg90H21EOLACvtfcHk0lgUUx39gywLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI&md5=dc0717e4b389cb4191e52b15aaff96a6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DRutigliano%26aufirst%3DG.%26aulast%3DStazi%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DOriglia%26aufirst%3DN.%26atitle%3DAn%2520Isoform-Selective%2520p38%25CE%25B1%2520Mitogen-Activated%2520Protein%2520Kinase%2520Inhibitor%2520Rescues%2520Early%2520Entorhinal%2520Cortex%2520Dysfunctions%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2018%26volume%3D70%26spage%3D86%26epage%3D91%26doi%3D10.1016%2Fj.neurobiolaging.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Kinases in Central Nervous System Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">892</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1038/nrd2999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnrd2999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=19876042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=892-909&author=L.+K.+Chicoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=Targeting+Protein+Kinases+in+Central+Nervous+System+Disorders&doi=10.1038%2Fnrd2999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein kinases in central nervous system disorders</span></div><div class="casAuthors">Chico, Laura K.; Van Eldik, Linda J.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">892-909</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues assocd. specifically with CNS drug discovery.  However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclin. and clin. development.  We review candidate compds. and discuss selected CNS protein kinases that are emerging as important therapeutic targets.  In addn., we analyze trends in small-mol. properties that correlate with key challenges in CNS drug discovery, such as blood-brain barrier penetrance and cytochrome P 450-mediated metab., and discuss the potential of future approaches that will integrate mol.-fragment expansion with pharmacoinformatics to address these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzQo2JmuPNlrVg90H21EOLACvtfcHk0lgUUx39gywLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO&md5=4dc1f6b7542e59c99f91525d37c49973</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2999%26sid%3Dliteratum%253Aachs%26aulast%3DChico%26aufirst%3DL.%2BK.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520Protein%2520Kinases%2520in%2520Central%2520Nervous%2520System%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D892%26epage%3D909%26doi%3D10.1038%2Fnrd2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behanna, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties and CYP2D6 Substrates: Central Nervous System Therapeutics Case Study and Pattern Analysis of a Substrate Database</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2204</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1124%2Fdmd.109.028134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=19661215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOqtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2204-2211&author=L.+K.+Chicoauthor=H.+A.+Behannaauthor=W.+Huauthor=G.+Zhongauthor=S.+M.+Royauthor=D.+M.+Watterson&title=Molecular+Properties+and+CYP2D6+Substrates%3A+Central+Nervous+System+Therapeutics+Case+Study+and+Pattern+Analysis+of+a+Substrate+Database&doi=10.1124%2Fdmd.109.028134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database</span></div><div class="casAuthors">Chico, Laura K.; Behanna, Heather A.; Hu, Wenhui; Zhong, Guifa; Roy, Saktimayee Mitra; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2204-2211</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CYP2D6 substrate status is a crit. Go/No Go decision criteria in central nervous system (CNS) drug discovery efforts because the polymorphic nature of CYP2D6 can lead to variable patient safety and drug efficacy.  In addn., CYP2D6 is disproportionately involved in the metab. of CNS drugs compared with other drug classes.  Therefore, identifying trends in small mol. properties of CNS-penetrant compds. that can help discriminate potential CYP2D6 substrates from nonsubstrates would allow addnl. prioritization in the synthesis and biol. evaluation of new therapeutic candidates.  The authors report the conversion of the CNS drug minaprine from substrate to nonsubstrate, as well as the conversion of the related CNS drug minozac from nonsubstrate to substrate, through the use of analog synthesis and CYP2D6 enzyme kinetic analyses.  No single mol. property strongly correlated with substrate status for this 3-amino-4-methyl-6-phenylpyridazine scaffold, although mol. vol. and charge appeared to be indirectly related.  A parsed database of CYP2D6 substrates across diverse chem. structures was assembled and analyzed for phys. property trends correlating with substrate status.  The authors found that a complex interplay of properties influenced CYP2D6 substrate status and that the particular chem. scaffold affects which properties are most prominent.  The results also identified an unexpected issue in CNS drug discovery, in that some property trends correlative with CYP2D6 substrates overlap previously reported properties that correlate with CNS penetrance.  These results suggest the need for a careful balance in the design and synthesis of new CNS therapeutic candidates to avoid CYP2D6 substrate status while maintaining CNS penetrance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD8Pr6CQrxuLVg90H21EOLACvtfcHk0lhGn_7dm_OU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOqtbfI&md5=4cbb608ecd32316c291d3b90095bb768</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028134%26sid%3Dliteratum%253Aachs%26aulast%3DChico%26aufirst%3DL.%2BK.%26aulast%3DBehanna%26aufirst%3DH.%2BA.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DG.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DMolecular%2520Properties%2520and%2520CYP2D6%2520Substrates%253A%2520Central%2520Nervous%2520System%2520Therapeutics%2520Case%2520Study%2520and%2520Pattern%2520Analysis%2520of%2520a%2520Substrate%2520Database%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2204%26epage%3D2211%26doi%3D10.1124%2Fdmd.109.028134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RalayRanaivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behanna, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wing, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Development of a Novel Therapeutic Suppressor of Brain Proinflammatory Cytokine Up-Regulation that Attenuates Synaptic Dysfunction and Behavioral Deficits</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2Fj.bmcl.2006.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=17079143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFGktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=414-418&author=W.+Huauthor=H.+RalayRanaivoauthor=S.+M.+Royauthor=H.+A.+Behannaauthor=L.+K.+Wingauthor=L.+Munozauthor=L.+Guoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=Development+of+a+Novel+Therapeutic+Suppressor+of+Brain+Proinflammatory+Cytokine+Up-Regulation+that+Attenuates+Synaptic+Dysfunction+and+Behavioral+Deficits&doi=10.1016%2Fj.bmcl.2006.10.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits</span></div><div class="casAuthors">Hu, Wenhui; Ranaivo, Hantamalala Ralay; Roy, Saktimayee M.; Behanna, Heather A.; Wing, Laura K.; Munoz, Lenka; Guo, Ling; Van Eldik, Linda J.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">414-418</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We report the development of a novel, aq.-sol., safe, small mol., exptl. therapeutic I that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits.  A good manufg. protocol prodn. of the dihydrochloride hydrate of I as potential active pharmaceutical ingredient is presented.  The development and large-scale availability of this novel compd. allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWTGYkJ4FPULVg90H21EOLACvtfcHk0lhGn_7dm_OU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFGktQ%253D%253D&md5=6b55207ab3e1230193a7122eae3b4e84</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DRalayRanaivo%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DBehanna%26aufirst%3DH.%2BA.%26aulast%3DWing%26aufirst%3DL.%2BK.%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520Novel%2520Therapeutic%2520Suppressor%2520of%2520Brain%2520Proinflammatory%2520Cytokine%2520Up-Regulation%2520that%2520Attenuates%2520Synaptic%2520Dysfunction%2520and%2520Behavioral%2520Deficits%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D414%26epage%3D418%26doi%3D10.1016%2Fj.bmcl.2006.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+Fluorinated+Motifs+in+the+Design+and+Application+of+Bioisosteres+for+Drug+Design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lhGn_7dm_OU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520Fluorinated%2520Motifs%2520in%2520the%2520Design%2520and%2520Application%2520of%2520Bioisosteres%2520for%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J. J.</span></span> <span> </span><span class="NLM_article-title">Selective Brain-Targeted Antagonism of p38 MAPKp Reduces Hippocampal IL-1 Levels and Improves Morris Water Maze Performance in Aged Rats</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.3233/JAD-150277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.3233%2FJAD-150277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=26401942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=219-227&author=J.+J.+Alam&title=Selective+Brain-Targeted+Antagonism+of+p38+MAPKp+Reduces+Hippocampal+IL-1+Levels+and+Improves+Morris+Water+Maze+Performance+in+Aged+Rats&doi=10.3233%2FJAD-150277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats</span></div><div class="casAuthors">Alam John J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  P38 mitogen activated protein kinase (MAPK) α modulates microglia-mediated inflammatory responses and a number of neuronal physiological processes.  OBJECTIVE:  To evaluate pre-clinically the pharmacological effects in the brain of p38 MAPKα inhibition with a brain-penetrant specific chemical antagonist.  METHODS:  VX-745, a blood-brain barrier penetrant, highly selective p38 MAPKα inhibitor, and clinical stage investigational drug, was utilized.  Initially, a pilot study in 26-month-old Tg2576 mice was conducted.  Subsequently, a definitive dose-response study was conducted in aged (20-22 months) rats with identified cognitive deficits; n = 15 per group: vehicle, 0.5, 1.5, and 4.5 mg/kg VX-745 by oral gavage twice daily for 3 weeks.  Assessments in aged rats included IL-1β, PSD-95, TNFα protein levels in hippocampus; and Morris water maze (MWM) test for cognitive performance.  RESULTS:  Drug effect could not be assessed in Tg2576 mice, as little inflammation was evident.  In cognitively-impaired aged rats, VX-745 led to significantly improved performance in the MWM and significant reduction in hippocampal IL-1β protein levels, though the effects were dissociated as the MWM effect was evident at a lower dose level than that required to lower IL-1β.  Drug concentration-effect relationships and predicted human doses were determined.  CONCLUSIONS:  Selective inhibition of p38 MAPKα with VX-745 in aged rats reduces hippocampal IL-1β levels and improves performance in the MWM.  As the two effects occur at different dose levels, the behavioral effect appears to be via a mechanism that is independent of reducing cytokine production.  The predicted human doses should minimize risks of systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfUvQHd8XXxf6BottYdIAWfW6udTcc2eYMU8kh319uZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D&md5=cec29afedc9795bd0680734acc367146</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3233%2FJAD-150277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150277%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DJ.%2BJ.%26atitle%3DSelective%2520Brain-Targeted%2520Antagonism%2520of%2520p38%2520MAPKp%2520Reduces%2520Hippocampal%2520IL-1%2520Levels%2520and%2520Improves%2520Morris%2520Water%2520Maze%2520Performance%2520in%2520Aged%2520Rats%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D48%26spage%3D219%26epage%3D227%26doi%3D10.3233%2FJAD-150277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule–Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule%E2%80%93Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0li1dnX_O0P1ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule%25E2%2580%2593Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhw7HC3UzRvSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrzaszcz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragisic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, M. S.</span></span> <span> </span><span class="NLM_article-title">MinozacTreatment Prevents Increased Seizure Susceptibility in a Mouse “two-hit” Model of Closed Skull Traumatic Brain Injury and ElectroconvulsiveShock-induced Seizures</span>. <i>J. Neurotrauma.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1295</span>, <span class="refDoi"> DOI: 10.1089/neu.2009.1227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1089%2Fneu.2009.1227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=20486807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A280%3ADC%252BC3cjgtVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=1283-1295&author=M.+Chrzaszczauthor=C.+Venkatesanauthor=T.+Dragisicauthor=D.+M.+Wattersonauthor=M.+S.+Wainwright&title=MinozacTreatment+Prevents+Increased+Seizure+Susceptibility+in+a+Mouse+%E2%80%9Ctwo-hit%E2%80%9D+Model+of+Closed+Skull+Traumatic+Brain+Injury+and+ElectroconvulsiveShock-induced+Seizures&doi=10.1089%2Fneu.2009.1227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures</span></div><div class="casAuthors">Chrzaszcz MaryAnn; Venkatesan Charu; Dragisic Tina; Watterson D Martin; Wainwright Mark S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurotrauma</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1283-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mechanisms linking traumatic brain injury (TBI) to post-traumatic epilepsy (PTE) are not known and no therapy for prevention of PTE is available.  We used a mouse closed-skull midline impact model to test the hypotheses that TBI increases susceptibility to seizures in a "two-hit" injury model, and that suppression of cytokine upregulation after the first hit will attenuate the increased susceptibility to the second neurological insult.  Adult male CD-1 mice underwent midline closed skull pneumatic impact.  At 3 and 6 h after impact or sham procedure, the mice were injected IP with either Minozac (Mzc), a suppressor of proinflammatory cytokine upregulation, or vehicle (saline).  On day 7 after sham operation or TBI, seizures were induced using electroconvulsive shock (ECS), and susceptibility to seizures was measured by the current required for seizure induction.  Activation of glia, neuronal injury, and metallothionein-immunoreactive cells were quantified in the hippocampus by immunohistochemical methods.  Neurobehavioral function over 14-day recovery was quantified using the Barnes maze.  Following TBI there was a significant increase in susceptibility to seizures induced by ECS, and this susceptibility was prevented by suppression of cytokine upregulation with Mzc.  Astrocyte activation, metallothionein expression, and neurobehavioral impairment were also increased in the two-hit group subjected to combined TBI and ECS.  These enhanced responses in the two-hit group were also prevented by suppression of proinflammatory cytokine upregulation with Mzc.  These data implicate glial activation in the mechanisms of epileptogenesis after TBI, and identify a potential therapeutic approach to attenuate the delayed neurological sequelae of TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Un0OlAnsP3thwrmtH4OBfW6udTcc2eYGHp-v3ESUarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjgtVOltQ%253D%253D&md5=e67925069732fb365586beaadd0c0879</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1089%2Fneu.2009.1227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fneu.2009.1227%26sid%3Dliteratum%253Aachs%26aulast%3DChrzaszcz%26aufirst%3DM.%26aulast%3DVenkatesan%26aufirst%3DC.%26aulast%3DDragisic%26aufirst%3DT.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DWainwright%26aufirst%3DM.%2BS.%26atitle%3DMinozacTreatment%2520Prevents%2520Increased%2520Seizure%2520Susceptibility%2520in%2520a%2520Mouse%2520%25E2%2580%259Ctwo-hit%25E2%2580%259D%2520Model%2520of%2520Closed%2520Skull%2520Traumatic%2520Brain%2520Injury%2520and%2520ElectroconvulsiveShock-induced%2520Seizures%26jtitle%3DJ.%2520Neurotrauma.%26date%3D2010%26volume%3D27%26spage%3D1283%26epage%3D1295%26doi%3D10.1089%2Fneu.2009.1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span> <span> </span><span class="NLM_article-title">The Dynamic Nature of the Kinome</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1042/BJ20121456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1042%2FBJ20121456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23343193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2013&pages=1-8&author=L.+M.+Gravesauthor=J.+S.+Duncanauthor=M.+C.+Whittleauthor=G.+L.+Johnson&title=The+Dynamic+Nature+of+the+Kinome&doi=10.1042%2FBJ20121456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The dynamic nature of the kinome</span></div><div class="casAuthors">Graves, Lee M.; Duncan, James S.; Whittle, Martin C.; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in proteomics have facilitated the anal. of the kinome 'en masse'.  What these studies have revealed is a surprisingly dynamic network of kinase responses to highly selective kinase inhibitors, thereby illustrating the complex biol. responses to these small mols.  Moreover these studies have identified key transcription factors, such as c-Myc and FOXO (forkhead box O), that play pivotal roles in kinome reprogramming in cancer cells.  Since many kinase inhibitors fail despite a high efficacy of blocking their intended targets, elucidating kinome changes at a more global level will be essential to understanding the mechanisms of kinase inhibitor pharmacol.  The development of technologies to study the kinome, as well as examples of kinome resilience and reprogramming, will be discussed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruuFxman4qSbVg90H21EOLACvtfcHk0lhw7HC3UzRvSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgs78%253D&md5=9748c28a92494f1e9342911b0f77cef4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1042%2FBJ20121456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121456%26sid%3Dliteratum%253Aachs%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DWhittle%26aufirst%3DM.%2BC.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DThe%2520Dynamic%2520Nature%2520of%2520the%2520Kinome%26jtitle%3DBiochem.%2520J.%26date%3D2013%26volume%3D450%26spage%3D1%26epage%3D8%26doi%3D10.1042%2FBJ20121456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. C.</span></span> <span> </span><span class="NLM_article-title">Mitogen-Activated Protein Kinases in Innate Immunity</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nri3495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fnri3495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23954936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=679-692&author=J.+S.+C.+Arthurauthor=S.+C.+Ley&title=Mitogen-Activated+Protein+Kinases+in+Innate+Immunity&doi=10.1038%2Fnri3495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinases in innate immunity</span></div><div class="casAuthors">Arthur, J. Simon C.; Ley, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Following pathogen infection or tissue damage, the stimulation of pattern recognition receptors on the cell surface and in the cytoplasm of innate immune cells activates members of each of the major mitogen-activated protein kinase (MAPK) subfamilies - the extracellular signal-regulated kinase (ERK), p38 and Jun N-terminal kinase (JNK) subfamilies.  In conjunction with the activation of nuclear factor-κB and interferon-regulatory factor transcription factors, MAPK activation induces the expression of multiple genes that together regulate the inflammatory response.  In this Review, we discuss our current knowledge about the regulation and the function of MAPKs in innate immunity, as well as the importance of neg. feedback loops in limiting MAPK activity to prevent host tissue damage.  We also examine how pathogens have evolved complex mechanisms to manipulate MAPK activation to increase their virulence.  Finally, we consider the potential of the pharmacol. targeting of MAPK pathways to treat autoimmune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokaFaArJ0-rLVg90H21EOLACvtfcHk0lhw7HC3UzRvSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI&md5=385a2fc463805b41ec03296345fb5d86</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnri3495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3495%26sid%3Dliteratum%253Aachs%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DLey%26aufirst%3DS.%2BC.%26atitle%3DMitogen-Activated%2520Protein%2520Kinases%2520in%2520Innate%2520Immunity%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnri3495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">The p383 MAPK Regulates Microglial Responsiveness to Diffuse Traumatic Brain Injury</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">6143</span>– <span class="NLM_lpage">6153</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5399-12.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1523%2FJNEUROSCI.5399-12.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23554495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyjtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=6143-6153&author=A.+D.+Bachstetterauthor=R.+K.+Roweauthor=M.+Kanekoauthor=D.+Gouldingauthor=J.+Lifshitzauthor=L.+J.+Van+Eldik&title=The+p383+MAPK+Regulates+Microglial+Responsiveness+to+Diffuse+Traumatic+Brain+Injury&doi=10.1523%2FJNEUROSCI.5399-12.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury</span></div><div class="casAuthors">Bachstetter, Adam D.; Rowe, Rachel K.; Kaneko, Machi; Goulding, Danielle; Lifshitz, Jonathan; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6143-6153</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neuropathol. after traumatic brain injury (TBI) is the result of both the immediate impact injury and secondary injury mechanisms.  Unresolved post-traumatic glial activation is a secondary injury mechanism that contributes to a chronic state of neuroinflammation in both animal models of TBI and human head injury patients.  We recently demonstrated, using in vitro models, that p38α MAPK signaling in microglia is a key event in promoting cytokine prodn. in response to diverse disease-relevant stressors and subsequent inflammatory neuronal dysfunction.  From these findings, we hypothesized that the p38α signaling pathway in microglia could be contributing to the secondary neuropathol. sequelae after a diffuse TBI.  Mice where microglia were p38α-deficient (p38α KO) were protected against TBI-induced motor deficits and synaptic protein loss.  In wild-type (WT) mice, diffuse TBI produced microglia morphol. activation that lasted for at least 7 d; however, p38α KO mice failed to activate this response.  Unexpectedly, we found that the peak of the early, acute phase cytokine and chemokine levels was increased in injured p38α KO mice compared with injured WT mice.  The increased cytokine levels in the p38α KO mice could not be accounted for by more infiltration of macrophages or neutrophils, or increased astrogliosis.  By 7 d after injury, the cytokine and chemokine levels remained elevated in injured WT mice but not in p38α KO mice.  Together, these data suggest that p38α balances the inflammatory response by acutely attenuating the early proinflammatory cytokine surge while perpetuating the chronic microglia activation after TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeH0wYYUgxmLVg90H21EOLACvtfcHk0ljzcY3KrYlvjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyjtL%252FP&md5=e34ee60c9ccb4785fcf474530cec4fa2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5399-12.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5399-12.2013%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DRowe%26aufirst%3DR.%2BK.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DGoulding%26aufirst%3DD.%26aulast%3DLifshitz%26aufirst%3DJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DThe%2520p383%2520MAPK%2520Regulates%2520Microglial%2520Responsiveness%2520to%2520Diffuse%2520Traumatic%2520Brain%2520Injury%26jtitle%3DJ.%2520Neurosci.%26date%3D2013%26volume%3D33%26spage%3D6143%26epage%3D6153%26doi%3D10.1523%2FJNEUROSCI.5399-12.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Microglia p38M MAPK is Critical for LPS-Induced Neuron Degeneration Through a Mechanism Involving TNF</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">84</span>, <span class="refDoi"> DOI: 10.1186/1750-1326-6-84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1186%2F1750-1326-6-84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=22185458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVOqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=84&author=B.+Xingauthor=A.+D.+Bachstetterauthor=L.+J.+Van+Eldik&title=Microglia+p38M+MAPK+is+Critical+for+LPS-Induced+Neuron+Degeneration+Through+a+Mechanism+Involving+TNF&doi=10.1186%2F1750-1326-6-84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα</span></div><div class="casAuthors">Xing, Bin; Bachstetter, Adam D.; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The p38α MAPK isoform is a well-established therapeutic target in peripheral inflammatory diseases, but the importance of this kinase in pathol. microglial activation and detrimental inflammation in CNS disorders is less well understood.  To test the role of the p38α MAPK isoform in microglia-dependent neuron damage, we used primary microglia from wild-type (WT) or p38α MAPK conditional knockout (KO) mice in co-culture with WT cortical neurons, and measured neuron damage after LPS insult.  Results: We found that neurons in co-culture with p38α-deficient microglia were protected against LPS-induced synaptic loss, neurite degeneration, and neuronal death.  The involvement of the proinflammatory cytokine TNFα was demonstrated by the findings that p38α KO microglia produced much less TNFα in response to LPS compared to WT microglia, that adding back TNFα to KO microglia/neuron co-cultures increased the LPS-induced neuron damage, and that neutralization of TNFα in WT microglia/neuron co-cultures prevented the neuron damage.  These results using cell-selective, isoform-specific KO mice demonstrate that the p38α MAPK isoform in microglia is a key mediator of LPS-induced neuronal and synaptic dysfunction.  The findings also provide evidence that a major mechanism by which LPS activation of microglia p38α MAPK signaling leads to neuron damage is through up-regulation of the proinflammatory cytokine TNFα.  Conclusions: The data suggest that selective targeting of p38α MAPK signaling should be explored as a potential therapeutic strategy for CNS disorders where overprodn. of proinflammatory cytokines is implicated in disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_XrXkCLeNbVg90H21EOLACvtfcHk0ljzcY3KrYlvjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVOqurY%253D&md5=cb3f5f671704d3262be633221f517f7e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-6-84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-6-84%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DB.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DMicroglia%2520p38M%2520MAPK%2520is%2520Critical%2520for%2520LPS-Induced%2520Neuron%2520Degeneration%2520Through%2520a%2520Mechanism%2520Involving%2520TNF%26jtitle%3DMol.%2520Neurodegener.%26date%3D2011%26volume%3D6%26spage%3D84%26doi%3D10.1186%2F1750-1326-6-84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiorito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakkar, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Quinoline Derivatives: Discovery of a Potent and Selective Phosphodiesterase 5 Inhibitor for the Treatment of Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1016%2Fj.ejmech.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=23313637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVemsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=285-294&author=J.+Fioritoauthor=F.+Saeedauthor=H.+Zhangauthor=A.+Staniszewskiauthor=Y.+Fengauthor=Y.+I.+Francisauthor=S.+Raoauthor=D.+M.+Thakkarauthor=S.-X.+Dengauthor=D.+W.+Landryauthor=O.+Arancio&title=Synthesis+of+Quinoline+Derivatives%3A+Discovery+of+a+Potent+and+Selective+Phosphodiesterase+5+Inhibitor+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Fiorito, Jole; Saeed, Faisal; Zhang, Hong; Staniszewski, Agnieszka; Feng, Yan; Francis, Yitshak I.; Rao, Sudha; Thakkar, Devarshi M.; Deng, Shi-Xian; Landry, Donald W.; Arancio, Ottavio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">285-294</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphodiesterase type 5 (PDE5) mediates the degrdn. of cGMP in a variety of tissues including brain.  Recent studies have demonstrated the importance of the nitric oxide/cGMP/cAMP-responsive element-binding protein (CREB) pathway to the process of learning and memory.  Thus, PDE5 inhibitors (PDE5Is) are thought to be promising new therapeutic agents for the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory loss.  To explore this possibility, a series of quinoline derivs. were synthesized and evaluated.  We found that compd. I selectively inhibits PDE5 with an IC50 of 0.27 nM and readily crosses the blood brain barrier.  In an in vivo mouse model of AD, compd. I rescues synaptic and memory defects.  Quinoline-based, CNS-permeant PDE5Is have potential for AD therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6B39cj4LBh7Vg90H21EOLACvtfcHk0ljzcY3KrYlvjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVemsrg%253D&md5=335f11f0576ec3fe8dc1bcf5df2cebdc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DFiorito%26aufirst%3DJ.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DFrancis%26aufirst%3DY.%2BI.%26aulast%3DRao%26aufirst%3DS.%26aulast%3DThakkar%26aufirst%3DD.%2BM.%26aulast%3DDeng%26aufirst%3DS.-X.%26aulast%3DLandry%26aufirst%3DD.%2BW.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DSynthesis%2520of%2520Quinoline%2520Derivatives%253A%2520Discovery%2520of%2520a%2520Potent%2520and%2520Selective%2520Phosphodiesterase%25205%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D60%26spage%3D285%26epage%3D294%26doi%3D10.1016%2Fj.ejmech.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piacentini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltrons, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li Puma, D.D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulisano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidowitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroutunian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honig, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moe, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Adamio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaan, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Extracellular Tau Oligomers Produce an Immediate Impairment of LTP and Memory</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19393</span>, <span class="refDoi"> DOI: 10.1038/srep19393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1038%2Fsrep19393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=26786552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ertrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=19393&author=M.+Faauthor=D.+Puzzoauthor=R.+Piacentiniauthor=A.+Staniszewskiauthor=H.+Zhangauthor=M.+A.+Baltronsauthor=D.D.+Li+Pumaauthor=I.+Chatterjeeauthor=J.+Liauthor=F.+Saeedauthor=H.+L.+Bermanauthor=C.+Ripoliauthor=W.+Gulisanoauthor=J.+Gonzalezauthor=H.+Tianauthor=J.+A.+Costaauthor=P.+Lopezauthor=E.+Davidowitzauthor=W.+H.+Yuauthor=V.+Haroutunianauthor=L.+M.+Brownauthor=A.+Palmeriauthor=E.+M.+Sigurdssonauthor=K.+E.+Duffauthor=A.+F.+Teichauthor=L.+S.+Honigauthor=M.+Sierksauthor=J.+G.+Moeauthor=L.+D%E2%80%99Adamioauthor=C.+Grassiauthor=N.+M.+Kanaanauthor=P.+E.+Fraserauthor=O.+Arancio&title=Extracellular+Tau+Oligomers+Produce+an+Immediate+Impairment+of+LTP+and+Memory&doi=10.1038%2Fsrep19393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory</span></div><div class="casAuthors">Fa, M.; Puzzo, D.; Piacentini, R.; Staniszewski, A.; Zhang, H.; Baltrons, M. A.; Li Puma, D. D.; Chatterjee, I.; Li, J.; Saeed, F.; Berman, H. L.; Ripoli, C.; Gulisano, W.; Gonzalez, J.; Tian, H.; Costa, J. A.; Lopez, P.; Davidowitz, E.; Yu, W. H.; Haroutunian, V.; Brown, L. M.; Palmeri, A.; Sigurdsson, E. M.; Duff, K. E.; Teich, A. F.; Honig, L. S.; Sierks, M.; Moe, J. G.; D'Adamio, L.; Grassi, C.; Kanaan, N. M.; Fraser, P. E.; Arancio, O.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19393</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Non-fibrillar sol. oligomeric forms of amyloid-β peptide (oAβ) and tau proteins are likely to play a major role in Alzheimer's disease (AD).  The prevailing hypothesis on the disease etiopathogenesis is that oAβ initiates tau pathol. that slowly spreads throughout the medial temporal cortex and neocortices independently of Aβ, eventually leading to memory loss.  Here we show that a brief exposure to extracellular recombinant human tau oligomers (oTau), but not monomers, produces an impairment of long-term potentiation (LTP) and memory, independent of the presence of high oAβ levels.  The impairment is immediate as it raises as soon as 20 min after exposure to the oligomers.  These effects are reproduced either by oTau extd. from AD human specimens, or naturally produced in mice overexpressing human tau.  Finally, we found that oTau could also act in combination with Aβ to produce these effects, as sub-toxic doses of the two peptides combined lead to LTP and memory impairment.  These findings provide a novel view of the effects of tau and Aβ on memory loss, offering new therapeutic opportunities in the therapy of AD and other neurodegenerative diseases assocd. with Aβ and tau pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnnD-KPPHPobVg90H21EOLACvtfcHk0lgb48bVWJoDUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ertrg%253D&md5=72adf9bf06a4051973905912b73931d4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fsrep19393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep19393%26sid%3Dliteratum%253Aachs%26aulast%3DFa%26aufirst%3DM.%26aulast%3DPuzzo%26aufirst%3DD.%26aulast%3DPiacentini%26aufirst%3DR.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBaltrons%26aufirst%3DM.%2BA.%26aulast%3DLi%2BPuma%26aufirst%3DD.D.%26aulast%3DChatterjee%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DBerman%26aufirst%3DH.%2BL.%26aulast%3DRipoli%26aufirst%3DC.%26aulast%3DGulisano%26aufirst%3DW.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DCosta%26aufirst%3DJ.%2BA.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DDavidowitz%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DW.%2BH.%26aulast%3DHaroutunian%26aufirst%3DV.%26aulast%3DBrown%26aufirst%3DL.%2BM.%26aulast%3DPalmeri%26aufirst%3DA.%26aulast%3DSigurdsson%26aufirst%3DE.%2BM.%26aulast%3DDuff%26aufirst%3DK.%2BE.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DHonig%26aufirst%3DL.%2BS.%26aulast%3DSierks%26aufirst%3DM.%26aulast%3DMoe%26aufirst%3DJ.%2BG.%26aulast%3DD%25E2%2580%2599Adamio%26aufirst%3DL.%26aulast%3DGrassi%26aufirst%3DC.%26aulast%3DKanaan%26aufirst%3DN.%2BM.%26aulast%3DFraser%26aufirst%3DP.%2BE.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DExtracellular%2520Tau%2520Oligomers%2520Produce%2520an%2520Immediate%2520Impairment%2520of%2520LTP%2520and%2520Memory%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D19393%26doi%3D10.1038%2Fsrep19393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolomanov, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puschmann, H.</span></span> <span> </span><span class="NLM_article-title">OLEX2: A Complete Structure Solution, Refinement and Analysis Program</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1107/S0021889808042726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1107%2FS0021889808042726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=339-341&author=O.+V.+Dolomanovauthor=L.+J.+Bourhisauthor=R.+J.+Gildeaauthor=J.+A.+K.+Howardauthor=H.+Puschmann&title=OLEX2%3A+A+Complete+Structure+Solution%2C+Refinement+and+Analysis+Program&doi=10.1107%2FS0021889808042726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">OLEX2: a complete structure solution, refinement and analysis program</span></div><div class="casAuthors">Dolomanov, Oleg V.; Bourhis, Luc J.; Gildea, Richard J.; Howard, Judith A. K.; Puschmann, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-341</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">New software, OLEX2, was developed for the detn., visualization and anal. of mol. crystal structures.  The software has a portable mouse-driven workflow-oriented and fully comprehensive graphical user interface for structure soln., refinement and report generation, as well as novel tools for structure anal.  OLEX2 seamlessly links all aspects of the structure soln., refinement and publication process and presents them in a single workflow-driven package, with the ultimate goal of producing an application which will be useful to both chemists and crystallographers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIYSUbyzIgxbVg90H21EOLACvtfcHk0lgb48bVWJoDUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D&md5=7a2f9697b13b8e76de0e7dc5074ab229</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0021889808042726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889808042726%26sid%3Dliteratum%253Aachs%26aulast%3DDolomanov%26aufirst%3DO.%2BV.%26aulast%3DBourhis%26aufirst%3DL.%2BJ.%26aulast%3DGildea%26aufirst%3DR.%2BJ.%26aulast%3DHoward%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DPuschmann%26aufirst%3DH.%26atitle%3DOLEX2%253A%2520A%2520Complete%2520Structure%2520Solution%252C%2520Refinement%2520and%2520Analysis%2520Program%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2009%26volume%3D42%26spage%3D339%26epage%3D341%26doi%3D10.1107%2FS0021889808042726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">A Short History of SHELX</span>. <i>Acta Crystallogr., Sect. A: Found. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>A64</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/S0108767307043930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1107%2FS0108767307043930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=A64&publication_year=2008&pages=112-122&author=G.+M.+Sheldrick&title=A+Short+History+of+SHELX&doi=10.1107%2FS0108767307043930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of SHELX</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section A: Foundations of Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACACEQ</span>;
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An account is given of the development of the SHELX system of computer programs from SHELX-76 to the present day.  In addn. to identifying useful innovations that have come into general use through their implementation in SHELX, a crit. anal. is presented of the less-successful features, missed opportunities and desirable improvements for future releases of the software.  An attempt is made to understand how a program originally designed for photog. intensity data, punched cards and computers over 10000 times slower than an av. modern personal computer has managed to survive for so long.  SHELXL is the most widely used program for small-mol. refinement and SHELXS and SHELXD are often employed for structure soln. despite the availability of objectively superior programs.  SHELXL also finds a niche for the refinement of macromols. against high-resoln. or twinned data; SHELXPRO acts as an interface for macromol. applications.  SHELXC, SHELXD and SHELXE are proving useful for the exptl. phasing of macromols., esp. because they are fast and robust and so are often employed in pipelines for high-throughput phasing.  This paper could serve as a general literature citation when one or more of the open-source SHELX programs (and the Bruker AXS version SHELXTL) are employed in the course of a crystal-structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLPYyJyJ2RbVg90H21EOLACvtfcHk0lgb48bVWJoDUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO&md5=8f91f10be4a9df74b2a9dad522c71e6e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0108767307043930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767307043930%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DA%2520Short%2520History%2520of%2520SHELX%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D2008%26volume%3DA64%26spage%3D112%26epage%3D122%26doi%3D10.1107%2FS0108767307043930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure Refinement with SHELXL</span>. <i>Acta Crystallogr., Sect. C: Struct. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>C71</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1107/S2053229614024218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;key=10.1107%2FS2053229614024218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=C71&publication_year=2015&pages=3-8&author=G.+M.+Sheldrick&title=Crystal+Structure+Refinement+with+SHELXL&doi=10.1107%2FS2053229614024218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS2053229614024218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053229614024218%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DCrystal%2520Structure%2520Refinement%2520with%2520SHELXL%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520C%253A%2520Struct.%2520Chem.%26date%3D2015%26volume%3DC71%26spage%3D3%26epage%3D8%26doi%3D10.1107%2FS2053229614024218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C','PDB','4R3C'); return false;">PDB: 4R3C</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH','PDB','4ZTH'); return false;">PDB: 4ZTH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ','PDB','4EWQ'); return false;">PDB: 4EWQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y','PDB','4F9Y'); return false;">PDB: 4F9Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9W','PDB','4F9W'); return false;">PDB: 4F9W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2','PDB','4FA2'); return false;">PDB: 4FA2</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00058">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21387"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00058">10.1021/acs.jmedchem.9b00058</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Tables 1S–8S listing clinical trials of previous p38MAPK inhibitors, SMILES for compounds mentioned in this article, accession numbers and summary data for protein kinases and GPCR tested as part of secondary pharmacology, X-ray crystal structure and additional characterizations of the GMP drug substance (API) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00058/suppl_file/jm9b00058_si_001.pdf">jm9b00058_si_001.pdf (3.9 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes for structures of p38αMAPK:compound complexes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZTH">4ZTH</a> (p38αMAPK:<b>1</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWQ">4EWQ</a> (p38αMAPK:<b>3</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9Y">4F9Y</a> (p38αMAPK:<b>9</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9W">4F9W</a> (p38αMAPK:<b>10</b>); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R3C">4R3C</a> (p38αMAPK:<b>11</b> (MW150)); <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FA2">4FA2</a> (p38αMAPK:SB239063).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00058%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00058" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995db4c9653c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
